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Abstract
At the height of its popularity, mephedrone was the most common
recreationally used cathinone. This is thought to be due to its perceived
likeness to MDMA. Therefore the aim of this thesis was to examine
mephedrone-induced changes in behaviour, body temperature or
neurochemistry in the rat and to compare these changes to those observed
following MDMA administration. This was achieved by assessing changes in
body temperature following acute mephedrone, MDMA, cathinone or
methcathinone administration. Additionally, locomotor activity and
cognitive tasks were performed following chronic intermittent
administration of mephedrone, MDMA or cathinone. These behaviours, as
well as mephedrone-induced changes to body temperature and anxiety-
related behaviour, were also assessed following either pre-treatment with
MDMA or co-administration of caffeine. Finally, locomotor activity, body
temperature changes and in vivo striatal dopamine release were assessed
following rapid repeated dosing of mephedrone, and the roles of dopamine,
5-HT and noradrenaline in these responses were examined. Post mortem
monoamine concentrations from specific brain regions were also assessed
following acute, chronic intermittent and rapid repeated dosing of
mephedrone.
It was found that the neurochemical, behavioural and physiological effects
of mephedrone in the rat include hyperactivity, hypothermia, cognitive
deficits, anxiety-related behaviour and increased striatal dopamine efflux.
Pre-exposure to MDMA, or concomitant caffeine administration, caused an
increase in rectal temperature following mephedrone injection while
caffeine co-administration prolonged the hyperactive profile of
mephedrone. Importantly, unlike MDMA, rapid repeated mephedrone
administration (3 x 10 mg kg-1 at 2 h intervals) had no cumulative effect
on mephedrone-induced hypothermia or hyperactivity. It is also clear that
mephedrone is inducing its effects via noradrenergic, dopaminergic and
serotonergic mechanisms. The cathinones and MDMA had varying effects
on post mortem tissue levels of the monoamines and their metabolites.
Importantly, these effects of mephedrone appear to be occurring by
mechanisms that are different, but similar, to MDMA.
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Cathinone is a naturally occurring psychostimulant found in the leaves of
the Khat plant. Recent years have seen the development of synthetic
derivatives of this compound known as designer cathinones or simply
cathinones. The term designer drug is used to describe psychostimulants
or other drugs of abuse that are used illicitly and produced from the
structures of existing drugs. The designer cathinones have structures
similar to the amphetamines and are taken recreationally for their
psychostimulant effects. The cathinone derivative mephedrone is a popular
recreational drug which has received a lot of media attention, but little was
known on its pharmacology or adverse effects at the commencement of
the studies presented in this thesis. The aim of this thesis is to perform a
preclinical examination of the effects of selected synthetic cathinones in
rats, with a particular focus on mephedrone, and to compare these effects
to 3,4-methylenedioxymethamphetamine (MDMA).
MDMA is a ring substituted amphetamine with a methylenedioxy
substitution at positions 3 and 4 of the aromatic ring of the amphetamine
molecule (Fig 1.1). The cathinones are structurally similar to amphetamine
ZLWKWKHRQO\GLIIHUHQFHEHLQJDVXEVWLWXWHGNHWRQHJURXSDWWKHǃSRVLWLRQ
RQ WKH VLGH FKDLQ )LJ  &DWKLQRQH DQG PHWKFDWKLQRQH DUH ǃNHWR
derivatives of amphetamine and methamphetamine, respectively (Fig 1.1).
Mephedrone, however, does not have a commonly used amphetamine
analogue.
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both the individual and society as a whole. Most amphetamines are
classified as Class B drugs under this act however MDMA was declared a
Class A drug in 1977 due to its abuse potential (ACMD 2008). In recent
years the purity of ecstasy tablets has declined due to strict restrictions on
its manufacturing and distribution. For example, less than 50% of ecstasy
tablets confiscated in the Netherlands in 2009 contained MDMA as their
primary component, compared to 90% in previous years and, in the US,
results from an online testing service revealed that 39% of ecstasy tablets
contained MDMA only from 1999-2005 (Tanner-Smith 2006; Brunt et al.
2011). It is thought that this decline in purity and availability is one factor
that has led to the increased popularity of MDMA-like legal highs in recent
years.
Unlike MDMA, cathinone is a naturally occurring compound. The leaves of
the Khat shrub (Catha eludis), originating from the Arabian peninsula and
East Africa (ACMD 2010), are commonly chewed or sometimes brewed as
tea for their psychostimulant effects. Traditionally khat use was confined to
areas surrounding its natural habitat (for example Sudan, Ethiopia, Yemen
and Somalia) as it must be used fresh to obtain its desired effects (Feyissa
and Kelly 2008). However, improved transportation, as well as the
movement of ethnic groups outside of the plants natural habitat, has led
to its more recent introduction to the United States, Canada, Australia and
Europe in the form of harvested leaves (Feyissa and Kelly 2008). Cathine
was isolated from khat leaves in 1930 and was initially thought to be the
main active psychostimulant component in these leaves. However, since it
had only modest stimulant properties further investigation was conducted,
leading to the discovery of the much more potent stimulant, cathinone, in
1975. The World Health Organisation labelled the active constituents of
khat, namely cathinone and cathine, as schedule I and schedule III
substances, respectively, in 1971 (Feyissa and Kelly 2008). The khat plant
remains legal in many African countries, but is illegal in other countries
such as France, Germany, Ireland, Canada and the US, and very recently
in the UK, amongst others. Cathinone is now a class C drug in the UK and
both methcathinone and mephedrone are classified as class B drugs
although at the time of the ban very little scientific evidence existed to
indicate that either is more harmful to the individual than cathinone.
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The synthetic cathinone derivatives have recently received substantial
media attention, but they are not newly discovered compounds.
Methcathinone was first synthesised in the late 1920s and originally
marketed as an antidepressant in the Soviet Union in the 1930s and 40s,
and subsequently developed as a potential appetite suppressant but never
marketed as such due to its addictive potential (Kelly 2011).
Methcathinone was declared illegal in several countries in the 1990s
following its widespread abuse. Additionally, although considered a
designer drug, mephedrone was first synthesised in 1929 but it received
little interest until the late 2000s, when it started being sold on the
internet as plant food and bath salts and in high street head shops as a
legal high. This coincided with a decrease in the availability of MDMA and
also in the purity of ecstasy tablets (Tanner-Smith 2006; Brunt et al.
2011). In many of these tablets MDMA was substituted by other
compounds and in 2009 mephedrone was found to be one of the most
prevalent new designer drugs to be misleadingly sold as ecstasy (Brunt et
al. 2011).
Although mephedrone has been implicated in a number of deaths and
became illegal in Europe and the USA between 2010 and 2012 (Dargan et
al. 2011; Gershman and Fass 2012) it remains available and popular for
illicit use (McElrath and O'Neill 2011; Ayres and Bond 2012; Van Hout and
Bingham 2012; Kelly et al. 2013; Yamamoto et al. 2013). Before being
classified as an illegal substance, mephedrone was the most popular of the
cathinone derivatives used recreationally because of its reported
psychostimulant properties and empathetic effects. One online survey of
2289 experienced polydrug users conducted in 2009 showed 42% had tried
mephedrone at least once, with approximately 30% using it every two
weeks or more frequently (Winstock et al. 2011). A recent review of new
psychoactive drugs detected in post-mortem and criminal casework
collated between 2010 and 2012 in the UK demonstrated that of 203 cases
mephedrone was identified in 106 cases (Elliott and Evans, 2014; Fig 1.2).
Recreational users of mephedrone have compared its stimulant effects to
those of MDMA and cocaine (Winstock et al. 2011) and some users
considered mephedrone to be superior to MDMA (Vardakou et al. 2011).
Chapter 1. General Introduction
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Figure 1.2 Mephedrone was the most popular new psychoactive substance
identified in post-mortem and criminal casework between 2010 and 2012
in the UK (n=203 cases).
Figure taken from (Elliott and Evans 2014).
Number of cases
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1.2 Metabolism and pharmacokinetics
MDMA is most commonly consumed orally in the form of ecstasy tablets,
which typically contain between 80 and 150 mg of MDMA but as previously
stated the composition and purity of these tablets can vary (section 1.1).
An oral dose of 1 mg kg-1 to MDMA users produces a peak plasma
concentration (Cmax) of 150 ng ml
-1 2 h post-administration, with a half-life
of 5.5 h, and a clearance of 620 ml h-1 kg-1 (Desrosiers et al. 2013). Similar
data have been found in other studies (Mas et al. 1999; Kolbrich et al.
2008). In rats, an oral dose of 2 mg kg-1 gives a Cmax of 46 ng ml
-1 at 34
min post-administration, with a much shorter half-life of 46 min (Baumann
et al. 2009). MDMA mainly undergoes both phase I and phase II
metabolism in the liver by O-demethylenation to form 3,4-
dihydroxymethamphetamine (HHMA) by the CYP450 enzyme, CYP2D6 in
humans. HHMA is then O-demethylated to 4-hydroxy-3-
methoxymethamphetamine by catechol-O-methyltransferase. MDMA is also
N-demethylated to form 3,4-methylenedioxyamphetamine (MDA), which is
subsequently metabolised to 3,4-hydroxyamphetamine and then to 4-
hydroxy-3-methoxyamphetamine (Rietjens et al. 2012). In rats, at low
doses the formation of MDA is one of the main metabolic pathways, where
as in humans the formation of HHMA is predominant (de la Torre and Farre
2004; Baumann et al. 2009). Not only is MDMA metabolised by CYP2D6
but it is also inhibited by it, resulting in non-linear kinetics with inhibition
occurring within 1 h (Yang et al. 2006). In humans, there is an increased
gradient in the dose-plasma drug concentration slope for MDMA such that
a two-fold increase in dose gives rise to a four-fold increase in plasma
concentration (Green et al. 2012). In contrast, there is a linear relationship
between dose and plasma concentration in rats, which is lost at higher
doses, so that the dose-plasma concentration curves in humans and rats
are not very different at low doses but vary markedly at higher doses.
Administration of a second dose of MDMA 24 h later to humans causes an
increase in plasma concentration disproportionate to that observed
following the first, due to accumulation of the drug and auto-inhibition of
its own metabolism, which may account for the increased cardiovascular
effects and acute toxicity observed with repeated dosing (Farre et al.
2004).
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As previously stated, the most common route of administration of
cathinone is by consuming the leaves of the plant, typically by chewing the
fresh leaves, but sometimes the dried leaves are brewed as tea or very
rarely smoked. Since the leaves contain low concentrations of cathinone
and cathine, large quantities (100-500 g) must be chewed to obtain its
desired stimulant effects, meaning that sessions can last for several hours.
In healthy, non-drug using volunteers, the peak plasma concentration of
cathinone (Cmax=58.9 ng ml
-1) after chewing 36-59 g of khat leaves for 1
h (0.63 mg kg-1 of cathinone) was reached 2.3 h after the start of chewing
and the terminal elimination half-life was 1.5 h (Toennes et al. 2003). A
separate study where volunteers chewed 54-71 g of khat leaves for 1 h
(0.8 mg kg-1 of cathinone) found the peak plasma concentration of
cathinone to be 127 ng ml-1 at a Tmax of 2.1 h, with a terminal elimination
half-life of 4.3 h (Widler et al. 1994). The same group found similar effects
of a pure cathinone dose of 0.5 mg kg-1 administered in gelatine capsules,
the only exception being a more rapid Tmax following administration of pure
cathinone presumably due to delayed absorption of cathinone by chewing
the leaves (Brenneisen et al. 1990).
Methcathinone is typically taken by the intranasal or oral route and users
tend to re-dose several times a day, taking between 1 and 3 g per day for
a number of consecutive days (McCann et al. 1998). There is no
information on the pharmacokinetics of methcathinone in either humans or
laboratory animals.
Like methcathinone, mephedrone is consumed orally or intranasally with a
typical oral dose being in the region of 100-200 mg. This oral dose is
similar to a typical MDMA oral dose of 1-2 tablets (140-180 mg), however,
due to the short duration of action, mephedrone users tend to rapidly re-
dose meaning that they can consume 1 g or more of mephedrone in a
single session which most typically last for 3-12 h (Winstock et al. 2011).
Plasma concentrations of mephedrone in users following fatal doses are
approximately 2000 ng ml-1, which is very similar to concentrations
following fatal MDMA toxicity (Maskell et al. 2011; Schifano et al. 2012). In
Sprague-Dawley rats, a 5.6 mg kg-1 subcutaneous (s.c.) dose of
mephedrone gave a peak plasma concentration of 1206 ng ml-1 with a tmax
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of 0.25 h (Miller et al. 2013). In rapid repeated dosing studies where
Sprague-Dawley rats received a total of four injections of mephedrone at a
dose of either s.c. 10 or 25 mg kg-1 at 2 h intervals, plasma levels were
found to be 384.2 and 1294 ng ml-1 1 h after the final injection (Hadlock et
al. 2011). In the same study, whole brain tissue levels of 2.1 ng mg-1 and
7.8 ng mg-1 were found 1 h after the final injection. Mephedrone has
greater blood-brain permeability than MDMA (Simmler et al. 2013). Peak
brain levels of mephedrone (4 ng mg-1) were observed 2 min after a 1 mg
kg-1 i.v. injection and rapidly reduced to 0.4 ng mg-1 by 60 min post-
injection (Aarde et al. 2013).
Cathinone and methcathinone are metabolised to norephedrine and
QRUSVHXGRHSKHGULQH E\ 3KDVH , UHGXFWLRQ RI WKH ǃNHWR PRLHW\ WR DQ
alcohol (Brenneisen et al. 1990; Widler et al. 1994; Kelly 2011). Like
MDMA, mephedrone undergoes hepatic metabolism and CYP2D6 is the
main enzyme involved (Aarde et al. 2013; Pedersen et al. 2013).
Mephedrone is metabolised to nor-mephedrone, nor-dihydro-mephedrone,
hydroxytolyl-mephedrone and nor-hydroxytolyl-mephedrone by N-
demethylation to the primary amine, reduction of the keto moiety to the
respective alcohol and, oxidation of the tolyl moiety to the corresponding
alcohols (Meyer et al. 2010). These metabolites were identified in Wistar
rats after oral dosing, but an additional metabolite, 4-carboxy-dihydro
mephedrone was identified in human urine following an oral dose. It is
unclear whether any of these metabolites are pharmacologically active.
1.3 Neurochemistry
1.3.1 Monoamine transporters and receptors
MDMA binds to the 5-hydroxytrptamine (5-HT; SERT), dopamine (DAT)
and noradrenaline (NET) transporters, having the highest affinity for NET
SERT in mice and rats (Battaglia et al. 1988). While MDMA-induced 5-HT
release occurs by binding and reversal of the 5-HT transporter, it is
thought that MDMA releases dopamine by entering the dopamine terminal
by diffusion since the dopamine uptake inhibitor, GBR 12909, does not
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block dopamine release following MDMA administration to mice (O'Shea et
al. 2001; Camarero et al. 2002). MDMA is also a substrate for the vesicular
monoamine transporter (VMAT) so once in the cell it may enter the
vesicles via VMAT and deplete vesicular storage by reversal of VMAT
activity (Capela et al., 2009, see Fig 1.3 for schematic diagram). Equally
MDMA increases extracellular levels of the monoamines by inhibiting the
monoamine metabolising enzyme, monoamine oxidase (MAO). MDMA also
has a high affinity (Ki0IRUĮ2-adrenoceptors, 5-HT2, M1 muscarinic
and H1 histamine receptors (Table 1.1), with less affinity (Ki<10-100 µM)
IRUĮ1DQGǃDGUHQRFHSWRUV+71, M2muscarinic, dopamine D2 receptors
and a low affinity for dopamine D1įDQGǉRSLRLGDQGEHQ]RGLD]HSLQH
receptors (Battaglia et al. 1988). More recently it has also been found that
MDMA has an affinity for the rat trace amine 1 receptor as well as for
FHQWUDO QLFRWLQLF DFHW\OFKROLQH UHFHSWRUV SDUWLFXODUO\ WKH Į QLFRWLQLF
acetylcholine receptor (Ki=0.7 µM) (Bunzow et al. 2001; Garcia-Rates et
al. 2010).
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Table 1.1 Human transporter and receptor binding affinities of the
cathinones examined in this thesis and MDMA.
MDMA Mephedrone Cathinone Methcathinone
SERT 0.61 ± 0.051 >302 >302 >302
DAT 15.8 ± 1.71 3.4 ± 0.82 19.8 ± 1.92 1.28 ± 0.22
NET 24.4 ± 1.91 >252 3.5 ± 2.72 1.45 ± 0.72
5-HT1A 12.2 ± 0.8
2 >202 >202 12.7 ± 3.52
5-HT2A 7.8 ± 2.4
2 2.1 ± 0.72 >132 3.0 ± 0.62
Į1A 18.4 ± 1.21 3.48 ± 2.22 5.4 ± 1.12 3.93 ± 1.32
Į 2A 3.6 ± 0.81 11.0 ± 5.02 8.9 ± 2.72 11.9 ± 3.92
ǃ 19.2 ± 2.11 NA NA NA
D1 148 ± 14
1 >13.62 >13.62 >13.62
D2 95 ± 15
1 >302 >302 >302
H1 5.7 ± 2.4
1 >14.42 >14.42 >14.42
TA1Rat 0.37 ± 0.12
2 4.3 ± 2.02 2.2 ± 0.72 4.1 ± 1.22
M1 5.8 ± 0.3
1 NA NA NA
M2 15.1 ± 0.1
1 NA NA NA
Values are Ki (µM); NA, data not available;
1Battaglia et al., (1988), 2Simmler et
al., (2013)
&DWKLQRQH DQG PHWKFDWKLQRQH KDYH ORZ PLFURPRODU UDQJH  ǋ0
affinity for DAT and NET, which is similar to amphetamine and
methamphetamine (Simmler et al. 2013). Mephedrone, like MDMA, also
causes non-selective release of monoamines by acting as a substrate for
SERT, DAT and NET, however it is unlikely that it causes neurotransmitter
release via VMAT as its effects on this transporter occur at high micromolar
concentrations that are unlikely to occur in vivo (Hadlock et al. 2011;
Baumann et al. 2012; Lopez-Arnau et al. 2012; Martinez-Clemente et al.
2012; Eshleman et al. 2013; Simmler et al. 2013; Opacka-Juffry et al.
2014). Mephedrone has a high affinity (Ki0 IRUĮ1A-adrenoceptors,
5-HT2A and rat trace amine 1 receptors (Table 1.1), with lower affinity
(Ki 0 IRU Į2A-adrenoceptors (Simmler et al. 2013). While
FDWKLQRQH DQG PHWKFDWKLQRQH VKRZ VLPLODU DIILQLWLHV IRU Į1A DQG Į2A-
adrenoceptors and the rat trace amine 1 receptor, methcathinone also
binds to the 5-HT1A and 5-HT2A receptors.
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1.3.2 Brain monoamines
5-HT modulates many central and peripheral processes including regulation
of sleep, appetite, mood, sensory transmission, gastrointestinal function
and blood flow. In the rat, MDMA causes rapid release of 5-HT in a dose
dependent manner which leads to reduced tissue concentrations of both 5-
HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the first few
hours following administration (Stone et al. 1986; Battaglia et al. 1988;
Crespi et al. 1997; McCann et al. 2000; Ricaurte et al. 2000; Mechan et al.
2002; Green et al. 2003; Hall and Henry 2006). 5-HT release has been
demonstrated following MDMA administration to rat brain synaptosomes
and slices (Berger et al. 1992; Crespi et al. 1997) and in vivo microdialysis
studies have identified a rapid 5-HT release in the striatum, frontal cortex
and hippocampus (Yamamoto et al. 1995; Gudelsky and Nash 1996;
Mechan et al. 2002). An acute dose of MDMA also inhibits the activity of
the rate limiting enzyme for 5-HT production, tryptophan hydroxylase
(TPH) in rat striatum, hippocampus, hypothalamus and frontal cortex, as
well as the metabolising enzyme, MAO (Stone et al. 1986; Schmidt and
Taylor 1987; Stone et al. 1987; Che et al. 1995; Hall and Henry 2006). In
mice, however, there is a small decrease in tissue hippocampal and cortical
5-HT 3 h after 3 x 20 or 30 mg kg-1, but no effect on striatal 5-HT
concentration following the same dosing schedule (O'Shea et al. 2001).
Both cathinone and methcathinone cause 5-HT release from synaptosomes
(Gygi et al. 1997). Ex vivo high performance liquid chromatography (HPLC)
analysis of rat brain tissue has shown a decrease in 5-HT and 5-HIAA in
the prefrontal cortex, but an increase in dopamine in the nucleus
accumbens following repeated administration of cathinone (Banjaw et al.
2003). An acute s.c. injection of methcathinone has no effect on striatal
tissue monoamine concentrations at 30 min and 2 h post-injection,
however the activity of the rate limiting enzyme in 5-HT synthesis, TPH is
decreased at these time points (Gygi et al. 1996). However, in the same
study repeated methcathinone did decrease striatal tissue 5-HT and its
metabolite (5-HIAA) 18 h after four doses of methcathinone (30 mg kg-1)
at 4 h intervals. Additionally, hippocampal and frontal cortical tissue 5-HT
and 5-HIAA were also decreased following the same dosing schedule and
Chapter 1. General Introduction
14
activity of TPH and tyrosine hydroxylase (TH) were reduced in the
striatum, hippocampus and frontal cortex.
Dopamine is an essential modulator of motivated behaviour associated
with natural rewards, such as food. Recreational drugs which alter
dopamine release or function would therefore be expected to affect this
reward pathway. Indeed in addition to elevating 5-HT, MDMA also causes
rapid release of dopamine after administration (Sharp et al. 1987; Crespi
et al. 1997; Green et al. 2003; Benamar et al. 2008). However, unlike 5-
HT, tissue concentrations of dopamine in the rat brain are raised in the few
hours following MDMA administration while the levels of its metabolites,
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), are
reduced (Stone et al. 1986). MDMA causes the release of dopamine from
brain slices and prevents reuptake of dopamine into brain synaptosomes
(Schmidt et al. 1987; Steele et al. 1987). Both cathinone and
methcathinone cause dopamine release from synaptosomes (Kalix 1984;
Kalix and Glennon 1986; Gygi et al. 1997) and ex vivo HPLC analysis of rat
brain tissue has shown an increase in tissue dopamine in the nucleus
accumbens following repeated administration of cathinone (Banjaw et al.
2003). Further evidence for cathinone acting upon the dopaminergic
system comes from its anticataleptic effects in a Parkinsons disease model
(Banjaw et al. 2003) where cathinone antagonises haloperidol-induced
catalepsy, in a similar manner to MDMA. Methcathinone also increases
striatal HVA 3 h post-injection (Gygi et al. 1996). In the same study,
microdialysis was used to determine the acute effects of methcathinone (1
mg kg-1) on extracellular dopamine where a 409% increase in extracellular
DA was observed. Changes in 5-HT were also prevented by depletion of
dopamine by striatal lesioning with 6-hydroxydopamine (6-OHDA), further
suggesting the important role of dopamine in the serotonergic response to
methcathinone.
Few studies have examined the effect of mephedrone on central
monoamines. In vivo microdialysis studies showed that mephedrone
rapidly increases nucleus accumbens dopamine and 5-HT levels to a
greater extent than MDMA, and that release of 5-HT is also greater than
dopamine (Kehr et al. 2011; Baumann et al. 2012; Wright et al. 2012).
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This is in marked contrast to MDMA which causes a much greater release
of dopamine than 5-HT in the same region (O'Shea et al. 2005). Motbey et
al., (2012) found that acute injection or 10 daily injections of 30 mg kg-1 of
mephedrone increased striatal and hippocampal tissue dopamine levels,
but decreased 5-HT in the same regions 60 min post-injection. The
decrease in 5-HT levels may reflect the greater release of 5-HT than
dopamine.
1.3.3 Monoamine neurotoxicity
Administration of a single high dose or multiple doses of MDMA to rats
causes long term serotonergic neurotoxicity in several brain areas (Stone
et al. 1986; Battaglia et al. 1987) which is distinct from the acute initial
(<24 h) 5-HT release and begins between one and seven days post-
administration (Schmidt et al. 1987). The most severe depletions occur in
the striatum, frontal cortex and hippocampus, and coincide with decreased
binding to and uptake of radio-labelled paroxetine by SERT, as well as long
term decreases in TPH activity (O'Shea et al. 2006; Xie et al. 2006).
Amphetamine-induced damage to 5-HT neurons in rats is known to return
to normal over time with abstinence (Scanzello et al. 1993; Lew et al.
1996). This neurotoxicity is strain dependent where Dark Agouti rats are
more sensitive (single doses of 10-15 mg kg-1 cause greater than 50%
depletion of 5-HT) compared to other strains, where multiple or high doses
are required to cause the same level of 5-HT depletion (Colado et al. 1993;
Aguirre et al. 1998; O'Shea et al. 1998; Shankaran and Gudelsky 1999).
In contrast, MDMA administration causes long term dopamine depletion in
mice, without any accompanying 5-HT loss (Stone et al. 1987; Logan et al.
1988).
MDMA neurotoxicity is observed following systemic administration but not
central administration, suggesting that peripheral metabolism is required
for neurotoxic damage to occur (Paris and Cunningham 1992). The exact
mechanism of MDMA neurotoxicity is unknown, but there is a close
relationship between MDMA-induced hyperthermia and neurotoxicity
(Malberg and Seiden 1998) whereby pharmacological interventions and
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other manipulations which prevent hyperthermia, such as reduced room
temperature, also prevent neurotoxicity (Farfel and Seiden 1995; Malberg
et al. 1996; Sprague et al. 2003; Johnson and Yamamoto 2010; Granado
et al. 2011). MDMA-induced hyperthermia also promotes free radical
formation which is thought to contribute to neurotoxicity, and 5-HT
metabolism in an oxidising environment also leads to the formation of toxic
metabolites (Wrona et al. 1995; Colado et al. 1999). However, repeated
low doses of MDMA can cause long term neurotoxicity without any
coinciding hyperthermic response (O'Shea et al. 1998). MDMA may also
induce neurotoxicity by increasing intracellular monoamine
neurotransmitter release thereby increasing MAO activity which causes the
formation of H2O2which can be converted to a hydroxyl radical, resulting in
further oxidative stress-related damage (Alves et al. 2007). Furthermore,
lesioning of dopamine neurons in the brain by 6-OHDA prevents MDMA-
induced neurotoxicity while pre-treatment with the dopamine precursor L-
DOPA enhances neurotoxicity (Schmidt et al. 1990).
There is little published data on the neurotoxic effects of cathinone but
chronic administration of 100 mg kg-1 to rats does result in dopamine
depletion (Feyissa and Kelly 2008). Methcathinone is available in a racemic
mixture but is mostly consumed in the S(-) enantiomer with small amounts
of R(+)-methcathinone. Sparago et al. (1996) identified that in the mouse
both enantiomers have a neurotoxic effect on striatal dopamine with the
R(+) form producing greater depletion than the S(-) form. Similar results
were observed in the rat, where a dose of 50 mg kg-1 of either enantiomer
depleted striatal dopamine however the S(-) enantiomer was found to
cause the greatest decrease. Additionally, in the same study, while
methcathinone had no effect on 5-HT and 5-HIAA in mice, S(-)-
methcathinone depleted 5-HT and 5-HIAA in the hippocampus and cortex
of rats following 50 mg kg-1. Repeated methcathinone (4 x 30 mg kg-1) has
also been shown to cause depletion of 5-HT, dopamine and their
metabolites in the rat striatum 30 days after the last injection (Gygi et al.
1997). Importantly, neurotoxicity is not observed following methcathinone
at a dose required to produce behavioural changes, much higher doses are
needed for neurotoxicity (Gygi et al. 1996).
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The development of neurotoxicity following mephedrone administration is
more controversial. To date, one study identified neurotoxic loss of
hippocampal 5-HT seven days after 4 x 10 or 25 mg kg-1, s.c. in rats,
where loss of SERT was also reported (Hadlock et al. 2011). Subsequent
studies using repeated doing schedules (4 x 3 or 10 mg kg-1 at 2 h
intervals or 30 mg kg-1 twice daily for four days) found no neurotoxic loss
of 5-HT, dopamine or their metabolites two weeks after the final injection
(Baumann et al. 2012; den Hollander et al. 2013). Once daily injections of
7.5, 15 or 30 mg kg-1 for ten days also failed to produce any decrease in 5-
HT or dopamine levels in the striatum or hippocampus (Motbey et al.
2012). One study in mice has demonstrated dopamine and 5-HT
neurotoxicity seven days after 4 x 50 mg kg-1, s.c., but only transient
dopamine depletion (3 days post-injection) was observed after 4 x 25 mg
kg-1 (Martinez-Clemente et al. 2014). However, other studies in mice failed
to detect any mephedrone-induced neurotoxic loss of striatal dopamine
terminal integrity seven days after 4 x 40 mg kg-1 (Angoa-Perez et al.
2012) or 30 mg kg-1 twice daily for four days (den Hollander et al. 2013)
and a single i.p. injection of mephedrone (20 mg kg-1) also fails to produce
hippocampal 5-HT depletions two days after administration (Angoa-Perez
et al. 2014).
1.4 Preclinical studies
1.4.1 Locomotor effects and stereotypical behaviour
The serotonin syndrome includes various behaviours associated with 5-HT
releasing compounds, such as hyperactivity, head weaving, piloerection,
protrusion of the eye, fore-paw treading, salivation, defecation, penile
erection and ejaculation. MDMA produces dose-dependent hyperactivity
along with the other symptoms of the serotonin syndrome (Callaway et al.
1990; Fone et al. 2002; Bull et al. 2004). It is attenuated by
administration of 5-HT re-uptake inhibitors and 5-HT receptor antagonists
(Callaway et al. 1990; Kehne et al. 1996; Bankson and Cunningham
2002), as well as by bilateral 6-OHDA lesioning of the nucleus accumbens
and dopamine receptor antagonist administration, thereby implicating both
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5-HT and dopamine in this hyperactivity (Gold et al. 1989; Ball et al. 2003;
Bubar et al. 2004). Rapid repeat injections of MDMA cause sensitisation to
the locomotor stimulant effects of this amphetamine (Rodsiri et al. 2011).
Since it is thought that cathinone has a similar pharmacological profile to
amphetamine it is not surprising that they both produce similar
stereotypical behaviours. For example, cathinone increases locomotor
activity, rearing and active sitting at low doses in rats (Glennon et al.
1987; Banjaw et al. 2003; Banjaw et al. 2005) as well as wing extension,
loss of righting reflex, distress vocalisation and flat body posture in chicks
(Bronson et al. 1995). Methcathinone also produces hyperactivity in mice
and rats (Glennon et al. 1987; Glennon et al. 1995) and is much more
potent than cathinone in producing locomotor hyperactivity in mice
(Glennon et al. 1987). These behavioural changes occur at doses much
lower than those required to produce neurotoxicity (Gygi et al. 1996).
Numerous studies have shown that mephedrone induces hyperactivity in
rodents. Considering its short plasma half-life, it is unsurprising that the
locomotor response to mephedrone is short in duration following
intraperitoneal (i.p.) injection; however a more sustained hyperactivity
profile is observed with oral dosing (Kehr et al. 2011; Martinez-Clemente
et al. 2013). Sensitisation to mephedrone-induced hyperactivity has been
observed when measured ten days after 0.5 mg kg-1 once daily for five
days or following seven daily injections of 15 mg kg-1 (Lisek et al. 2012;
Gregg et al. 2013), but not after 10 daily injections of 30 mg kg-1 (Motbey
et al. 2012).
1.4.2 Body temperature
MDMA can cause hyperthermia in humans and this is considered one of its
most harmful adverse effects. However, MDMA-induced changes in body
temperature are more complicated in rats where they depend on a number
of factors such as room temperature, whether the animals are individually
or group-housed, housing conditions (such as bedding type) and dose
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(Green et al. 2005). At normal ambient temperatures (20-22 °C) MDMA
generally causes hyperthermia (+1-2 °C), however hypothermia has been
reported in a number of studies. Typically, group housing, high ambient
temperature (>25 °C) and administration of repeated doses or a high dose
of MDMA will cause hyperthermia in rats, where as individual housing, low
ambient temperature and acute low dose of MDMA will cause hypothermia
(Gordon et al. 1991; Colado et al. 1993; Dafters 1994; Rodsiri et al.
2011). Additionally, rapid repeated dosing of MDMA causes a biphasic
temperature response where initial hypothermia is converted to
hyperthermia after the third injection (Rodsiri et al. 2011).
In rats, dopamine D1 receptors are involved in the hyperthermic response
to MDMA, while D2 receptors are involved in MDMA-induced hypothermia
0HFKDQ HW DO  *UHHQ HW DO  $FWLYDWLRQ RI Į1-adrenoceptors
causes peripheral vasoconstriction thereby reducing blood flow to prevent
KHDW ORVV ZKLOH Į2-adrenoceptor activation is involved in vasodilatation
FDXVLQJ LQFUHDVHG EORRG IORZ WR SURPRWH KHDW ORVV DQG ǃDGUHQRFHSWRU
activation in brown adipose tissue promotes heat generation. In rats,
FRPELQHG Į1 DQG ǃDGUHQRFHSWRU EORFNDGH DWWHQXDWHV 0'0$LQGXFHG
hyperthermia (Sprague et al. 2004). Where rats display a biphasic
WHPSHUDWXUH UHVSRQVH WR 0'0$ EORFNDGH RI Į2A-adrenoceptors prolongs
the initial hypothermia induced by MDMA so that the subsequent transition
to hyperthermia is not observed within 300 min post-injection (Bexis and
'RFKHUW\  ,Q PLFH DGPLQLVWUDWLRQ RI DQ Į1- or Į2A-adrenoceptor
antagonist prevents an initial MDMA-induced hyperthermia, causing a
biphasic temperature response to this amphetamine where hypothermia is
first observed followed by hyperthermia. Collectively, this evidence
suggests a role of the noradrenergic system in MDMA-induced changes to
thermoregulation.
Direct action of MDMA on 5-HT release is not involved in the temperature
response to MDMA but 5-HT receptor activation is involved in modulating
the hyperthermic response. MDMA-induced hyperthermia is closely
correlated with 5-HT neurotoxicity such that the severity of neurotoxicity is
associated with the level of hyperthermia induced where ambient room
temperatures above 26 °C (1-2 °C change in core body temperature)
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caused greater 5-HT depletion (Malberg and Seiden 1998). Equally, 5-HT
depletion by prior administration of a neurotoxic dose of MDMA causes a
disruption in thermoregulation at high ambient temperature and drugs that
protect against MDMA-induced hyperthermia also prevent 5-HT
neurotoxicity (Malberg et al. 1996; Mechan et al. 2001). Importantly,
increased room temperature does not cause 5-HT, dopamine or
noradrenaline depletion in saline treated rats.
Cathinone and methcathinone reportedly cause hyperthermia in humans
(Emerson and Cisek 1993; Kelly 2011) and mephedrone users have
reported uncontrollable changes in body temperature, with cold or blue
fingers being among the most commonly reported adverse effects
(Schifano et al. 2011; Winstock et al. 2011). Although there is limited
preclinical data available on the acute effects of these compounds, some
studies have shown cathinone- and methcathinone- induced hyperthermia
in rabbits and rats (Kalix 1980; Tariq et al. 1989; Rockhold et al. 1997).
Additionally, acute s.c. mephedrone injection causes hypothermia in rats
(Wright et al. 2012; Miller et al. 2013), while repeated injection has been
shown to cause hyperthermia at normal ambient temperature (Baumann et
al. 2012) or at a room temperature of 27 °C (Hadlock et al. 2011).
1.4.3 Cardiovascular effects
MDMA has a high affinity for adrenoceptors which regulate peripheral blood
flow by promoting vasoconstriction or dilatation. In rats, MDMA causes
tachycardia, arrhythmia and vasoconstriction, as indicated by decreased
tail temperature (Gordon et al. 1991; Badon et al. 2002) and evidence
suggests that combined adrenoceptor and 5-HT receptor actions of MDMA
are involved in the peripheral vasoconstriction effects of MDMA (McDaid
and Docherty 2001).
The cathinones elicit tachycardia in human users (section 1.4), however
there are few preclinical studies investigating the cardiovascular effects of
these compounds. Cathinone induces vasoconstriction of rabbit perfused
Chapter 1. General Introduction
21
ear artery by electrical field stimulation, as well as causing direct
vasoconstriction of guinea pig aortic rings, coronary vasoconstriction in
guinea pig isolated Langendorff hearts and coronary arteries (Broadley
2010). In rats, mephedrone also causes a dose-dependent increase in
arterial pressure and tachycardia (Meng et al. 2012; Varner et al. 2013).
7KH DUWHULDO SUHVVXUH UHVSRQVH LV DWWHQXDWHG E\ WKH QRQVHOHFWLYH Į
adrenoceptor antagonist, phentolamine, suggesting that peripheral
DFWLYDWLRQRIĮDGUHQRFHSWRUV LV LPSRUWDQW LQHOLFLWLQJWKLVUHVSRQVHZKLOH
PHSKHGURQHLQGXFHG WDFK\FDUGLD ZDV EORFNHG E\ WKH ǃ1-adrenoceptor
antagonist, atenolol (Varner et al. 2013). It is likely that mephedrone is
causing these responses by acting as a substrate at NET to release
noradrenaline from cytoplasmic stores as it causes pressor responses and
tachycardia in reserpine pre-treated rats making it unlikely that it is
eliciting its cardiovascular effects by noradrenaline release from vesicular
stores in peripheral sympathetic nerve terminals (Meng et al. 2012; Varner
et al. 2013).
1.4.4 Cognitive tests
The term cognition is used to describe the process of learning and
memory. Learning is classified as either associative (forming a connection
between two stimuli) or non-associative (by repeated exposure to a
stimulus). There are also several subtypes of memory, these being broadly
categorised as sensory, short-term (or working memory) and long-term
memory. The effect of MDMA on learning and memory in animal models is
controversial as results vary depending on the task, dose and dose
schedule used between studies. The novel object discrimination (NOD) task
utilises the rodents natural instinct to explore a novel object as an
indicator of non-spatial visual recognition memory without the need for
training or reinforcement (Ennaceur and Delacour 1988). MDMA disrupts
NOD in a dose related manner, such that single administration of 10 mg
kg-1 to mice did not alter the preference for the novel object in the choice
trial one day post-injection, whereas mice that had received repeated daily
administrations (for seven days) were unable to discriminate novel from
familiar objects (Nawata et al. 2010). NOD was impaired further when it
was measured seven days after the final repeated injection, which may be
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attributed to the long term neurotoxic effects of MDMA already discussed
(section 1.3.1.3). Assessment of NOD in rats have shown varied results
where acute MDMA administration caused either reduced exploration in the
familiarisation trial, repeated MDMA (4 x 5 mg kg-1 over 4 h on two
consecutive days, i.p.) disrupted NOD after a 15 min but not 60 min ITI,
while rapid repeated MDMA (3 x 5.6 mg kg-1 over 4 h, i.p.) disrupts NOD
14 days post-injection (Morley et al. 2001; Camarasa et al. 2008; Rodsiri
et al. 2011). In contrast, there is conclusive evidence that both acute and
repeated MDMA administration disrupts spatial visual recognition memory
in water maze tasks (Camarasa et al. 2008; Skelton et al. 2008; Vorhees
et al. 2009).
There are few studies investigating the effects of the cathinones on
cognition. Acute mephedrone improves visual spatial memory and learning,
but not spatial working memory in rhesus macaques (Wright et al. 2012).
Mephedrone also disrupts NOD 36 days following once daily administration
of 30 mg kg-1 to rats for 10 days (Motbey et al. 2012). Additionally, the
same dose administered twice daily to mice over four days reduces
working memory on the T-maze when measured three weeks post-
administration (den Hollander et al. 2013), but there was no effect on
spatial visual recognition memory (as measured by the Morris water maze
task) in the same animals five weeks after the final mephedrone injection.
Pre-pulse inhibition of acoustic startle (PPI) is a behavioural test which
uses sound as the startling stimulus to measure sensorimotor gating.
Acute MDMA injection reduces auditory and visual PPI in rats (Kehne et al.
1996; Vollenweider et al. 1999). In contrast, repeated administration of
cathinone reduces PPI in rats at a dose of 1.5 mg kg-1, but acute cathinone
has no affect on PPI (Banjaw et al. 2005).
1.4.5 Anxiety behaviour
The elevated plus maze is used to assess anxiety-related behaviour in
rodents where time spent in the more aversive open arms, the number of
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head dips over the side of the open arms and stretch attends are used as
indicators of anxiety-related behaviour (Pellow et al. 1985). MDMA causes
a dose-related decrease in elevated plus maze behaviours (Ho et al. 2004)
where administration of low to medium doses (<10 mg kg-1) cause
increased avoidance of the open arms and reduced exploratory head dips,
but this effect is less marked with higher doses. Previous repeated
exposure to MDMA (4 x 5 mg kg-1 on two consecutive days) followed by
eight weeks of abstinence did not have any effect on anxiety related
behaviour (Bull et al. 2004). Repeated mephedrone administration does
not cause any change in anxiety-related behaviour when rats were tested
11 days after the last of ten injections of 30 mg kg-1, or 14 days following
twice daily injections of 30 mg kg-1 for four days (Motbey et al. 2012; den
Hollander et al. 2013). The effects of cathinone and methcathinone on
elevated plus maze behaviour have not been evaluated.
1.4.6 Drug discrimination studies
In drug discrimination studies, subjects are typically trained to distinguish
a particular dose of a rewarding drug from non-rewarding vehicle (most
common), a different dose of the same drug or a different training drug
using a two-lever operant chamber (Glennon et al. 1983; Young 2009).
MDMA substitutes for cathinone and amphetamine in rats but
amphetamine does not substitute for MDMA in rats trained to discriminate
MDMA from saline (Schechter 1987; Oberlender and Nichols 1988;
Glennon 1991). Additionally, MDMA partially substitutes for cocaine
(Broadbent et al. 1989). It has also been demonstrated that
methcathinone elicits amphetamine lever responding in rats, at a dose of
0.5-1.0mg kg-1, and cocaine lever responding in rats, at doses of 0.25-
0.75 mg kg-1 (Schechter, 1997; Young and Glennon, 1993; Glennon et al,
1987). Baboons that were previously treated to self-inject cocaine were
also observed to frequently self-inject methcathinone (Kaminski and
Griffiths, 1994).
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1.5 Effects in humans
MDMA has a range of desirable effects in users including euphoria and
empathy, but these can be accompanied by adverse effects such as
tachycardia, nausea, tremors, jaw clenching, insomnia, numbness, anxiety,
fear, paranoia, headache and uncomfortable changes in body temperature
(Baylen and Rosenberg 2006). Severe hyperthermia is considered among
the most harmful adverse effects of MDMA as it is the most frequent and
can cause other problems to arise such as dehydration, the breakdown of
muscle fibres and increased water consumption which can lead to water
intoxication and death (Chadwick et al. 1991; Campkin and Davies 1992;
Kalant 2001; Hall and Henry 2006). Studies investigating the role of
different neurotransmitter systems on the effects of MDMA in humans have
suggested that the overall psychological effects of MDMA, such as positive
mood, thought disturbances, self-confidence and reduced control over
thought and body are related to 5-HT release, while the euphoric effects
may be partially related to dopamine (Liechti and Vollenweider 2001). In
these studies the subjective effects of MDMA began 30-60 min post-
administration and last for approximately 3.5 h.
Frequent MDMA use is associated with the development of tolerance, with
several studies indicating a decline in effect with increased use, as well as
an increase in dosing amongst users (Parrott 2002). MDMA can cause
impairment on word list learning of one or two words out of a total of 20
words, which is similar to that observed in a person who has a blood
alcohol concentration of 80mg 100ml-1 (the maximum legal level for
driving; ACMD, 2008). Users of mephedrone have claimed that it is similar
to MDMA in its capability to produce feelings of euphoria and empathy;
however, recent reports from emergency rooms and individuals have
revealed that mephedrone may be similar to MDMA in its adverse effects
also. However, care must be taken in interpreting these user reports as
MDMA and mephedrone can be mis-sold as each other or different
compounds. For a comparison of some of the reported clinical effects of
mephedrone, MDMA, cathinone and methcathinone see Tables 1.2 and 1.3.
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Table 1.2 Comparison of the desired effects of the cathinones and
MDMA.
Reported effects MDMA Mephedrone Cathinone Methcathinone
Euphoria 9 9 9
Increased energy 9 9 9
Increased alertness 9 9 9
Excitation 9 9
Increased sociability 9 9
Calm 9
Sexual arousal 9 9
Analgesia 9
Sharpened senses 9
Data taken from Feyissa and Kelly, (2008); Kalant, (2001); Kelly, (2011);
Newcombe, (2009); Emersen and Cisek, (1993).
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Table 1.3 Comparison of the adverse effects of the cathinones and MDMA.
Reported effects MDMA Mephedrone Cathinone Methcathinone
Bruxism 9 9 9
Temperature changes 9 9 9 9
Fatigue 9
Tachycardia 9 9 9 9
Hypertension 9 9
Cold/blue Fingers 9
Sweating 9 9
Dry mouth 9 9 9
Nausea/vomiting 9 9 9
Difficulty urinating 9
Headache 9 9 9
Muscle ache 9
Dizziness 9 9 9
Numbness/tingling 9 9
Tremors 9 9 9
Agitation 9 9 9 9
Confusion 9 9
Cognitive impairment 9 9 9
Insomnia 9 9 9 9
Changes in appetite 9 9 9 9
Anxiety 9 9 9 9
Anhedonia 9 9 9
Fear/paranoia 9 9 9 9
Hallucinations 9 9 9 9
Skin rash 9
Blurred vision 9 9
Nose/throat bleeds 9
Data taken from Baylan and Rosenberg (2006); Cox and Rampes (2003); Dargan
et al. (2010); Freeman et al. (2012), Feyissa and Kelly (2008); Kalant (2001);
Kelly (2011); Newcombe (2009); Emersen and Cisek (1993).
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Although little is known about the long term toxic effects of mephedrone,
adverse events, such as, headaches, nausea/vomiting, nose bleeds,
tachycardia, hypertension, seizures and uncomfortable changes in body
temperature (sweating, cold/blue fingers), amongst others, have been
reported in mephedrone users and in the UK it has been implicated as
cause of death of a number of young people (ACMD 2010). For some of
these individuals it is difficult to infer that mephedrone is the sole cause of
death, as toxicological tests have found other stimulants, such as cocaine,
post-mortem suggesting that the cause of death may have been polydrug
toxicity (Gerace et al. 2014). Corkery et al. (2012) compiled available data
on suspected mephedrone-related deaths in the UK up until August 2011.
Of the 125 deaths reported to be as a result of mephedrone use, 87 have
tested positive for mephedrone post-mortem, and 13 were awaiting
toxicological confirmation at the time of publication. Mephedrone toxicity
was mentioned as cause of death in 24 of these cases, and polydrug
toxicity in a further ten cases. Therefore studies are needed that will
provide evidence as to the direct effects of mephedrone on
neurotransmitter systems as well as its physiological and behavioural
effects.
1.6 Experimental approach
Due to its substantial media attention, implication in a number of deaths in
the UK in recent years and limited published pharmacological data,
mephedrone is the main focus of the work presented in this thesis. At the
commencement of this research there were no published data on the
effects of mephedrone in preclinical animal models, or on its mechanisms
of action or adverse effects. Therefore, due to the reported subjective
similarity of mephedrone to MDMA by users and the similar chemical
structure to cathinones, initial studies compared the effect of mephedrone
to that of these amphetamines in the rat. The known effect of MDMA in the
rat was used as a source of reference to design experiments and select
drug doses in these studies.
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Animal models are an important asset in studying the effects of
recreational drugs as the high risk of toxicity limits the ability of
researchers to study the effects of these drugs in humans. Both mice and
rats are commonly used in such studies. Rats were used in the current set
of studies as their neurochemical response to MDMA more closely
resembles that observed in humans, compared to mice. There are a
number of different rat strains used to assess the behavioural and
neurochemical effects of MDMA. In the current study, Lister hooded rats
were chosen as they have better eyesight than albino strains for NOD
studies and were therefore used in all studies for consistency and
comparison with selected previous studies with MDMA (Rodsiri et al. 2011).
Given the differences in the pharmacokinetic profile of MDMA in humans
and rats (as discussed in section 1.2), it is important to select doses used
in preclinical models that are of translational value to recreationally
relevant doses. A dose of 4 mg kg-1 of MDMA in the rat is comparable with
a user taking approximately one ecstasy tablet containing 70 mg of MDMA
(Green et al. 2012). However, the half-life of MDMA is much shorter in rats
than in humans, so a higher dose of 10 mg kg-1 was also administered to
provide a longer duration of action of MDMA (Baumann et al. 2009). Using
allometric scaling, this dose would equate to a human taking
approximately 455 mg of MDMA. While caution should be taken in
extrapolating animal data to humans, the work presented in this thesis can
be used as a starting point for further human-based research.
Changes in body temperature are amongst the more harmful adverse
effects of MDMA and, in rats, these changes are sensitive to environmental
variations (section 1.5.1.2). Therefore, the studies presented in Chapter 2
investigated the effects of mephedrone, cathinone and methcathinone on
rectal and tail temperature in individually housed rats in comparison to
MDMA. Ex vivo tissue monoamine levels in the striatum, hippocampus and
frontal cortex were also measured at the end of recording as MDMA is
known to cause monoamine release in these regions. Ex vivo tissue
monoamine levels in the hypothalamus were also examined due to its role
in temperature regulation. To further compare mephedrone and MDMA,
these parameters were also measured in group housed rats. To decipher
the mechanism of action of mephedrone-induced temperature changes, the
effects of dopamine and noradrenaline antagonist pre-treatments were
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also measured, as well as plasma noradrenaline and adrenaline levels after
mephedrone injection to get an index of any sympathomimetic actions.
In Chapter 3, the effects of chronic intermittent mephedrone on behaviour
were investigated, in comparison to MDMA and cathinone. MDMA causes
hyperactivity, changes in cognition and sensorimotor gating, as well as
long term neurotransmitter changes (sections 1.3 and 1.5). Therefore
locomotor activity (LMA), NOD, conditioned emotional response (CER),
prepulse inhibition to acoustic startle response were assessed, as well as
ex vivo monoamine levels in specific brain regions seven days post-
injection. Locomotor activity was assessed twice, once at the start of the
study (day one) and again at the end of the study (day 16) to evaluate any
drug-induced locomotor sensitisation.
In the NOD task the rat explores two identical objects in the first,
familiarisation trial, followed by an inter trial interval (ITI) after which the
rat is re-exposed to one of the familiar object and one novel object in the
choice trial. The ability of the rat to distinguish novel from familiar objects
is sensitive to pharmacological intervention and influenced by the length of
the ITI. As previously discussed, MDMA disrupts NOD in a dose related
manner (section 1.5.1.4). The CER task is a measurement of amygdala
and hippocampal dependent associative memory. This task pairs an
unconditioned stimulus (footshock) with a conditioned stimulus (context,
light or tone), such that re-exposure to the non-aversive conditioned
stimulus in the absence of the unconditioned stimulus will evoke a freezing
behaviour that can be measured as an index of memory. Finally, pre-pulse
inhibition refers to the decrease in the response to a startling stimulus
when another weak stimulus precedes it closely in time. PPI is a
measurement of sensorimotor gating (the brains ability to modulate its
sensitivity to incoming sensory stimuli) which is known to be inhibited in a
number of disorders such as schizophrenia and autism, as well as in
amphetamine users. These tasks were chosen as they can be performed
without prior training and are known to be disrupted by MDMA
administration.
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Mephedrone users are likely to have previously taken MDMA and caffeine is
known to exacerbate MDMA toxicity and is often taken concomitantly with
other psychostimulants (Brandt et al. 2010; Carhart-Harris et al. 2011;
Vanattou-Saifoudine et al. 2012; Rosenauer et al. 2013). Therefore,
Chapter 4 investigated the effects of MDMA pre-treatment or concomitant
caffeine administration on chronic intermittent mephedrone administration.
A preliminary dose-response study was conducted where rats received 10
or 30 mg kg-1 of mephedrone and LMA was recorded for 60 min, at the end
of which a single rectal temperature recording was made. This was
conducted to ensure the selection of a submaximal mephedrone dose in
subsequent studies. In the following two studies presented in this chapter,
rats received pre-treatment of MDMA or concomitant caffeine
administration and again locomotor activity, novel object discrimination,
rectal and tail temperature, prepulse inhibition to acoustic startle response
and ex vivo monoamine levels in specific brain regions were evaluated, in
addition to assessment of anxiety-related behaviour on the elevated plus
maze. The elevated plus maze is used to assess anxiety-related behaviour
in rodents where time spent in the open arms, the number of head dips
over the side of the open arms and stretch attends are used as indicators
of anxiety-related behaviour (Pellow et al. 1985). Anxiogenic drugs
enhance avoidance of the open arms, reduced number of head dips and
stretch attends, while anxiolytic drugs cause the opposite of these
behaviours.
Rapid repeated dosing of MDMA causes locomotor sensitisation as well as
converting MDMA-induced hypothermia into a hyperthermic response
(Rodsiri et al. 2011). Therefore, Chapter 5 investigated the effects of rapid
repeat injection of mephedrone on locomotor activity and core body
temperature, as measured by radiotelemetry, and used in vivo
microdialysis to examine the effect of the same dosing schedule on
dopamine levels within the striatum. To further determine the role of 5-HT
and dopamine in the hyperlocomotor and hypothermic response to
mephedrone, bilateral intracerebroventricular (i.c.v.) injections of 5,7-
dihydroxytrptamine (5,7-DHT) and 6-OHDA to deplete brain 5-HT and
dopamine, respectively, were administered to rats with radiotelemetry
implants for continual recording of locomotion and body temperature. In a
final study rats were pre-treated with 5-HT1A and 5-HT7 antagonists to
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determine the role of these receptors in mephedrone-induced changes in
rectal and tail temperature.
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Chapter 2 Acute effects of the cathinones and
MDMA on body temperature and
neurochemistry
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2.1 Introduction
Severe hyperthermia is considered among the most harmful adverse
effects of recreational MDMA use as it can lead to potentially fatal
complications such as rhabdomyolysis, renal and liver failure and
myoglobinuria (see Docherty and Green, 2010). MDMA-induced changes in
body temperature are more complicated in rats and appear to depend on a
number of factors such as room temperature, whether rats are individually
or group-housed, housing conditions (such as sawdust on the floor) and
dose (Green et al. 2005). Typically, with group housing, high ambient
temperature (>25 °C) and/or administration of high or repeated doses of
MDMA tend to produce hyperthermia in rats, where as individual housing,
low ambient temperature and acute low dose of MDMA result in
hypothermia (Gordon et al. 1991; Colado et al. 1993; Dafters 1994;
Rodsiri et al. 2011).
Cathinone and methcathinone reportedly cause hyperthermia in humans
(Emerson and Cisek 1993; Kelly 2011) and mephedrone users have
reported uncomfortable changes in body temperature, with cold or blue
fingers being amongst the most commonly reported adverse effects
(Schifano et al. 2011; Winstock et al. 2011). Although there is limited
preclinical data available on the acute effects of these compounds, some
studies have shown cathinone- and methcathinone-induced hyperthermia
in rabbits and rats (Kalix 1980; Tariq et al. 1989; Rockhold et al. 1997).
Additionally, acute mephedrone injection causes hypothermia in rats
(Wright et al. 2012; Miller et al. 2013), while repeated injection at 2 h
intervals over 4 or 6 h has been shown to cause hyperthermia at both
normal (Baumann et al. 2012) and elevated (27 °C) ambient room
temperature (Hadlock et al. 2011).
In the first study in this chapter, in order to examine the potential
similarities or differences between the cathinones and MDMA, rats received
a single intraperitoneal (i.p.) injection of MDMA, mephedrone, cathinone or
methcathinone at doses of 4 or 10 mg kg-1with measurement of rectal and
tail temperature for 2 h post-injection. Rectal temperature was measured
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to monitor core body temperature and tail temperature was measured as
an indication of changes in peripheral heat loss or conservation. At the
time this study was performed there was very little comparative
pharmacokinetic information mephedrone in rats and humans, and since
the cathinones used in this study have similar molecular weights, the
selected doses were based in part on doses relevant to those taken by
MDMA users. A dose of 4 mg kg-1 of MDMA in the rat produces comparable
plasma levels to those seen in a user taking approximately 70 mg of MDMA
(Green et al. 2012). However, the half-life of MDMA is much shorter in rats
than in humans, so a higher dose of 10 mg kg-1 was also included to
provide a longer duration of action in the rat (Baumann et al. 2009). Using
allometric scaling, this dose would equate to a human taking
approximately 455 mg of MDMA.
In the rat, tissue levels of 5-HT are typically lowered in the first few hours
following MDMA administration, while dopamine levels are raised (see
section 1.3.1). In the current study, ex vivo tissue levels of dopamine, 5-
HT and their metabolites were measured in the frontal cortex,
hippocampus, striatum and hypothalamus 2 h post-injection by HPLC-ED
since MDMA is a potent releaser of these monoamines in the selected
regions and the hypothalamus in particular is an important brain region for
regulating body temperature (Colado and Green 1994; Gudelsky and Nash
1996; Mechan et al. 2002).
As mephedrone is the most common synthetic cathinone to be taken by
users it became the focus of further temperature studies. In the second
study, the possible mechanisms of action for mephedrone-induced body
temperature changes were investigated by pre-treating rats with
compounds known to alter the temperature response to MDMA. In rats,
MDMA-induced hyperthermia is completely abolished by the D1 dopamine
receptor antagonist SCH 23390 (2 mg kg-1 DQG DWWHQXDWHG E\ WKH Į1-
adrenoceptor antagonist Prazosin (0.2 mg kg-1) (Mechan et al. 2002;
Sprague et al. 2003). MDMA-induced hypothermia in rats is blocked by the
D2 dopamine receptor antagonist remoxipride (Green et al. 2005), and
SURORQJHG E\ WKH Į2-adrenoceptor antagonist BRL 44408 (1 mg kg-1),
(Bexis and Docherty 2006). Plasma catecholamine levels were also
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measured at the end of this experiment as an indication of the effects of
mephedrone on the sympathetic nervous system regulation of peripheral
vascular tone and adrenal medullary function which could influence
thermoregulation.
The final study in this chapter investigated the effect of group housing on
mephedrone-induced changes in rectal and tail temperature (again with
measurement of plasma catecholamines 2 h post-injection) since group
housing is known to exacerbate MDMA-induced hyperthermia and convert
MDMA-induced hypothermia to hyperthermia (Docherty and Green 2010),
and since these compounds (particularly mephedrone and MDMA) are more
likely to be taken in crowded environments. Since the predominant effect
of mephedrone in rats is hypothermia, this study was conducted to
examine whether mephedrone would increase body temperature in
conditions more similar to recreational users (i.e. crowded night clubs).
The temperature response to mephedrone in increased ambient
temperature conditions was not examined as studies have shown that
increased ambient temperature fails to produce hyperthermia in response
to mephedrone (Wright et al. 2012; Miller et al. 2013).
2.2 Aims
The aims of this set of experiments were to:
(1) compare the effects of cathinone, methcathinone and mephedrone on
rectal and tail temperature and ex vivo brain tissue monoamine levels to
those of MDMA in individually-housed rats;
FKDUDFWHULVHWKHUROHRIĮ1- DQGĮ2- adrenoceptors and dopamine D1 and
D2 receptors in mephedrone-induced changes in rectal temperature and
plasma catecholamine levels;
(3) identify the effect of group housing on mephedrone-induced changes in
rectal temperature and plasma catecholamine levels.
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2.3 Materials & Methods
2.3.1 Animals
All experiments used experimentally naïve adult male Lister hooded rats
(190-390 g) obtained from Charles River UK or University of Nottingham
BioSupport Unit (BSU). Rats were housed in groups of 3-4 on a 12 h light-
dark cycle (lights on at 07.00 h) in wire top cages (56 x 38 x 22 cm) lined
with sawdust, and with cardboard tubes and wooden blocks for
HQYLURQPHQWDO HQULFKPHQW $PELHQW WHPSHUDWXUH Û& DQG UHODWLYH
humidity 55±10% were constant and food (Beekay rat and mouse diet, B
& K Universal Ltd, UK) and water were freely available. All temperature
experiments were conducted during the light phase between 09.00 and
14.00 h. Rats were assigned to treatment groups in a pseudorandom
order, while ensuring that weight distribution between groups was even.
The doses of all drugs used were selected to comply with the three Rs of
humane animal testing and by reference to previous publications. All
experiments were conducted in accordance with the Animals (Scientific
Procedures) Act, 1986, and ARRIVE guidelines with approval from the
University of Nottingham Local Ethical Committee.
2.3.2 Drugs
(-)-cathinone HCl, (±)-methcathinone HCl, (±)-3,4-
methylenedioxymethamphetamine HCl (MDMA), prazosin HCl and SCH
23390 HCl were purchased from Sigma Aldrich (UK). (±)-mephedrone HCl
was obtained from Ascent Scientific (UK) and BRL 44408 maleate was
purchased from Tocris Bioscience (UK). L-741,626 was a gift from Institut
de Reserches Servier (France). Cathinone, methcathinone, mephedrone
and MDMA were dissolved in 0.154 M saline vehicle. All other compounds
were dissolved in lactic acid and saline then adjusted to pH 6.5 with
sodium hydroxide.
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2.3.3 Study 1: Effect of the cathinones and MDMA on rectal and
tail temperature, and neurochemistry in individually-
housed rats
2.3.3.1 Temperature recording
Rats (n=6 per treatment group) were placed in individual Perspex arenas
(39 x 23.5 x 24.5 cm) with wire mesh lids. An initial temperature recording
was measured at -40 min to allow for acclimatisation to the procedure and
prevent a stress-induced hyperthermic response that would confound data.
A rectal probe (Portec Instrumentation, UK) was inserted approximately
6.5 cm, after allowing any visible faeces to pass out of the rectum. While
measuring temperature, rats were gently held by the base of the tail to
raise their back legs while ensuring that the front paws were still in contact
with the arena floor. Tail temperature was measured by briefly placing a
MicroFlo DSP Digital Laser Perfusion Monitor (Oxford Optronix, UK) against
the base of the tail. Rectal and tail temperature devices were allowed to
stabilise for approximately 20 s before recording temperature. Forty min
after the habituation recording, baseline temperatures were taken and rats
received a single i.p. injection of saline vehicle (1 ml kg-1), cathinone,
methcathinone, mephedrone or MDMA (4, 10 mg kg-1). Temperatures were
measured at 20 min intervals for the following 2 h. Temperature
measurements for low and high doses were performed on different days
for all compounds except cathinone.
2.3.3.2 Tissue collection and neurochemical detection by HPLC-ED
Rats were killed 2 h post-injection by concussion and immediate
decapitation. Brains were rapidly removed for dissection of hypothalamus
DQG ULJKW IURQWDO FRUWH[ KLSSRFDPSXV DQG VWULDWXP DW  Û& RQ D
refrigerated table (BC72: Osborne refrigeration, UK). Tissue was snap
IUR]HQ LQ OLTXLG QLWURJHQ DQG VWRUHG DW  Û& XQWLO DQDO\VLV E\ KLJK
performance liquid chromatography with electrochemical detection (HPLC-
ED) to measure levels of 5-HT, dopamine and their major metabolites.
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HPLC-ED was performed according to previous methods (King et al. 2009).
In summary, samples were sonicated for approximately 30 s in 800 µl of
0.05 M perchloric acid (PCA) containing 1 µM sodium metabisulfite then
centrifuged at 17500 g at 4 °C for 20 min and the supernatant was filtered
through a 0.45 µm syringe tip filter (Kinesis Ltd, UK). All samples were
LQMHFWHGDWDYROXPHRIǋORQWRD7$5*$&0FROXPQ[
mm, Phenomenex) using a Perkin Elmer AS200 autosampler. Mobile phase
consisting of 50 mM citric acid, 50 mM phosphoric acid, 0.1 mM
ethylenediaminetetraacetic acid (EDTA), 8 mM potassium chloride, 0.15
mM octanesulfonic acid and 10 % methanol (pH 3.8-4) was circulated
through the system at a flow rate of 0.2 ml min-1 via an Ultimate 3000
pump (Dionex) at a constant pressure of 1200 psi. Analytes were detected
using an Antec VT-03 cell with a glassy carbon 2 mm working electrode set
to 0.59 V with an in situ Ag/AgCl ISAAC reference electrode.
Mixed standards solutions were prepared daily from a stock solution (1 x
10-4 M) and diluted with 0.05 M PCA to concentrations of 1 x 10-8, 1 x 10-7
and 2 x 10-7 M. Standards were injected at the start of each day and then
after every 12 samples (see Fig 2.1 for example calibration curves).
Quantification was performed using Galaxie chromatography workstation, v
1.8 against standards.
Figure 2.1 Illust
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2.3.4 6WXG\(IIHFWRIĮ1DQGĮ2- adrenoceptor antagonists,
and dopamine D1 and D2 receptor antagonists on
mephedrone-induced changes in rectal temperature, and
plasma catecholamine levels in individually-housed rats
2.3.4.1 Temperature recording
Rats (n=6-7 per treatment group) were placed in the same arenas as
described in section 2.3.3.1 and habituated to the rectal temperature
measurement 40 min prior to the start of the experiment. They then
received i.p. saline vehicle (1 ml kg-1), prazosin HCl (0.2 mg kg-1), BRL
44408 maleate (1 mg kg-1), SCH 23390 HCl (2 mg kg-1) or L-741,626
(0.63 mg kg-1), followed 30 min later by i.p. vehicle (1 ml kg-1) or
mephedrone HCl (10 mg kg-1). Rectal temperature was measured
immediately prior to each injection and then at 20 min intervals for 2 h
following vehicle mephedrone injections, as described in section 2.3.3.1.
2.3.4.2 Plasma collection and catecholamine measurements by HPLC-
ED
Using a schedule 1 procedure, rats were killed by concussion and
immediate decapitation 2 h post-injection. Mixed arteriovenous trunk blood
was immediately collected into lithium heparin Vacutainer blood collection
WXEHV%'GLDJQRVWLFV8.FRQWDLQLQJǋORIP0(*7$DQGP0
glutathione per ml of whole blood. Samples were centrifuged at 1000 x g
for 5 min (Centaur 2: MSE Scientific Instruments, UK) and the plasma was
removed, stored on ice and then at -80 °C.
Extraction and analysis were adapted from methods by Forster and
MacDonald (1999). Plasma was thawed, mixed and centrifuged (1000 x g
IRU PLQ DV SUHYLRXVO\ WKHQ ǋO RI VDPSOHZDV DGGHG WR  ǋO RI
ǋ0GLK\GUR[\EHQ[\ODPLQH+&OLQWHUQDOVWDQGDUG6LJPD$OGULFK
7KLV ZDV IROORZHG E\ WKH DGGLWLRQ RI  ǋO DPPRQLD EXIIHU  0
ammonium chloride adjusted to pH 8.8 with 2 M ammonium hydroxide,
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and containing 22 mM diphenylboric acid ethanolamine complex 13 mM
disodium EDTA) and 1 ml heptanes mixture (heptane containing 6 mM
tetraoctylammonium bromide and 1 % v/v octanol). This resulted in a two-
layer mixture which was centrifuged again at 1000 x g for 5 min. A volume
RIǋOZDVUHPRYHGIURPWKHRUJDQLFWRSOD\HUWRZKLFKǋORFWDQ
RODQGǋOP0DFHWLFDFLGZHUHDGGHG7KHVDPSOHZDVYRUWH[HG
for 3 min (Mulit Tube Vortex Mixer: Labnet International, USA) and then
FHQWULIXJHGDVSUHYLRXVO\ǋOZDVUHPRYHGIURPWKHDFLGGURSOHWDW
the base of the tube and stored at -80 ° C. Samples were injected into a
+\SHUFORQH &  ǋ0 FROXPQ  [  PP 3KHQRPHQH[ 8. DQG
detected at a potential of +0.65 V by an Antec VT-03 cell with a glassy
carbon 2 mm working electrode set to 0.65 V with an in situ Ag/AgCl
reference electrode.
7KHPRELOHSKDVHFRQVLVWHGRIP0VRGLXPDFHWDWHǋ0GLVRGLXP
('7$ǋ0VRGLXPGRGHF\OVXOSKDWHDQGPHWKDQRODGMXVWHGWR
pH 5.2 with glacial acetic acid. Quantification was achieved manually
(ChromJet Integrator: Thermo Separation Products, Waltham, MA, USA)
using the internal standard to establish recovery. The mean ± SEM
recovery was 80 ± 1 % and the estimated limit of detection for
noradrenaline and adrenaline was 1.2-1.4 nmol L-1.
2.3.5 Study 3: Effect of mephedrone on rectal and tail
temperature, and plasma catecholamine levels in group-
housed rats
2.3.5.1 Temperature recording
Rectal and tail temperatures were recorded as described in section 2.3.3.1,
except rats remained within their home cages in groups of three
throughout the procedure. Cages contained sawdust bedding as described
in section 2.3.1, but environmental enrichment was removed and the
cages were placed in a separate procedure room for the duration of the
experiment. Rats (n=6 per treatment group) received a single i.p. injection
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of saline vehicle (1 ml kg-1) or mephedrone (10 mg kg-1). All rats within a
cage received the same treatment.
2.3.5.2 Plasma collection and measurement of catecholamine levels by
HPLC-ED
Using a schedule 1 procedure, rats were killed by concussion and
immediate decapitation 2 h post-injection. Plasma was collected and
catecholamine levels were measured as described in section 2.3.4.2.
2.3.6 Statistical analysis
All statistical analyses were performed using GraphPad Prism v 6.02 and
SPSS v 21 software. All data were checked for normality and homogeneity
of variance using Shapiro-Wilks and Levenes test, respectively. All
temperature and plasma catecholamine data displayed normality and
homogeneity of variance. All temperature data is presented as change
from baseline (t=0 min), and statistical analyses were conducted on
change from baseline, not absolute temperature. In study two, antagonists
were administered at t=-30 min.
For studies one and three, which involved a single drug or vehicle injection,
temperature data were analysed by two-way repeated analysis of variance
(ANOVA) with treatment and time as between- and within- group factors,
respectively and Bonferroni post-hoc where appropriate. The low and high
doses of MDMA, mephedrone and methcathinone were administered on
separate test days and since there were no between- group differences the
vehicle data from each day have been pooled for clarity of presentation,
however all statistical comparisons relate to the original vehicle control
group on the same test day not the pooled data. Brain tissue monoamine
levels and plasma catecholamine levels were analysed by one-way ANOVA
with Bonferroni post-hoc test (homogeneous variance between groups) or
Tamhanes post-hoc test (heterogeneous variance between groups) where
appropriate. Analysis was applied separately to each neurotransmitter or
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metabolite in each brain region. There was no between-group difference in
vehicle data (one-way ANOVA) so for clarity of presentation, vehicle data
for each region have been pooled but all statistical comparisons relate to
the relevant vehicle control group.
Temperature data from study two, which involved two separate drug or
vehicle injections, were analysed by three-way repeated measures ANOVA
with pre-treatment (antagonist) and challenge (mephedrone) injection as
between-group factors and time as the within-group factor. Plasma
catecholamine levels from study three were analysed by two-way ANOVA
with pre-treatment (antagonist) and challenge (mephedrone) injection as
between-group factors. Bonferroni multiple comparisons post-hoc test was
performed where appropriate. All data are presented as mean ± SEM and
p<0.05 was considered significant.
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2.4 Results
2.4.1 Effect of the cathinones and MDMA on rectal and tail
temperature, and neurochemistry in individually-housed
rats
There were no significant between-group differences in basal rectal or tail
temperature immediately prior to injection, which were 40.4 ± 0.03 °C
(mean ± SEM) and 29.7 ± 0.2 °C, respectively.
2.4.1.1 Rectal and tail temperature changes post-injection
MDMA and mephedrone (Fig 2.2A,B) reduced rectal temperature compared
to vehicle such that there were significant main effects of treatment (4 mg
kg-1: F(3,20)=24.34, p<0.001; 10 mg kg
-1: F(2,15)=32.50, p<0.001) and time
(4 mg kg-1: F(6,120)=20.02, p<0.001; 10 mg kg
-1: F(6,90)=30.87, p<0.001)
as well as a significant treatment x time interaction (4 mg kg-1:
F(18,120)=13.23, p<0.001; 10 mg kg
-1: F(12,90)=19.58, p<0.001). Both doses
of MDMA caused sustained hypothermia that was present for the duration
of testing and in the case of the high dose did not return to baseline levels
within the 120 min monitoring period. Mephedrone caused a transient
decrease in rectal temperature at 20 min following 4 mg kg-1 and from 20-
40 min post-injection for the 10 mg kg-1 dose.
Cathinone (10 mg kg-1, Fig 2.2E) caused a marked increase in rectal
temperature from 40-80 min post-injection, such that there were
significant main effects of treatment (F(2,15)=8.73, p<0.01), time
(F(6,90)=9.59, p<0.001) and a treatment x time interaction (F(12,90)=7.62,
p<0.001). Treatment with 4 mg kg-1 of cathinone had no significant effect
on rectal temperature. Similarly, methcathinone (Fig 2.2G) administered at
a dose of 10 mg kg-1 also caused an elevation in rectal temperature from
40-120 min (treatment: F(1,10)=18.46, p<0.01; time: F(6,60)=4.01, p<0.01;
treatment x time interaction: F(6,60)=9.44, p<0.001), but 4 mg kg
-1 had no
effect on rectal temperature.
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MDMA and mephedrone caused a significant decrease in tail temperature
from 40-60 min post-injection for MDMA, and from 60-80 and 120 min
post-injection for mephedrone (treatment: F(2,15)=10.29, p<0.01; time:
F(6,90)=3.16, p<0.01; treatment x time interaction: F(12,90)=4.00, p<0.001).
Methcathinone (10 mg kg-1) had no significant effect on tail temperature
(treatment: F(1,10)=1.029, p>0.05; time: F(6,60)=1.12, p>0.05; treatment x
time interaction: F(6,60)=0.92, p>0.05). Cathinone had no significant effect
on tail temperature at either dose (treatment: F(2,15)=2.43, p>0.05; time:
F(6,90)=1.98, p>0.05; treatment x time interaction: F(12,90)=1.55, p>0.05).
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Figure 2.2 Effects of acute MDMA, mephedrone, cathinone or
methcathinone on rectal and tail temperature.
Adult male Lister hooded rats (n=5-6 per treatment group) received a single i.p.
injection of saline vehicle (1 ml kg-1) or (A, E) 4 or 10 mg kg-1 of MDMA, (B, F)
mephedrone (meph), cathinone (cath; C, G) or methcathinone (methcath; D, H) at
0 min and (A, B, C, D) rectal and (E, F, G, H) tail temperatures were assessed for
the following 2 h. Data are expressed as temperature change (°C, mean ± SEM)
from baseline temperature (0 min). In cases where different dose levels were
administered on different test days vehicle data for each compound have been
pooled for clarity of presentation, after first confirming no significant difference
between each vehicle group. All statistical analysis refer to the vehicle for the
relevant individual test day. ***p<0.001, **p<0.01, *p<0.05 compared to saline
vehicle, Bonferroni multiple comparisons post-hoc test following two-way repeated
measures ANOVA.
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2.4.1.2 Neurochemistry
Mephedrone had no effect on ex vivo tissue levels of dopamine, 5-HT or
their metabolites at 2 h post-injection. MDMA had no effect on ex vivo
dopamine levels 2 h post-injection but the 10 mg kg-1 dose reduced DOPAC
(F(2,14)=3.77, p<0.05, table 2.1) and HVA (F(2,14)=5.30, p<0.05) in the
striatum only. Cathinone (10 mg kg-1) increased striatal dopamine
(F(2,15)=7.87, p<0.01) while both doses of cathinone increased
hypothalamic DOPAC (F(2,15)=10.02, p<0.01). The highest dose of
methcathinone increased dopamine and HVA levels in the frontal cortex
(dopamine: F(1,10)=5.82, p<0.05; HVA: (F(1,10)=6.40, p<0.05),
hippocampus (dopamine: F(1,10)=7.63, p<0.05; HVA: (F(1,10)=11.02,
p<0.01) and striatum (dopamine: F(1,10)=4.77, p=0.05; HVA:
(F(1,10)=10.86, p<0.01).
Both doses of MDMA caused a significant reduction in hippocampal 5-HT (4
mg kg-1: F(3,20)=3.08, p=0.05; 10 mg kg
-1: F(2,14)=22.66, p<0.001, table
2.2). The highest dose of MDMA also reduced levels of 5-HIAA in the
hippocampus (F(2,14)=30.27, p<0.05), hypothalamus (F(2,15)=5.40, p<0.05)
and striatum (F(2,14)=8.48, p<0.01). In contrast the highest dose of
cathinone increased 5-HT levels in the hypothalamus (F(2,15)=5.31, p<0.05)
and both 5-HT (F(2,15)=3.69, p=0.05) and 5-HIAA (F(2,15)=13.68, p<0.001)
levels in the striatum. The highest dose of methcathinone also increased
striatal 5-HIAA levels (F(1,10)=18.31, p<0.01).
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Table 2.1 Ex vivo brain tissue dopamine, DOPAC and HVA levels.
Tissue levels (% of vehicle)
Treatment FCtx Hip Str Hyp
Dopamine
MDMA 4 93.5 ± 10 98.9 ± 9 116.4 ± 49 -
MDMA 10 177.9 ± 66 122.0 ± 9 133.4 ± 7 141.2 ± 32
Meph 4 114.4 ± 24 100.9 ± 10 88.1 ± 39 -
Meph 10 114.1 ± 19 226 ± 122 85.6 ± 10 92.2 ± 12
Cath 4 73.1 ± 10 27.3 ± 8 117.2 ± 11 94.2 ± 12
Cath 10 102.9 ± 21 33.1 ± 19 145.5 ± 5** 99.7 ± 8
Methcath 4 103.7 ± 12 99.9 ± 9 111.6 ± 47 -
Methcath 10 156.3 ± 18* 192.3 ± 28* 117.4 ± 7* 78.9 ± 7
DOPAC
MDMA 4 101.5 ± 29 97.8 ± 9 107.5 ± 17.4 -
MDMA 10 95.2 ± 33 97.7 ± 6 61.0 ± 4* 102.3 ± 27
Meph 4 93.3 ± 20 93.4 ± 7 99.7 ± 10 -
Meph 10 102.9 ± 20 173.0 ± 46 69.5 ± 9 86.5 ± 15
Cath 4 74.1 ± 10 37.8 ± 8 106.1 ± 9 78.6 ± 5*
Cath 10 80.5 ± 10 44.8 ± 21 125.3 ± 10 69.2 ± 2**
Methcath 4 71.5 ± 9 121.8 ± 11 79.9 ± 11 -
Methcath 10 130.1 ± 10 126.8 ± 16 92.0 ± 8 84.8 ± 13
HVA
MDMA 4 - - 110.8 ± 16 -
MDMA 10 174.9 ± 71 151.1 ± 43 60.9 ± 2* 93.0 ± 24
Meph 4 - - 106.2 ± 12 -
Meph 10 166.8 ± 44 225.4 ± 38 78.3 ± 16 82.6 ± 14
Cath 4 38.6 ± 11 29.9 ± 8 105.7 ± 9 67.6 ± 7
Cath 10 71.8 ± 18 56.5 ± 15 127.6 ± 14 91.8 ± 9
Methcath 4 - - 100.0 ± 14 -
Methcath 10 198.6 ± 30* 381.8 ± 73** 175.7 ± 18** 93.6 ± 14
Neurotransmitter and metabolite levels were measured 2 h after i.p. injection of
saline vehicle (1 ml kg-1), MDMA, mephedrone, cathinone or methcathinone (4 or
10 mg kg-1) to individually-housed adult male Lister hooded rats (n=5-6 per
treatment group). Data are expressed as mean percentage (± SEM) of the
dopamine, DOPAC and HVA levels in the relevant vehicle control group. Pooled
levels (pmol mg-1 tissue; mean ± SEM) of dopamine in vehicle controls were frontal
cortex (FCtx): 0.5 ± 0.08, hippocampus (Hip): 0.4 ± 0.2, striatum (Str): 45.6 ±
7.6, hypothalamus (Hyp): 4.9 ± 0.4. These values for DOPAC were FCtx: 0.3 ±
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0.07, Hip: 0.2 ± 0.07, Str: 11.4 ± 1.4, Hyp: 1.4 ± 0.1 and for HVA were FCtx: 0.9
± 0.2, Hip: 0.5 ± 0.2, Str: 7.5 ± 0.9, Hyp: 1.0 ± 0.1. Hypothalamus was not
collected in all studies. Data are presented as percent of vehicle control but
statistics were performed on the raw data. **p<0.01, *p<0.05 Bonferroni post-hoc
following one-way ANOVA.
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Table 2.2 Ex vivo brain tissue 5-HT and 5-HIAA levels.
Tissue levels (% of vehicle)
Treatment FCtx Hip Str Hyp
5-HT
MDMA 4 130.6 ± 41 91.1 ± 7* 77.1 ± 10 -
MDMA 10 72.9 ± 39 42.0 ± 4*** 85.6 ± 8 101.3 ± 24
Meph 4 149.5 ± 16 99.0 ± 14 93.3 ± 15 -
Meph 10 76.3 ± 13 99.7 ± 8 110.3 ± 9 93.7 ± 15.1
Cath 4 84.6 ± 9 93.2 ± 7 108.1 ± 6 103.6 ± 7
Cath 10 95.5 ± 17 99.3 ± 8 139.2 ± 15* 112.2 ± 5*
Methcath 4 137.6 ± 14 65.8 ± 6 103.2 ± 18 -
Methcath 10 130.5 ± 18 109.3 ± 22 104.0 ± 7 83.6 ± 11
5-HIAA
MDMA 4 70.8 ± 14 73.6 ± 9 144.5 ± 61 -
MDMA 10 81.1 ± 32 59.0 ± 3*** 70.5 ± 4** 54.9 ± 9*
Meph 4 103.4 ± 12 187.5 ± 93 99.0 ± 36 -
Meph 10 86.6 ± 9 94.5 ± 5 95.6 ± 4 84.7 ± 12
Cath 4 89.2 ± 13 89.3 ± 4 113.7 ± 7 97.5 ± 9
Cath 10 111.4 ± 15 97.4 ± 6 161.9 ± 12*** 108.2 ± 4
Methcath 4 97.3 ± 12 87.5 ± 8 133.0 ± 32 -
Methcath 10 154.1 ± 20 96.8 ± 16 132.2 ± 7** 98.8 ± 7
Neurotransmitter and metabolite levels were measured 2 h after i.p. injection of
saline vehicle (V, 1 ml kg-1), MDMA, mephedrone (Meph), cathinone (Cath) or
methcathinone (Methcath, 4 or 10 mg kg-1) to individually-housed adult male Lister
hooded rats (n=5-6 per treatment group). Data are expressed as mean percentage
(± SEM) of the 5-HT and 5-HIAA levels in the relevant vehicle control group. Pooled
levels (pmol mg-1 tissue; mean ± SEM) of 5-HT in vehicle controls were frontal
cortex (FCtx): 3.14 ± 0.4, hippocampus (Hip): 4.4 ± 0.5, striatum (Str): 3.5 ±
0.4, hypothalamus (Hyp): 7.3 ± 0.5. These values for 5-HIAA were FCtx: 3.2 ±
0.5, Hip: 5.6 ± 0.4, Str: 4.0 ± 0.4, Hyp: 7.6 ± 0.4. Hypothalamus was not
collected for all doses. Data are presented as percent of vehicle control but
statistics were performed on the raw data. ***p<0.001, **p<0.01, *p<0.05
Bonferroni post-hoc following one-way ANOVA.
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2.4.2 (IIHFW RI Į1 DQG Į2- adrenoceptor antagonists, and
dopamine D1 and D2 receptor antagonists on
mephedrone-induced changes in rectal temperature, and
plasma catecholamine levels in individually-housed rats
There were no significant between-group differences in basal rectal
temperature immediately prior to mephedrone injection, which was 39.1 ±
0.1 °C (mean ± SEM).
2.4.2.1 Rectal temperature
3UHWUHDWPHQW ZLWK WKH Į1-adrenoceptor antagonist prazosin, (Fig 2.3A),
Į2A-adrenoceptor antagonist, BRL 44408 (Fig 2.3C), or dopamine D2
receptor antagonist, L-741,626 (Fig 2.3D), did not have any significant
influence on temperature in rats which received saline vehicle 30 min later.
Pre-treatment with the dopamine D1 receptor antagonist, SCH 23390 (Fig
2.3B), decreased rectal temperature at a single time point 100 min after
subsequent vehicle administration compared to vehicle pre-treated rats.
Mephedrone (10 mg kg-1) caused a transient decrease in rectal
temperature in vehicle pre-treated rats, which was evident at 10 min post-
injection and is consistent with the findings of experiment 1 (Fig 2.2B).
Pre-treatment with prazosin prolonged mephedrone-induced hypothermia
for 60 min, for an additional 40 min than that observed in rats which
received mephedrone alone (pre-treatment: F(2,31)=0.49, p>0.05;
challenge: F(1,31)=13.40, p<0.001; time: F(7,217)=12.52, p<0.001; pre-
treatment x challenge: F(2,31)=1.53, p>0.05; pre-treatment x time:
F(14,217)=2.16, p<0.01; challenge x time: F(7,217)=19.34, p<0.001; pre-
treatment x challenge x time: F(14,217)=1.05, p>0.05, Fig 2.3A). SCH 23390
enhanced the mephedrone-induced decrease in rectal temperature at 40
and 60 min post-injection by over 0.6 °C (pre-treatment: F(2,30)=9.97,
p<0.001; challenge: F(1,30)=19.93, p<0.001; time: F(7,210)=18.08,
p<0.001; pre-treatment x challenge: F(2,30)=0.51, p>0.05; pre-treatment x
time: F(14,210)=4.07, p<0.001; challenge x time: F(7,210)=31.87, p<0.001;
pre-treatment x challenge x time: F(14,210)=1.20, p>0.05, Fig 2.3B). In
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contrast, pre-treatment with BRL 44408 (Fig 2.3C) or L-741,626 (Fig 2.3D)
did not alter the mephedrone-induced decrease in rectal temperature.
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Figure 2.3 Effects of adrenoceptor or dopamine receptor antagonism on
mephedrone-induced hypothermia.
Individually-housed adult male Lister hooded rats (n=6-7 per treatment group)
received i.p. vehicle (1 ml kg-1) or (A WKH Į1-adrenoceptor antagonist, prazosin
(0.2 mg kg-1), (B) the dopamine D1 receptor antagonist, SCH 23390 (2 mg kg
-1),
(CWKHĮ2A-adrenoceptor antagonist, BRL 44408 (1 mg kg-1), or (D) the dopamine
D2 receptor antagonist, L-741,626 (0.63 mg kg
-1) 30 min prior to i.p. injection with
saline vehicle or mephedrone (10 mg kg-1). Rectal temperature was recorded at
pre-treatment (-30 min) and at the time of mephedrone injection (0 min) and then
every 20 min for a further 2 h. Data are expressed as temperature change (°C,
mean ± SEM) from baseline temperature (0 min). ***p<0.001, **p<0.01,
*p<0.05 vehicle + mephedrone compared to vehicle + vehicle; p<0.01, p<0.05
antagonist + vehicle compared to vehicle + vehicle; ***p<0.001, **<0.01,
*p<0.05 antagonist + mephedrone compared to vehicle + vehicle; p<0.001,
<0.01, p<0.05 antagonist + mephedrone compared to antagonist + vehicle;
p<0.01, p<0.05 vehicle + mephedrone compared to antagonist + mephedrone,
Bonferroni multiple comparisons post-hoc following three-way repeated measures
ANOVA.
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2.4.2.2 Plasma catecholamine levels
Mephedrone significantly elevated the plasma noradrenaline levels 2 h
post-injection in individually-housed rats (p<0.05, Fig 2.4A-D). This effect
was abolished by pre-treatment with prazosin, BRL 44408, SCH 23390 and
L-741,626. Mephedrone also appeared to increase plasma adrenaline levels
but this failed to reach statistical significance in each of the individual drug
studies (Fig 2.4E-H).
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Figure 2.4 Effects of adrenoceptor or dopamine receptor antagonism on
mephedrone-induced changes in plasma catecholamine levels.
Individually-housed adult male Lister hooded rats (n=6-7 per treatment group)
received i.p. saline vehicle (1 ml kg-1) or (A, E WKH Į1-adrenoceptor antagonist,
prazosin (0.2 mg kg-1), (B, F) the dopamine D1 receptor antagonist, SCH 23390 (2
mg kg-1), (C, FWKHĮ2A-adrenoceptor antagonist, BRL 44408 (1 mg kg-1) or (D, H)
the dopamine D1 receptor antagonist, L-741,626 (0.63 mg kg
-1) 30 min prior to i.p.
injection with saline vehicle or mephedrone (10 mg kg-1). Arteriovenous trunk
blood was collected 2 h after vehicle or mephedrone injection for measurement of
plasma noradrenaline (A-D) and adrenaline (E-H). *p<0.05 Bonferroni post-hoc
following two-way ANOVA.
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2.4.3 Effect of mephedrone on rectal and tail temperature, and
plasma catecholamine levels in group-housed rats
There was no significant between-group difference in basal rectal or tail
temperature prior to drug injection. At the time of injection (t=0 min),
rectal and tail temperature was 39.2 ± 0.1 °C (mean ± SEM) and 33.0 ±
0.1 °C, respectively in vehicle, and 38.9 ± 0.1 °C and 32.9 ± 0.1 °C in
mephedrone groups. Mephedrone (10 mg kg-1) did not significantly alter
rectal (Fig 2.5A) or tail (Fig 2.5B) temperature in group-housed rats
(p>0.05). Plasma noradrenaline levels 2 h post-injection were 16.44 ± 3.9
nmol L-1 (mean ± SEM) in vehicle treated rats and 21.83 ± 4.0 nmol L-1 in
the mephedrone treated group. Plasma adrenaline levels were 19.53 ± 6
nmol L-1 in vehicle treated rats and 23.4 ± 14.7 nmol L-1 in mephedrone
treated rats. Mephedrone did not significantly alter plasma catecholamine
levels 2 h post-injection in group-housed rats (p>0.05).
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Figure 2.5 Effect of a acute mephedrone injection on rectal and tail
temperature in group-housed adult male Lister hooded rats.
Group-housed adult male Lister hooded rats (n=6 per treatment group) received
i.p. saline vehicle (1 ml kg-1) or mephedrone (10 mg kg-1) and (A) rectal and (B)
tail temperatures were recorded at 20 min intervals. Data are presented as
temperature change (mean ± SEM) from baseline temperature (0 min).
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2.5 Discussion
In summary this study found that cathinone and methcathinone had
different opposing effects on thermoregulation and post-mortem brain
monoamine tissue levels to mephedrone and MDMA. Further investigations
revealed that mephedrone produced a marked elevation in plasma
noradrenaline levels and that the mechanism and temporal profile of
mephedrone-induced hypothermia differs from that of MDMA.
MDMA can cause hyper- or hypothermia in rats depending on a number of
factors, such as housing conditions or dose. In the current study,
prolonged hypothermia was observed following acute MDMA administration
to individually-housed rats at normal ambient temperature, as has been
reported in previous studies (Malberg and Seiden 1998; Malpass et al.
1999; Daws et al. 2000; Green et al. 2005; Bexis and Docherty 2006)
While mephedrone also produced hypothermia in rats, this returned to
baseline levels more rapidly than that following MDMA. The speed of onset
is consistent with the high brain permeability of mephedrone and its speed
of onset may indicate a short plasma half-life with peak plasma levels
observed 15 min after s.c. injection with the drug completely cleared after
2 h (Miller et al. 2013; Simmler et al. 2013). Recent studies have also
demonstrated mephedrone-induced hypothermia following acute injection
to rats at both normal (20-23 °C) and high (27 °C) ambient room
temperatures (Wright et al. 2012; Miller et al. 2013) and the current study
showed that group housing of rats abolished mephedrone-induced
hypothermia but failed to produce hyperthermia. This is in contrast to
MDMA where hyperthermia is observed at both high ambient room
temperatures and with group housing (Nash et al. 1988; Colado et al.
1993; Mechan et al. 2002). At the time the current studies were conducted
there were little published pharmacokinetic data for the cathinones but
since the cathinones used in this study have similar molecular weights to
MDMA and each other, the doses used were selected based on doses of
MDMA relevant to those taken by users.
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Thermoregulation is controlled by both central and peripheral mechanisms
and in rats the tail is the major site of heat loss. In hot conditions,
vasodilatation (with an associated increase in tail skin temperature) occurs
to dissipate core body heat whereas, in cold conditions, vasoconstriction
(and a decrease in tail skin temperature) serves to conserve core body
heat. Since MDMA and mephedrone caused hypothermia in the current
study peripheral vasoconstriction and a corresponding decrease in tail
temperature would be expected in order to help normalise core body
temperature. The temporal mismatch between the brief decrease in tail
temperature observed in MDMA treated rats and the more sustained
decrease in rectal temperature suggest disruption of normal heat
conservation mechanisms by MDMA. In contrast, the sustained decreased
in tail temperature which follows a brief mephedrone-induced decrease in
rectal temperature appears consistent with both user reports of cold or
blue fingers (Schifano et al. 2011; Winstock et al. 2011) and the affinity of
PHSKHGURQHIRUĮ1DQGĮ2-adrenoceptors (Simmler et al. 2012).
In marked contrast to MDMA and mephedrone, both cathinone and
methcathinone caused a hyperthermic response that was maintained for
80 min following cathinone and 120 min following methcathinone
administration. These findings again appear consistent with reports from
users (Emerson and Cisek 1993; Kelly 2011). Previous studies have shown
that cathinone produces hyperthermia in anaesthetised rats (Tariq et al.
1989) and in rabbits (Kalix 1980) while methcathinone has also been
shown to produce hyperthermia in restrained rats (Rockhold et al. 1997).
In the current study, hyperthermia occurred without any change in tail
temperature which may suggest that these compounds are acting centrally
to mediate these temperature changes without causing any change to
peripheral vascular tone.
Since MDMA is a potent releaser of 5-HT and dopamine in the frontal
cortex, striatum and hippocampus (Green et al. 2003), post-mortem levels
of these monoamines were measured 2 h post-injection. Additionally, since
the hypothalamus is essential in body temperature regulation and MDMA
releases 5-HT and dopamine in this region (Benamar et al. 2008; Nisijima
et al. 2012), post-mortem levels of 5-HT and dopamine were also
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measured in this brain region. In addition to their differing
thermoregulatory effects the cathinone derivatives and MDMA also had
distinct effects on post-mortem tissue monoamine levels. MDMA decreased
5-HT and 5-HIAA in the hippocampus, hypothalamus and striatum, and the
dopamine metabolites, DOPAC and HVA in the striatum. These findings are
consistent with previous reports (Green et al. 2003). In contrast, cathinone
increased hypothalamic and striatal 5-HT, 5-HIAA and dopamine and
decreased hypothalamic DOPAC, while methcathinone increased frontal
cortical, hippocampal and striatal dopamine and HVA, as well as striatal 5-
HIAA. Interestingly, mephedrone had no effect on dopamine, 5-HT or their
metabolites 2 h post-injection. This is surprising as microdialysis studies
have shown that mephedrone is a potent releaser of both dopamine and 5-
HT (Hadlock et al. 2011; Kehr et al. 2011; Baumann et al. 2012).
However, the nature of ex vivo tissue analysis of monoamine levels means
that the results are indicative of what is happening exactly when the tissue
was taken and the short half-life of mephedrone would suggest that
monoamine levels may have returned to normal levels when the tissue was
FROOHFWHG  K SRVWLQMHFWLRQ 7KH GLIIHUHQWLDO HIIHFWV RI WKH ǃ
ketoamphetamines on thermoregulation and monoamine release matched
observations by Simmler et al. (2013), where mephedrone was found to be
most like MDMA as a non-selective monoamine reuptake inhibitor that
stimulates dopamine and 5-HT release while cathinone and methcathinone
are selective catecholamine reuptake inhibitors and releasers.
The serotonergic, dopaminergic and noradrenergic systems have all been
implicated in the thermoregulatory responses to MDMA. The evidence
suggests that dopamine is the most important of these neurotransmitters
in evoking the temperature changes observed following MDMA
administration. The dopamine D1 receptor antagonist SCH 23390 blocks
MDMA-induced hyperthermia but does not alter the hypothermic response
(Mechan et al. 2002). In contrast, the dopamine D2 receptor antagonist
remoxipride has no effect on MDMA-induced hypothermia but does block
the hyperthermic response (Green et al. 2005). The adrenoceptors also
have an important role in disruption of thermoregulation by MDMA, where
Į1DGUHQRFHSWRU DQWDJRQLVWV SUD]RVLQ DQG Į2-adrenoceptor antagonists
(BRL 44408) produce a biphasic temperature response with initial
hypothermia developing into hyperthermia (Bexis and Docherty 2005;
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%H[LV DQG 'RFKHUW\  DQG WKH ǃ3-adrenoceptor antagonist,
SR59230A, attenuates the hyperthermic response to MDMA (Bexis and
Docherty 2009).
Based on the findings of the current study it would appear that
mephedrone is influencing temperature changes via different mechanisms
to MDMA. Unlike MDMA, mephedrone-induced hypothermia was not
influenced by pre-treatment with a D1 dopamine receptor antagonist;
instead it was enhanced and prolonged by the D2 dopamine receptor
DQWDJRQLVW 6&+  ,Q DGGLWLRQ ZKLOH ERWK Į1 DQG Į2-adrenoceptor
antagonists cause a biphasic temperature response with MDMA
DGPLQLVWUDWLRQ RQO\ WKH Į1-adrenoceptor antagonist, prazosin prolonged
the hypothermic response following mephedrone administration.
Mephedrone increased plasma noradrenaline levels in a similar manner to
MDMA (Hysek et al. 2011; Hysek et al. 2012), and this effect was blocked
E\ Į1 Į2-adrenoceptor and D1 dopamine receptor antagonism. Further
demonstrating the differential effects of mephedrone and MDMA on body
temperature changes, while group housing conditions causes hyperthermia
in MDMA treated rats (Docherty and Green 2010), this failed to alter the
thermogenic response to mephedrone. These differences may be due to
the differing affinities that these compounds have for the monoamine
transporters, with mephedrone causing greater dopamine release than
MDMA.
In conclusion, the current data suggests that despite their similar
structures, the cathinone derivatives produce thermoregulatory changes
very different to each other and to MDMA. In addition, mephedrone-
induced temperature changes do not appear to be influenced by the same
manipulations of environment and/or housing conditions that affect MDMA-
induced changes. Therefore care should be taken when extrapolating the
effects of these and other compounds and it is likely that each novel
synthetic cathinone derivative will require individual study.
Since MDMA causes hyperactivity, changes in cognition and sensorimotor
gating, as well as long term neurotransmitter changes, the following
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chapter will investigate the effects of chronic intermittent mephedrone on
locomotion, cognition and sensorimotor gating and long term ex vivo
monoamine levels in specific brain regions, in comparison to cathinone and
MDMA. The possible development of locomotor sensitisation will also be
assessed.
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Chapter 3 Behavioural and neurochemical
effects of repeated intermittent
cathinone, mephedrone or MDMA
administration
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3.1 Introduction
Although the data presented in the previous study did not show any post-
mortem changes to monoamine tissue levels in specific brain regions 2 h
following acute mephedrone injection, other published work has indicated
that mephedrone alters central monoaminergic neurotransmission (Kehr et
al. 2011; Baumann et al. 2012; Martinez-Clemente et al. 2012; Motbey et
al. 2012). Additionally, mephedrone causes hyperactivity, conditioned
place preference and reduced social preference in rats (Kehr et al. 2011;
Baumann et al. 2012; Motbey et al. 2012), improves visuo-spatial learning
and memory in non-human primates (Wright et al. 2012), impairs working
memory in humans (Freeman et al. 2012), and previous repeated high
doses disrupt short term learning and memory in rats (Motbey et al.
2012). MDMA causes visual learning and memory deficits in rats (Morley et
al. 2001; Camarasa et al. 2008; Rodsiri et al. 2011) and acute doses
reduce auditory and visual PPI in rats (Kehne et al. 1996; Vollenweider et
al. 1999), and repeated cathinone disrupts auditory PPI in rats (Banjaw et
al. 2005).
The current study therefore examined the effects of mephedrone in
behavioural paradigms regulated by monoamine function, and compared
its effects to those of cathinone and MDMA in the adult rat, specifically,
locomotor activity and visual recognition memory, and since the
amphetamines have been reported to affect associative memory and
sensorimotor gating (Cappell et al. 1972; Vollenweider et al. 1999) these
behaviours were also measured. The NOD task was used to assess
hippocampal related recognition memory, CER was used to investigate any
potential effects on amygdala and/or hippocampal dependent associative
memory and finally any changes in mesolimbic dopamine dependent PPI
were assessed. These tasks are sensitive to a range of dopaminergic and
serotonergic manipulations and are routinely used in our laboratory (King
et al. 2004; Jones et al. 2011; Rodsiri et al. 2011; Watson et al. 2011;
Woods et al. 2012; McIntosh et al. 2013) and rely on the rats natural
instinct so do not require training and are therefore ideal for investigating
the short term effects of the test compounds.
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In the current study a dose schedule involving injection on two consecutive
days each week for three weeks was used to mimic typical patterns of
weekend recreational drug use. Doses of cathinone were selected from
previous studies in an attempt to produce plasma levels similar to those
reported in man (Feyissa and Kelly 2008). While an MDMA dose of 10 mg
kg-1 is higher than that required to produce plasma levels comparable to
that observed in recreational users (Green et al., 2012) it was chosen to
reflect the longer plasma half-life of the drug in humans compared with
rats (Green et al., 2012). Although it has been reported that human users
of mephedrone may on average ingest 0.5-4 g in a single session, this is
generally a cumulative dose following binge-style dosing (Schifano et al.
2011; Winstock et al. 2011). Previous studies have shown that significant
dopamine release in the rat nucleus accumbens following a 3 mg kg-1
mephedrone dose (Kehr et al., 2011) so doses of 1, 4 and 10 mg kg-1 of
mephedrone were selected to produce pharmacological effects in the
current study and to allow observation of resulting behavioural changes.
Low doses of cathinone have been shown to increase locomotor activity
and rearing in rats (Glennon et al. 1987; Banjaw et al. 2003; Banjaw et al.
2005; Banjaw et al. 2006). Additionally the extent of the hyperthermic
response (>1 °C change in rectal temperature) evoked by cathinone in the
previous chapter was taken into account when selecting doses of this
compound as repeated doses may have a cumulative effect. Doses of 1 or
4 mg kg-1 of cathinone were therefore chosen for comparison to
mephedrone. Since repeated MDMA administration can result in
behavioural sensitisation (Dafters 1995; Aberg et al. 2007; Atkins et al.
2009), locomotor activity was measured at both the start and end of the
study to identify any locomotor sensitisation to these compounds that may
have developed across the period of cognitive testing. Rats were killed
seven days after the final drug administration and the concentration of
dopamine, 5-HT and their metabolites were measured in the frontal cortex,
striatum and hippocampus to ascertain whether the two cathinone
compounds produced any longer-term monoaminergic neurotoxicity such
as previously reported following repeated administration of high MDMA
doses (Green et al. 2003; Carvalho et al. 2012).
Working memory is impaired in intoxicated mephedrone users (Freeman et
al. 2012) so in the current study behavioural testing was performed on the
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same day as drug administration to investigate the short term effects of
the test compounds in the behavioural paradigms used. Tests were also
conducted in order of least to most aversive to limit the effects of the
previous behavioural paradigm test while minimising animal use to comply
with the 3Rs of humane animal testing. Drugs were administered 30 min
prior to NOD and PPI tasks for consistency with the studies presented in
the previous chapter. On LMA test days, LMA recording was initiated
immediately post-injection so that a time course of mephedrone-induced
hyperactivity could be observed. For the CER task, rats were injected
immediately after testing on the conditioning day to avoid any potential
analgesic properties of these test compounds but still allowing any drug
effects on memory consolidation after the trial. On the second (retention)
day of CER rats were again injected after the trial so that the rat received a
second injection for that week.
3.2 Aims
The aims of this study were to:
(1) compare the effects of chronic intermittent cathinone, mephedrone and
MDMA on locomotor activity, visual learning and memory, associative
memory and sensorimotor gating in the rat;
(2) ascertain whether this dosing schedule used resulted in the
development of locomotor sensitisation to these compounds across the
period of cognitive testing;
(3) identify any neurotoxic effects of these compounds seven days after
the completion of chronic intermittent dosing.
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3.3 Materials and Methods
3.3.1 Animals
All experiments used experimentally naïve young-adult male Lister hooded
rats (170-250g; Charles River UK or University of Nottingham BSU) housed
in groups of 4-5 per cage under constant environmental conditions as
described in section 2.3.1. All experiments were conducted during the light
phase, between 9.00 and 16.00 h. The doses of drugs used were chosen to
comply with the three Rs of humane animal testing. All experiments were
conducted in accordance with the Animals (Scientific Procedures) Act,
1986, and ARRIVE guidelines with approval of University of Nottingham
Local Ethical Committee. The body weight of each rat was taken before the
first injection to ensure no basal weight differences between groups and
then monitored throughout the remainder of the experiment.
3.3.2 Drugs
(-)-cathinone-HCl was obtained from Sigma-Aldrich; (±)-mephedrone-HCl
was purchased from Ascent Scientific and (±)-MDMA-HCl from Tocris
Bioscience. All drugs were dissolved in 0.154 M saline and doses are
quoted as the salt.
3.3.3 Effects of chronic intermittent cathinone, mephedrone or
MDMA on behaviour and ex vivo neurochemistry
3.3.3.1 Experimental design
Rats (n=6-8 per treatment group) received i.p. injections of saline vehicle
(1 ml kg-1), (-)-cathinone-HCl (1 or 4 mg kg-1), (±)-mephedrone-HCl (1, 4
or 10 mg kg-1) or (±)-MDMA-HCl (10 mg kg-1) on two consecutive days a
week for three weeks (day 1, 2, 8, 9, 15 and 16 of the experiment, see Fig
3.1 for a summary of the dose schedule), with behavioural testing to
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evaluate effects on LMA (day 1 and again on day 16), NOD (day two), CER
(days eight and nine), and PPI (day 15). Seven days after the final dose
(day 23) brain tissue was collected for neurochemical measurements.
In all experiments, rats were allocated to a treatment group using a
pseudorandom design but initial body weights were checked to ensure no
basal weight differences between groups. Experiments were performed as
three separate studies broken into vehicle and cathinone (1 and 4 mg kg-
1); vehicle and mephedrone (1 and 4 mg kg-1); and vehicle, mephedrone
(10 mg kg-1) and MDMA (10 mg kg-1). All apparatus were cleaned with
20% ethanol prior to use and between animals to remove any odour cues.
Figure 3.1 Expe
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3.3.3.2 Locomotor activity
LMA was measured in a novel arena on day 1 of the experiment and
reassessed in the same arena on day 16 to assess potential development
of drug-induced sensitisation or tolerance. Rats were habituated to
individual test arenas (as described in section 2.3.3.1) for 60 min pre-
injection on each day during which LMA was recorded using a Photobeam
Activity System (San Diego Instruments, CA) consisting of two layers of
infra-red beams (the lower layer had eight parallel beams along its length
and four parallel beams along its width, and the upper layer had eight
parallel beams along its width only). Rats were then injected and
immediately returned to their box where LMA was recorded for a further 60
min. Cumulative beam breaks were recorded in 5 min time bins. Activity
counts were differentiated into locomotion (two consecutive adjacent lower
beam breaks), fine movement (one lower beam break) and rearing (one
upper beam break).
3.3.3.3 Novel object discrimination
Visual working memory is impaired in intoxicated human mephedrone
users (Freeman et al. 2012) so NOD was assessed on day 2 to determine
any drug-induced impairments in visual learning and memory in rats, using
a protocol routinely used in our laboratory (King et al. 2004; King et al.
2009; Watson et al. 2011; McIntosh et al. 2013). Rats were returned to
their individual LMA test arena 27 min following injection for an additional
3 min habituation. This was followed by 1 min in the home cage and then
two consecutive 3 min object exploration trials, separated by a 2 h inter-
trial interval in the home cage. In the first (familiarisation) trial rats
encountered two identical objects (water filled cylindrical plastic bottles, 8
cm high and 5 cm diameter, covered in white masking tape). For the
second (choice) trial one of these objects was randomly replaced with a
novel object of the same size and shape but with four additional horizontal
black stripes of black electrical insulation tape. The objects were placed at
the front left and back right of the arenas, 5 cm from the side and 10 cm
from the end wall.
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Active exploration of the objects (defined as sniffing, licking, chewing or
KDYLQJPRYLQJYLEULVVDHZKLOVWGLUHFWLQJWKHQRVHWRZDUGVDQGFPIURP
the object) was recorded using stopwatches but climbing on objects in the
absence of directed interest was excluded. Actual times spent exploring the
objects in the choice trial were used to calculate the discrimination ratio
[novel/(total choice trial object exploration)], where a discrimination ratio
>0.5 indicates more time spent exploring the novel than the familiar
object.
3.3.3.4 Conditioned emotional response
CER was performed on day 8 (conditioning) and day 9 (retention) of the
study to measure any potential drug-induced changes in associative
memory, using a previously described protocol (Jones et al. 2011; Woods
et al. 2012; McIntosh et al. 2013) with some modifications. This paradigm
utilised a two compartment box (25 x 25 x 27cm internal, Panlab S-Lab,
Spain), with one light white-walled and one dark black-walled chamber,
each with Perspex door fronts, separated by a computer operated door (8
x 8 cm). Each chamber had a grid floor connected to the shuttle box
control unit, as well as a light and a centrally located speaker. On the
conditioning day rats were individually placed in the light side of the
apparatus and after 30 s the door opened, latency to enter the dark side
 PLQ LQ DOO FDVHV ZDV UHFRUGHG DQG WKH GRRU FORVHG $IWHU  V
habituation to the dark side of the apparatus rats received a 5 s light (200
LUX) and tone (conditioned stimulus, 89 dB, 3 kHz) followed by a 1 s foot
shock (unconditioned stimulus, 0.4 mA) in the last second of the
conditioned stimulus. The light, tone and foot shock combination was
repeated twice, at 1 min intervals. Rats were removed after the final foot
shock, immediately injected and returned to the home cage. The duration
of freezing (defined as absence of all movement except that required for
respiration) during the 1 min periods following first and second foot shocks
was recorded using separate stopwatches to assess acquisition of the
association between conditioned and unconditioned stimuli.
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Twenty-four hours later, rats were returned to the dark side of the
apparatus and freezing duration recorded across a 5 min period (without
cue or foot shock) as an index of contextual fear motivated associative
learning and memory. The light and tone were then presented (without
foot shock) and freezing duration recorded for a further 5 min to assess
cued fear motivated associative learning and memory. Again, rats were
dosed immediately after the session so that they received two injections
that week.
3.3.3.5 Prepulse inhibition of acoustic startle response
PPI was measured on day 15 to assess drug-induced changes in
sensorimotor gating using a previously described protocol (Jones et al.
2011; McIntosh et al. 2013). Four SR-lab startle response chambers (San
Diego Instruments, CA) were used, each consisting of a clear Perspex
cylinder (8.8 x 19.5 cm) mounted on a piezoelectric transducer and
contained within a sound-attenuating individually ventilated chamber (39 x
38 x 58 cm). Test sessions commenced 30 min after injection and
consisted of 5 min acclimatisation to background white noise (62 dB), then
ten successive startle alone pulses (120 dB) followed by 50 further startle
trials (ten without any pre-pulse and ten each of startle preceded by a 72
dB, 76 dB, 80 dB and 84 dB pre-pulse in a pseudorandom order and with
an unpredictable inter-trial interval) and ending with five startle-alone
pulses. Individual whole body startle responses were recorded every 1 ms
over a 100 ms period starting from the initiation of the startle pulse using
Startle Reflex Testing software (San Diego Instruments, CA) to calculate a
total cumulative area under the curve (AUC) response. Results were
expressed as percentage PPI from the average AUC for each trial type
(using a conditional statement to eliminate any extreme values ± 2 SD
from the mean which can result from movement of the rat during startle
delivery) using the equation % PPI = [((pulse alone AUC - prepulse
AUC)/pulse alone AUC) x 100].
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3.3.3.6 Tissue collection and neurochemical detection by HPLC-ED
Rats were killed seven days after the final injection by concussion and
immediate decapitation. Right striatum, frontal cortex and hippocampus
were rapidly dissected on a refrigerated table (BC72: Osborne
UHIULJHUDWLRQ8.Û&ZHLJKHGIODVKIUR]HQLQOLTXLGQLWURJHQDQGVWRUHG
DW Û&XQWLO DQDO\VLV+3/&('ZDVSHUIRUPHGDVGHVFULEHG LQ VHFWLRQ
2.3.3.2.
3.3.4 Statistical analysis
All statistical analyses were performed using GraphPad Prism (v 6.02) or
SPSS v 21 software. Experiments were performed as three separate
studies broken into vehicle and cathinone (1 and 4 mg kg-1); vehicle and
mephedrone (1 and 4 mg kg-1); and vehicle, mephedrone (10 mg kg-1) and
MDMA (10 mg kg-1). Statistical analyses were performed against the
relevant vehicle control group for each of the three individual studies. LMA
time course data were analysed by two-way repeated measures ANOVA,
with drug treatment and time as the between- and within-group factors,
respectively. Total activity counts were also analysed by two-way repeated
measures ANOVA, with drug treatment and LMA day as the between- and
within-group factors. NOD familiarisation and choice trial data were
analysed by two-way repeated measures ANOVA, with drug treatment and
object as the between- and within-group factors. NOD total object
exploration data were analysed by two-way repeated measures ANOVA,
with drug treatment and NOD trial as the between- and within-group
factors. For the CER data, latency to enter the dark side was analysed by
one-way ANOVA. Freezing behaviour on the conditioning and retention
days were analysed by two-way repeated measures ANOVA with treatment
and stimuli as the as the between- and within-group factors. % PPI was
analysed by two-way repeated measures ANOVA with treatment and
prepulse amplitude as the between- and within-group factors. Startle
response magnitude to the 120 dB prepulse alone, as well as NOD choice
trial discrimination ratio and HPLC-ED data were analysed by one-way
ANOVA. Bonferroni multiple comparisons post-hoc tests were conducted
where appropriate. In each case, p<0.05 was considered significant. In
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addition, one sample t-tests with a hypothetical mean of 0.5 were applied
to NOD choice trial discrimination ratio data for each treatment group.
3.4 Results
3.4.1 Effects of chronic intermittent cathinone, mephedrone or
MDMA on behaviour and ex vivo neurochemistry
3.4.1.1 Body weight
All rats gained weight throughout the experiment (p<0.001 for all groups)
irrespective of treatment (Cathinone study treatment: F(2,21)=0.14,
p>0.05; low dose mephedrone study treatment: F(2,21)=0.70, p>0.05;
mephedrone and MDMA 10 mg kg-1 study treatment: F(2,19)=1.17, p>0.05,
Fig 3.2).
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Figure 3.2 Chronic intermittent drug treatment did not affect body weight.
Adult male Lister hooded rats (n=6-8 per treatment group) displayed a normal
increase in body weight (g, mean ± SEM) throughout the 4 week experiment which
was unaffected by twice weekly i.p. injection on consecutive days of saline vehicle
(V; 1 mg kg-1), (A) cathinone (Cath; 1 or 4 mg kg-1), (B) mephedrone (Meph; 1 or
4 mg kg-1) or (C) mephedrone or MDMA (10 mg kg-1).
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3.4.1.2 Locomotor activity
Habituation to the activity boxes prior to injection on days 1 and 16 was
confirmed by a decline in locomotion over the 60 min pre-injection period
on each occasion, with no significant between-group difference in any
study (Fig 3.3). On day 1 there was a marked increase in locomotion after
the first injection of cathinone, mephedrone or MDMA. This effect first
reached statistical significance from the relevant vehicle control group at
35 (p<0.001) and 15 (p<0.05) min post-injection for 1 and 4 mg kg-1 of
cathinone respectively (treatment: F(2,21)=41.65, p<0.001; time:
F(12,252)=7.17, p<0.001 treatment x time interaction: F(24,252)=7.66,
p<0.001, Fig 3.4A), 10 min (p<0.001) post-injection for 4 mg kg-1
mephedrone (treatment: F(2,21)=2.96, p=0.07; time: F(12,252)=11.32,
p=0.07; treatment x time interaction: F(24,252)=1.92, p<0.01, Fig 3.4B),
and 10 min post-injection (p<0.01/p<0.05 respectively) for 10 mg kg-1 of
mephedrone and MDMA (treatment: F(2,19)=9.91, p<0.001; time:
F(12,228)=9.15, p<0.001; treatment x time interaction: F(24,228)=4.23,
p<0.001, Fig 3.4C). This elevation in locomotion was transient following
mephedrone (4 and 10 mg kg-1) but prolonged following cathinone (4 mg
kg-1) and MDMA (10 mg kg-1) with no return to baseline levels by 60 min
post-injection.
Similar responses to drug administration were obtained on day 16
following the sixth dose. As on day one, cathinone and MDMA caused a
prolonged increase in horizontal activity (cathinone 4 mg kg-1; treatment:
F(2,21)=11.46, p<0.001; time: F(12,252)=6.52, p<0.001; treatment x time
interaction: F(24,252)=7.84, p<0.001, Fig 3.4D, MDMA 10 mg kg
-1;
treatment: F(2,19)=9.91, p<0.001; time: F(12,228)=8.35, p<0.001;
treatment x time interaction: F(24,228)=3.83, p<0.001 Fig 3.4F) such that
there was no return to baseline levels within the 60 min test period.
Mephedrone (4 mg kg-1) had a similar transient effect on locomotion on
day 16 as observed on day 1 (treatment: F(2,21)=4.13, p<0.05; time:
F(12,252)=16.27, p<0.001; treatment x time interaction: F(24,252)=3.18,
p<0.001, Fig 3.4E), however, of particular note the time course of
hyperactivity following the 10 mg kg-1 dose of mephedrone was more
prolonged on day 16 reaching statistical significance from vehicle from 10-
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55 min post-injection instead of 10-15 min post-injection on day 1. There
was no significant effect of the lowest dose of mephedrone (1 mg kg-1) on
locomotion on either day (p>0.05).
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Day 1 Day 16
Figure 3.3 All rats displayed habituation to the activity boxes in the 60 min
pre-injection period on day 1 and 16.
Adult male Lister hooded rats (n=6-8 per treatment group) displayed habituation to
the activity boxes as shown by a decrease in horizontal activity counts (mean ±
SEM) on days (A-C) one and (D-F) 16 of the experiment prior to the first or sixth
i.p. injection of saline vehicle (V; 1 ml kg-1) or (A, D) cathinone (Cath; 1 or 4 mg
kg-1), (B, E) mephedrone (Meph; 1 or 4 mg kg-1) or (C, F) Meph or MDMA (10 mg
kg-1) at time=0 min. There was no significant difference in horizontal activity
counts between treatment groups, two-way repeated measures ANOVA.
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Figure 3.4 Effects of acute and chronic intermittent cathinone,
mephedrone and MDMA on locomotor activity.
Adult male Lister hooded rats (n=6-8 per treatment group) displayed hyperactivity
as shown by an increase in horizontal activity counts (mean ± SEM) on days (A-C)
one and (D-F) 16 of the experiment following the first or sixth i.p. injection of
saline vehicle (V; 1 ml kg-1) or (A, D) cathinone (Cath; 1 or 4 mg kg-1), (B, E)
mephedrone (Meph; 1 or 4 mg kg-1) or (C, F) Meph or MDMA (10 mg kg-1) at
time=0 min. Experiments were performed as three separate studies broken into
vehicle and cathinone (1 and 4 mg kg-1); vehicle and mephedrone (1 and 4 mg kg-
1); and vehicle, mephedrone (10 mg kg-1) and MDMA (10 mg kg-1). Statistical
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analyses were performed for each individual study against its own vehicle control
group. *p<0.05, **p<0.01, ***p<0.001 compared to saline vehicle, Bonferroni
post-hoc following two-way repeated measures ANOVA.
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Further analysis of the cumulative horizontal activity counts over the entire
60 min post-injection recording period showed that cathinone (4 mg kg-1)
and MDMA (10 mg kg-1) both produced significant increases on day 1
(p<0.001 in each case, Table 3.1), but on day 16 the effects of cathinone
and mephedrone were both exacerbated such that previously sub-
threshold doses of 1 mg kg-1 cathinone and 10 mg kg-1 mephedrone
produced a significant elevation in total horizontal locomotion counts on
day 16 (p<0.05 and p<0.001 versus relevant vehicle control,
respectively). Furthermore, the total ambulation counts observed following
the final injection of cathinone (1 and 4 mg kg-1) and mephedrone (10 mg
kg-1) were significantly higher than those observed in the same animals in
response to the first injection (p<0.05-p<0.01).
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Table 3.1 Effects of acute and chronic intermittent cathinone, mephedrone
and MDMA on total horizontal ambulation counts following injection with
cathinone, mephedrone or MDMA.
Treatment First injection Sixth injection
Vehicle 488 ± 80 1084 ± 186
Cath 1 1329 ± 120 2457 ± 254*
Cath 4 2573 ± 242*** 3851 ± 634***
Vehicle 570 ± 113 823 ± 168
Meph 1 480 ± 103 609 ± 73
Meph 4 873 ± 139 1181 ± 166
Vehicle 395 ± 53 488 ± 73
Meph 10 1583 ± 220 2694 ± 347***
MDMA 10 2347 ± 418*** 1964 ± 416*
Cumulative horizontal activity counts (mean ± SEM) in a 60 min period following
the first and sixth injections of a chronic intermittent dosing schedule in adult male
Lister hooded rats (n=6-8 per treatment group). Experiments were performed as
three separate studies broken into i.p. saline vehicle (V, 1 ml kg-1) and cathinone
(1 and 4 mg kg-1); V and mephedrone (1 and 4 mg kg-1); and V, mephedrone (10
mg kg-1) and MDMA (10 mg kg-1) on two consecutive days a week for three weeks.
Statistical analyses were performed for each individual study against its own
vehicle control group. *p<0.05, ***p<0.001 compared to saline vehicle following
on the same day; p<0.05, p<0.01 compared to the same treatment after the
first injection, Bonferroni post-hoc following two-way repeated measures ANOVA.
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The total cumulative number of rears during the 60 min post-injection
period was increased by the first cathinone injection only (treatment:
F(2,21)=8.47, p<0.01), although this response did not differ between the
first and sixth injections (injection number: F(1,21)=0.09, p>0.05;
treatment x injection number interaction: F(2,21)=0.73, p>0.05, Table 3.2).
In a similar pattern to horizontal locomotion, 10 mg kg-1 mephedrone
increased the total number of rears following the sixth injection compared
to the first (F(1,19)=7.60, p<0.01), but MDMA had no significant effect on
rearing behaviour on either test day.
The total cumulative fine movement counts during the 60 min post-
injection period were also increased by cathinone (F(2,21)=118.6, p<0.001,
Table 3.2). This effect reached significance on both day 1 and 16 and
although the absolute counts were significantly higher on day 16 compared
to day 1 (F(1,21)=55.9, p<0.001) the vehicle group in this experiment also
displayed increased fine movement counts after the sixth injection
compared to the first. Mephedrone and MDMA (10 mg kg-1) increased fine
movement counts after the first and sixth injections (F(2,19)=28.21,
p<0.001).
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Table 3.2 Effects of acute and chronic intermittent cathinone, mephedrone
and MDMA on total rearing and fine movement counts.
Rearing counts Fine movement counts
Treatment First injection Sixth injection First injection Sixth injection
Vehicle 34 ± 8 89 ± 19 218 ± 28 455 ± 30

Cath 1 311 ± 127** 243 ± 40 540 ± 16*** 673 ± 37***
Cath 4 65 ± 11 121 ± 43 704 ± 33*** 880 ± 31***
Vehicle 85 ± 20 76 ± 12 308 ± 40 359 ± 50
Meph 1 108 ± 70 78 ± 18 268 ± 51 360 ± 45
Meph 4 101 ± 42 158 ± 53 373 ± 29 488 ± 37
Vehicle 33 ± 8 53 ± 18 233 ± 32 313 ± 22
Meph 10 135 ± 103 312 ± 101

565 ± 50*** 709 ± 32***
MDMA 10 23 ± 8 90 ± 34 557 ± 64*** 609 ± 58***
Cumulative rearing and fine movement counts (mean ± SEM) in a 60 min period
following the first and sixth injections of a chronic intermittent dosing schedule in
adult male Lister hooded rats (n=6-8 per treatment group). Experiments were
performed as three separate studies broken into i.p. saline vehicle (V, 1 ml kg-1)
and cathinone (1 and 4 mg kg-1); V and mephedrone (1 and 4 mg kg-1); and V,
mephedrone (10 mg kg-1) and MDMA (10 mg kg-1) on two consecutive days a week
for three weeks. Statistical analyses were performed for each individual study
against its own vehicle control group. **p<0.01, ***p<0.001 compared to saline
vehicle following the same number of injections, p<0.05, p<0.01, p<0.001
compared to the first injection of the same treatment, Bonferroni post-hoc
following two-way repeated measures ANOVA.
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3.4.1.3 Novel object discrimination
When NOD was assessed following the second injection none of the
treatment groups exhibited any spatial preference for either identical
object during the familiarisation trial (p>0.05, Fig 3.5A). However, it is
important to note that there was a significant drug-induced decrease in
total levels of object exploration during this first trial following all
treatments, except for the 1 mg kg-1 doses of cathinone and mephedrone
(Fig 3.5A).
During the choice trial 2 h later, all three groups of vehicle treated rats
successfully discriminated the novel from the familiar object during the
choice trial, as expected, but this was impaired by all three drugs
(p<0.001, Fig 3.5B). This redistribution of object exploration occurred
without any difference in total choice trial exploration levels, with the
exception of 10 mg kg-1mephedrone, which produced a significant increase
in exploration in the choice trial (p<0.01). In the case of high dose
mephedrone and MDMA (10 mg kg-1) the impaired discrimination
translated into a significant decrease in the choice trial discrimination ratio
(F(2,19)=10.11, p<0.001, Fig 3.5C) which was not observed with the other
treatments. Analysis of the discrimination ratio data by one sample t-test,
against a hypothetical chance mean of 0.5, showed a similar pattern to
two-way repeated measures ANOVA of novel versus familiar data, namely
performance above chance levels in vehicle, but not cathinone,
mephedrone or MDMA treated rats.
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Figure 3.5 Cathinone, mephedrone and MDMA impaired novel object
discrimination following the second injection in a chronic intermittent
dosing regime.
Young adult male Lister hooded rats (n=6-8 per treatment group) received i.p.
saline vehicle (1 ml kg-1), cathinone (Cath; 1 or 4 mg kg-1), mephedrone (Meph; 1,
4 or 10 mg kg-1) or MDMA (10 mg kg-1) on two consecutive days a week for three
weeks with assessed NOD 30 min after the second injection (mean ± SEM).
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Duration of object exploration (s) in the (A) familiarisation and (B) choice trials of
NOD which were separated by a 2 h inter-trial interval, and the (C) choice trial
discrimination ratio (time exploring novel object/total choice trial object
exploration) were measured after the second injection. Experiments were
performed as three separate studies each with their own vehicle control group and
vehicle data are pooled for clarity of presentation, but statistical analyses were
performed for each individual study against its own vehicle control group.
**p<0.01, ***p<0.001 compared to saline vehicle, p<0.05, p<0.01 compared
to the familiar object in the same treatment group, Bonferroni post-hoc following
two-way repeated measures ANOVA. p<0.001 compared to hypothetical mean of
0.5, one sample t-test.
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3.4.1.4 Conditioned emotional response
When CER conditioning was performed on day 8 of the study (7 days after
the previous injection) there was no significant difference between
treatment groups in the latency to cross to the dark side of the box
(p>0.05) and all rats crossed into the dark side of the CER box within 5
min. Irrespective of treatment history, all groups exhibited comparable
levels of freezing after foot shock administration (Cath 1 and 4 mg kg-1:
F(2,20)=0.15, p>0.05; Meph 1 and 4 mg kg
-1: F(2,21)=0.26, p>0.05; Meph
and MDMA 10 mg kg-1: F(2,19)=1.11, p>0.05, Fig 3.6A) and all groups
successfully acquired the CER, as demonstrated by a significant increase in
freezing after the second foot shock compared to the first (Cath 1 and 4
mg kg-1: F(1,20)=9.03, p<0.01, Meph 1 and 4 mg kg
-1: F(1,21)=34.84,
p<0.001, Meph and MDMA 10 mg kg-1: F(1,19)=33.24, p<0.001). Drug
treatments were administered immediately after the CER this trial (third
injection) to prevent any drug effect on nociception or anxiety which could
non-specifically alter conditioning and confound interpretation of any effect
on learning and memory in this paradigm.
During the retention trial, 24 h after the third injection, rats exhibited
freezing behaviour when returned to the environmental context where foot
shocks had been delivered, again confirming successful acquisition of the
CER. This contextual conditioning was impaired only by the highest dose of
mephedrone (10 mg kg-1) which significantly reduced freezing compared to
that in vehicle control such that there was a main effect of treatment
(F(2,19)=4.31, p<0.05, Fig 3.6B). Subsequent presentation of the light and
tone cue (in the absence of any further foot shock) significantly increased
freezing duration for all mephedrone and MDMA groups compared to the
context alone (main effects of Meph 1 and 4 mg kg-1: F(1,21)=47.77,
p<0.001; Meph and MDMA 10 mg kg-1: F(1,19)=5.11, p<0.01 p<0.001) but
there were no significant differences between any individual treatment
group and vehicle control.
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Figure 3.6 Mephedrone, but not cathinone or MDMA, impaired contextual
but not cued CER.
Young adult male Lister hooded rats (n=6-8 per treatment group) received i.p.
saline vehicle (V, 1 ml kg-1), cathinone (Cath, 1 or 4 mg kg-1), mephedrone (Meph,
1, 4 or 10 mg kg-1) or MDMA (10 mg kg-1) twice weekly on consecutive days for
three weeks. Duration (s, mean ± SEM) of freezing behaviour during (A)
conditioning and (B) retention trials of the CER task were measured on days 8 and
9 of the experiment. Injections were administered immediately after each trial to
prevent any drug effect on nociception or anxiety which could non-specifically alter
conditioning and confound interpretation of any effect on learning and memory in
the paradigm, such that the conditioning trial was conducted 7 days after the the
second injection and the requisition trial was performed 24 h after the third
injection. Experiments were performed as three separate studies each with their
own vehicle control group and vehicle data are pooled for clarity of presentation,
but statistical analyses were performed for each individual study against its own
vehicle control group. *p<0.01 compared to saline vehicle, p<0.05, p<0.01,
p<0.001 compared to freezing after the first shock, Bonferroni post-hoc
following two-way repeated measures ANOVA.
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3.4.1.5 Prepulse inhibition of the acoustic startle response
When PPI was assessed on day 15 of the experiment following the fifth
injection, all treatment groups exhibited the normal attenuation of startle
by exposure to increasing pre-pulse amplitude (Cath 1 and 4 mg kg-1:
F(2,42)=38.22, p<0.001; Meph 1 and 4 mg kg
-1: F(2,42)=50.21, p<0.001;
Meph and MDMA 10 mg kg-1: F(2,38)=37.18, p<0.001, Fig 3.7). There were
no between-group differences in % PPI at any pre-pulse amplitude (Cath 1
and 4 mg kg-1: F(2,21)=0.48, p>0.05; Meph 1 and 4 mg kg
-1: F(2,21)=0.55,
p>0.05; Meph and MDMA 10 mg kg-1: F(2,19)=1.45, p>0.05) and no
treatment effects on either basal reactivity to the startle pulse or
habituation to the startle pulse across the trial test session.
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Figure 3.7 Cathinone, mephedrone and MDMA did not affect prepulse
inhibition of the acoustic startle response.
Adult male Lister hooded rats (n=6-8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1), cathinone (Cath, 1 or 4 mg kg-1), mephedrone (Meph, 1, 4
or 10 mg kg-1) or MDMA (10 mg kg-1) twice weekly on consecutive days for three
weeks. Prepulse inhibition was measured on day 15 of the experiment 30 min after
the fifth injection. Experiments were performed as three separate studies each with
their own vehicle control group and vehicle data are pooled for clarity of
presentation, but statistical analyses were performed for each individual study
against its own vehicle control group.
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3.4.1.6 Neurochemistry
No dose of any compound had any significant long-term effect on tissue
concentrations of dopamine, 5-HT, or their metabolites in the striatum or
frontal cortex seven days after the last of six chronic intermittent
injections. Dopamine and 5-HT levels in the hippocampus were also
unaffected (Fig 3.8A,B) but the concentration of DOPAC in this region was
significantly increased following mephedrone (4 mg kg-1; F(2,19)=7.37,
p<0.01, Fig 3.8D) and, in contrast, significantly decreased following 10 mg
kg-1 mephedrone and MDMA (p<0.05; F(2,19)=33.48, p<0.001 Fig 3.8D).
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Figure 3.8. Effect of chronic intermittent cathinone, mephedrone or MDMA
on hippocampal monoamine levels seven days after the last of six
injections.
Adult male Lister hooded rats (n=6-8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1), cathinone (Cath, 1 or 4 mg kg-1), mephedrone (Meph, 1 or 4
mg kg-1) or meph or MDMA (10 mg kg-1) on two consecutive days a week for three
weeks. The hippocampus was dissected seven days after the final injection and
analysed for (A) 5-HT, (B) dopamine, (C) 5-HIAA and (D) DOPAC levels by HPLC-
ED. Experiments were performed as three separate studies each with their own
vehicle control group and vehicle data are pooled for clarity of presentation, but
statistical analyses were performed for each individual study against its own vehicle
control group. Data are presented as a percentage of respective vehicle but
statistical analysis were performed on the raw values (pmol mg-1 wet weight tissue,
mean ± SEM). *p<0.05 Bonferroni post-hoc following one-way ANOVA.
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3.5 Discussion
The main findings of this study were that cathinone, mephedrone and
MDMA caused hyperactivity in rats following the first injection of a chronic
intermittent dosing schedule, with evidence for sensitisation to cathinone-
and mephedrone-induced hyperactivity by the sixth injection 16 days later.
In addition, the three compounds all impaired performance in a NOD test
of visual recognition memory and the highest dose of mephedrone also
reduced context (but not cue) mediated freezing in the CER task. In
addition, mephedrone and MDMA both altered post-mortem hippocampal
DOPAC levels seven days after the final injection, but had no significant
effect on either dopamine or 5-HT in the hippocampus, frontal cortex or
striatum.
In the current study, cathinone, mephedrone and MDMA all produced
significant ambulatory hyperactivity when administered to rats. In the case
of cathinone and mephedrone (where different doses were examined)
these effects appeared to be dose-dependent. Dopaminergic neuronal
activity plays a key role in locomotion and dopamine release has been
reported in the nucleus accumbens of rats administered cathinone (Kalix
1982), mephedrone (Kehr et al. 2011; Baumann et al. 2012) and MDMA
(O'Shea et al. 2005) which may contribute to the observed hyperactivity.
The hyperactivity induced by cathinone was greater in both magnitude and
duration than that caused by mephedrone at the same dose. Although both
cathinone (3.2 mg kg-1) and mephedrone (3 mg kg-1) appear to increase
dopamine efflux (measured by microdialysis in the nucleus accumbens) to
a peak of approximately 550% of baseline values (Pehek et al. 1990; Kehr
et al. 2011) this effect is sustained in cathinone treated rats but more
transient following mephedrone. Therefore, both the transient nature of
mephedrone-induced hyperactivity and prolonged responses to cathinone
and MDMA in the current study are consistent with previous findings by
other groups (Callaway et al. 1990; Pehek et al. 1990; Bull et al. 2003;
Clemens et al. 2007; Kehr et al. 2011; Kelly 2011). Interestingly, the
duration of hyperactivity seen here also matches the time course of the
change in body temperature observed in Chapter 2, and the transient
effects of mephedrone on both LMA and temperature appear consistent
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with reports from recreational users that its effects are short-lasting
(Dargan et al. 2011; Winstock et al. 2011).
Behavioural sensitisation is a well established phenomenon which is seen
after repeated doses of amphetamines (e.g. 5 mg kg-1 twice daily for five
days; Robinson and Becker, 1986) and considered to result from enhanced
drug-induced dopamine and glutamate release (Robinson and Becker
1982; Beutler et al. 2011), as well as increase dopamine D1 receptor
sensitivity, particularly in the nucleus accumbens and striatum (see Kalivas
et al., 1983). Sensitisation to MDMA has been reported following several
different dosing schedules, including 5 mg kg-1 once daily for seven days
(Aberg et al. 2007). However behavioural sensitisation is both dose-level
and dose-interval related and despite the fact that MDMA sensitisation can
be induced by more intense dosing schedules, the intention in the current
study was to mimic weekend recreational use, so MDMA-sensitisation was
not observed in the current study. Following the sixth dose of cathinone (4
mg kg-1) and mephedrone (10 mg kg-1) there was a greater locomotor
response than that observed following the first dose. This is consistent with
reported locomotor sensitisation to cathinone after repeated daily dosing
(Banjaw et al. 2005) and indicates that such sensitisation can still occur
even when drug administration is intermittent. Although mephedrone-
induced hyperactivity has been observed previously following single
injection, repeated dosing on the same day and repeated injections over
five consecutive days (Kehr et al. 2011; Baumann et al. 2012; Lisek et al.
2012; Motbey et al. 2012; Wright et al. 2012) this is the first study to
show sensitisation to mephedrone following intermittent dosing.
Previous studies have indicated that MDMA administration can impair
working memory and sensorimotor gating in rats (Vollenweider et al.
1999; Piper and Meyer 2004; Rodsiri et al. 2011) as well as working
memory (Bolla et al. 1998; Parrott et al. 1998) and associative learning
(Montgomery et al. 2005) in current and abstinent human users. In
contrast, mephedrone has recently been shown to improve visuo-spatial
memory and learning in non-human primates (Wright et al. 2012) but
impair working memory in humans (Freeman et al. 2012), although there
is no information on its cognitive effects in rodents. In the current study,
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rats that had received two previous treatments with any dose of cathinone,
mephedrone or MDMA (at 24 h and 30 min prior to testing) were unable to
distinguish between the novel and the familiar object during the choice trial
of NOD. However, during the familiarisation trial, the higher doses (4 and
10 mg kg-1) of mephedrone, cathinone (4 mg kg-1) and MDMA decreased
total levels of object directed exploration, making it difficult to attribute the
absence of choice trial discrimination at these doses to specific memory
impairment, but may be due to attention deficits instead.
Neither cathinone nor MDMA influenced any aspect of associative memory
in the CER test. The highest dose of mephedrone significantly reduced
freezing on re-exposure to the context in which the shock was received,
but did not alter freezing in response to re-presentation of the light and
tone cue, suggesting that mephedrone may specifically attenuate
hippocampal-dependent contextual association but not hippocampal and
amygdala-dependent cued association (Phillips and Ledoux 1992; Fanselow
2000). CER acquisition was conducted seven days after the second dose
and CER retention 24 h after the third dose of mephedrone. Given that the
LMA response to the first and sixth mephedrone injections was significantly
different from vehicle only until 15 and 55 min post-injection respectively,
it is extremely unlikely that reduced freezing to context during the CER
retention trial was caused by any direct locomotor effects of mephedrone
injection 24 h earlier.
None of the drugs altered PPI of the acoustic startle response
(sensorimotor gating) assessed 30 min after the fifth injection in this
study, although importantly all vehicle treated controls showed the
expected increase in PPI with increasing pre-pulse amplitude consistent
with previous studies using the same equipment and protocol (Jones et al.
2011). The lack of cathinone effects herein contrast with the findings of
Banjaw et al. (2005) but the dose schedule required to produce cathinone-
induced deficits in PPI (2 mg kg-1 daily for 10 days) differed markedly from
the current study. The mean initial and final startle responses to the 120
dB pulse alone and the habituation to the startle pulse across the test
period were not significantly different across treatment groups, indicating
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that none of the compounds exerted any additional effects which could
confound interpretation of the PPI data.
Taken together, the current findings in adult male Lister hooded rats do
not appear to support profound effects of the current chronic intermittent
mephedrone or cathinone dosing regimen on visual or associative learning
and memory or pre-attentional processing, at least in the paradigms
tested. The different time points for behavioural tests resulted in animals
receiving different cumulative doses before each test employed. However,
since all compounds elevated LMA following the first and sixth injections,
and sensitisation to cathinone and mephedrone was apparent following the
sixth dose, it is unlikely that the lack of effect on PPI or CER was due to
development of tolerance to any of the drugs.
Acute MDMA administration to the rat causes 5-HT release and inhibits 5-
HT re-uptake, leading to decreased tissue 5-HT content (Green et al.,
2003). While repeated MDMA administration induces additional neurotoxic
loss of 5-HT in forebrain regions (Green et al. 2003), the extent of this
neurotoxicity is dependent both on dose and frequency of administration
(O'Shea et al. 1998). High dose methamphetamine also results in
neurotoxic damage to dopamine and 5-HT nerve endings in the brain
(Hotchkiss and Gibb 1980; Armstrong and Noguchi 2004). This study
therefore examined the concentration of 5-HT and dopamine in brain
regions known to be sensitive to acute and neurotoxic effects of cathinone,
mephedrone or MDMA seven days following the last of six intermittent
doses. There was no significant effect of any treatment on the
concentration of either 5-HT or dopamine in the striatum, frontal cortex or
hippocampus seven days after the sixth injection. However, mephedrone
(4 mg kg-1) significantly increased hippocampal DOPAC while the higher
dose (10 mg kg-1) caused a significant decrease. It is currently unclear
what mechanism might account for this biphasic change in tissue DOPAC.
It has previously been reported that MDMA causes depletion of brain 5-HT
seven days after administration (Green et al., 2003). The lack of effect of
MDMA on tissue 5-HT levels seven days post-injection in the current study
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may be because tissue monoamine levels are only indicative of
neurotransmitter levels at a single time point of a dynamic situation
involving changes in neurotransmitter release, synthesis, metabolism and
elimination. Additionally, hypothermia is neuroprotective against MDMA-
induced monoamine neurotoxicity (Malberg and Seiden 1998; Mueller et al.
2013). Since hypothermia was observed following acute MDMA
administration in the previous chapter it is possible that this is contributing
to the lack of effect of MDMA on tissue 5-HT levels seven days post-
injection. However, since rectal temperature was not measured in this
study this cannot be verified.
While mephedrone has recently been reported to induce neurotoxic loss of
5-HT in the hippocampus (Hadlock et al. 2011) this effect was observed
following a more intense dosing schedule (four doses of 10 or 25 mg kg-1
given at 2 h intervals) and at a higher ambient temperature selected to
ensure onset of hyperthermia, although importantly in both cases tissue
was collected seven days after the final dose. Other, more recent studies
have also failed to observe any neurotoxic loss of tissue monoamine levels
following mephedrone administration (Baumann et al. 2012; Motbey et al.
2012; den Hollander et al. 2013).
In summary, cathinone, mephedrone and MDMA caused hyperactivity in
rats with evidence of locomotor sensitisation following intermittent dosing
with cathinone and mephedrone. All drugs appeared to impair NOD,
although the decrease in total levels of object exploration during the
familiarisation trial suggests that this may be due to a non-specific
mechanism and not a deficit in visual recognition memory. Mephedrone
(10 mg kg-1) did selectively impair retention of fear motivated contextual
memory in CER but the mechanism involved in this effect is currently
unknown. There was no significant effect of the repeated intermittent
dosing regimen on CER acquisition, sensorimotor gating, or brain tissue
levels of dopamine or 5-HT seven days after the final injection. To
conclude, it appears that while cathinone, mephedrone and MDMA may
have similar mechanisms of action, the behavioural responses are clearly
dependent on both the dose and frequency of administration.
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Since mephedrone is often taken by previous MDMA users and can be
taken concomitantly with other psychostimulants (Moore et al. 2013), the
studies in the next chapter investigated the effects of previous MDMA
exposure during early adolescence administration or concomitant caffeine
administration on mephedrone-induced changes in LMA, NOD,
temperature, elevated plus maze and PPI.
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Chapter 4 Effects of MDMA pre-exposure or
caffeine co-administration on the
behavioural and neurochemical
responses to mephedrone
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4.1 Introduction
Toxicological investigations into the cause of death in mephedrone-related
fatalities in the UK (2009-2011) have confirmed poly-drug intoxication in a
number of cases (Winstock et al. 2011; Corkery et al. 2012). Mephedrone
users often report taking other stimulants, such as alcohol, cannabis,
MDMA or cocaine concurrently. For instance, in one survey the majority of
mephedrone users (87% of 1506 survey participants) admitted previous or
concurrent illicit use of MDMA (Carhart-Harris et al. 2011). Repeated
MDMA administration to rats produces behavioural sensitisation both to
MDMA itself as well as to other amphetamine-like psychostimulants. This
sensitisation is thought to result from enhanced dopamine release in the
nucleus accumbens and striatum (Robinson and Becker 1982) and is both
dose level and administration interval dependent (Kalivas et al. 1993). As
previously stated, mephedrone causes some similar effects to MDMA in
recreational users, including changes in thermoregulation, cognitive
deficits, hallucinations, anxiety, agitation and hypertension (Dargan et al.
2010; Freeman et al. 2012) most of which have been replicated in the
rodent (Meng et al. 2012; Motbey et al. 2012; den Hollander et al. 2013;
Shortall et al. 2013). Although the effects of mephedrone are short term in
comparison to those of MDMA and appears to have less potential long term
neurotoxicity (Baumann et al. 2012; Motbey et al. 2012; den Hollander et
al. 2013). Therefore the characterisation of any change in the acute effects
of mephedrone after MDMA pre-exposure is worth investigation.
Although mephedrone is now banned across Europe and the USA (Dargan
et al. 2011; Gershman and Fass 2012), analysis of legal high products
after the UK ban on mephedrone found that these products contained
mephedrone along with other psychostimulants, such as caffeine (Brandt
et al. 2010; Davies et al. 2010; Rosenauer et al. 2013). Caffeine is known
to increase the toxicity of MDMA in rats, characterised by seizures,
hyperthermia, tachycardia and lethality (for review see Vanattou-
Saïfoudine et al., 2012). The increase in caffeinated energy drink
consumption also means that mephedrone users may intentionally ingest
high levels of caffeine with mephedrone (Reissig et al. 2009). It is
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therefore worth investigating whether caffeine co-administration
exacerbates the acute effects of mephedrone.
Prior to examining the influence of MDMA or caffeine on responses to
mephedrone, a preliminary dose-response study was conducted to allow
selection of a submaximal mephedrone dose and ensuring any synergistic
interaction with the other drugs could be detected. Rats received 10 or 30
mg kg-1 of mephedrone and LMA was recorded for 60 min post-injection, at
the end of which a single rectal temperature measurement was made. On
the basis of this study a 10 mg kg-1 dose of mephedrone was chosen for
the further two studies in this chapter, which investigated the effects of
MDMA pre-exposure during early adolescence or concomitant caffeine
administration on the behavioural responses of rats to mephedrone during
adulthood. In the MDMA study, during the pre-exposure phase involved a
single i.p. injection of saline vehicle or MDMA (5 mg kg-1) once daily for
seven days, followed by a seven day washout period before behavioural
testing. This dosing schedule is known to produce locomotor sensitisation
to MDMA (Aberg et al. 2007) and in the current study rats received a
single injection of vehicle, MDMA (5 mg kg-1) or mephedrone (10 mg kg-1)
on each day of behavioural testing. In the caffeine study, rats received i.p.
saline vehicle, mephedrone (10 mg kg-1) or caffeine (10 mg kg-1) alone or
in combination on each behavioural test day. This dose of caffeine was
selected as it alters the locomotor activity and temperature responses to
MDMA in the rat (Vanattou-Saifoudine et al. 2010). The dose schedule
described in section 3.3.3 was used for the behavioural phase of both
studies, where rats received two injections per week over three weeks, and
Chapter 3 showed that this chronic intermittent administration of 10 mg
kg-1 of mephedrone alone produced marked pharmacological and
behavioural effects in the rat without any accompanying long-term
monoamine neurotoxicity. In both the MDMA and caffeine studies the
hypothalamus, frontal cortex, hippocampus and hypothalamus (selected
because of their known sensitivity to the acute effect of MDMA on
monoamine release) were collected 60 min (MDMA study) or 7 days (study
caffeine study) after the final mephedrone injection to measure any
changes in dopamine, 5-HT or their major metabolites.
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4.2 Aims
The main aims of this set of experiments were to:
(1) investigate the effects of MDMA administration to rats on subsequent
mephedrone or MDMA challenge;
(2) investigate the effects of concomitant caffeine and mephedrone
administration on various behavioural responses to mephedrone;
(3) identify any neurochemical changes that occur in specific brain regions
either 60 min (study two) or seven days (study three) after the final
mephedrone injection.
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4.3 Materials and Methods
4.3.1 Animals
Experimentally naïve young-adult male Lister hooded rats (210-250g at
start of behavioural testing; Charles River UK) were housed in groups of
four in wire-top cages (in Scantainer ventilated cabinets for the caffeine
study) under constant environmental conditions as described in section
2.3.1. All experiments were performed during the light phase between
9.00 h and 16.00 h. All procedures were conducted in accordance with the
U.K. Animals (Scientific Procedures) Act, 1986 and ARRIVE guidelines, with
approval of the University of Nottingham Local Ethical Committee. The
doses of drugs and behavioural schedule were chosen to comply with the
three Rs of humane animal testing. In all experiments, rats were allocated
to a treatment group using a pseudorandom design but initial body weights
were checked to ensure no basal weight differences between groups. The
body weight of each rat was taken before the first injection and then
monitored throughout the remainder of the experiment.
4.3.2 Drugs
Caffeine ReagentPlus was purchased from Sigma Aldrich, UK. (±)-MDMA-
HCl was obtained from Tocris Bioscience, UK and (±)-mephedrone-HCl was
purchased from Ascent Scientific, UK. All drugs were dissolved in saline
vehicle (0.154 M) and doses are quoted as the salt.
4.3.3 Experimental design
4.3.3.1 Study one: Mephedrone dose response
LMA was performed as described in section 3.3.3.2. Rectal and tail
temperatures were taken once immediately at the end of locomotor
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recording (60 min post-injection), using the equipment described in section
2.3.3.1.
4.3.3.2 Study two: Effects of MDMA pre-exposure on mephedrone-
induced changes to behaviour and temperature
To examine the effects of MDMA pre-exposure on the response to
subsequent mephedrone administration, rats (n=8 per treatment group)
received i.p. injections of saline vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1)
once daily for seven days (1-7), followed by a seven day washout period
(days 8-14). Rats were subsequently challenged with saline vehicle (V, 1
ml kg-1), MDMA (5 mg kg-1) or mephedrone (Meph, 10 mg kg-1) on two
consecutive days a week for three weeks (days 15, 16, 22, 23, 29 and 30),
to mimic typical patterns of weekend recreational use in humans (see Fig
4.1 for a summary of the dose schedule). On challenge injection days, rats
were assessed for LMA (days 15 and 29), NOD (day 16), elevated plus
maze behaviour (day 22), rectal and tail temperature changes (day 23) or
PPI (day 30). Brain regions were collected 60 min after the final challenge
injection for quantification of monoamine neurotransmitters and their
major metabolites by HPLC-ED.
Figure 4.1 Summ
Adolescent male
vehicle (V, 1 ml
period) followed b
challenge of eithe
(±)-mephedrone
weeks resulting
follows V+V, V+
Locomotor activit
16), elevated plu
(day 23) and pre
responses were m
4.3.3.3 Stud
indu
In order to exa
administration,
(V, 1 ml kg-1), m
or a combinatio
injection twice
weekend recrea
dose schedule)
and 16), NOD
temperature cha
injection, brain
neurotransmitte
Chapter 4. Psychostimu
108
ary of the experimental protocol for the M
Lister hooded rats (n=8 per treatment group)
kg-1) or MDMA (5 mg kg-1) once daily for seven d
y a 7 day washout period. Rats subsequently
r i.p. saline vehicle (V, 1 ml kg-1), (±)-MDMA
-HCl (Meph, 10 mg kg-1) on two consecutive day
in six pre-exposure and challenge combinatio
MDMA, V+Meph, MDMA+V, MDMA+MDMA
y (LMA, day 15 and 29), novel object discrimi
s maze behaviour (x-maze, day 22), rectal an
pulse inhibition of the acoustic startle respo
easured on each injection day.
y three: Effects of concomitant caffeine
ced changes to behaviour and temperature
mine the effects of concomitant caffeine
rats (n=8 per treatment group) received i
ephedrone (Meph, 10 mg kg-1), caffeine (
n of caffeine and mephedrone (Caff+Me
weekly on consecutive days for three
tional use in humans (see Fig 4.2 for a
. On each injection day rats were assessed
(day 2), elevated plus maze behaviour
nges (day 9) or PPI (day 15). Seven da
regions were collected for quantification
rs and their major metabolites by HPLC-ED
lant interactions
DMA study.
received i.p. saline
ays (pre-exposure
received an acute
-HCl (5 mg kg-1) or
s a week for three
ns abbreviated as
or MDMA+Meph.
nation (NOD, day
d tail temperature
nse (PPI, day 30)
on mephedrone-
and mephedrone
.p. saline vehicle
Caff, 10 mg kg-1)
ph) in the same
weeks to mimic
summary of the
for LMA (day 1
(day 8), rectal
ys after the final
of monoamine
.
4.2 Summary of
Adolescent male
vehicle (V, 1 ml
combination of b
consecutive days
novel object disc
rectal and tail temp
response (PPI, d
4.3.4 Beha
The sequence o
least to most
behavioural para
3Rs. All appara
between tests
4.3.4.1 Loco
Changes in LMA
sensitisation stu
section 3.3.4.
4.3.4.2 Nove
NOD was asses
on day 2 of the
Chapter 4. Psychostimu
109
the experimental protocol for the caffeine
Lister hooded rats (n=8 per treatment group)
kg-1), mephedrone (10 mg kg-1), caffeine
oth mephedrone and caffeine in the same
a week for three weeks. Locomotor activity (LM
rimination (NOD, day 2), elevated plus maze
erature (day 9) and prepulse inhibition of t
ay 15) responses were measured on each injecti
vioural testing
f behaviours in these studies were desig
aversive in order to limit the effects
digm test whilst minimising animal use to
tus used in each study were cleaned w
to remove any odour cues.
motor activity
were assessed on days 15 and 29 of
dy and days 1 and 16 of the caffeine stu
l object discrimination
sed on day 16 of the MDMA cross-sensiti
caffeine study as described in section 3.3.5
lant interactions
study
received i.p. saline
(10 mg kg-1), or a
injection on two
A, day 1 and 16),
(x-maze, day 8),
he acoustic startle
on day.
ned in order of
of the previous
comply with the
ith 20% ethanol
the MDMA cross-
dy as described in
sation study and
.
Chapter 4. Psychostimulant interactions
110
4.3.4.3 Elevated plus maze
Elevated plus maze was performed on day 22 of the MDMA cross-
sensitisation study and day 8 of the caffeine study to determine any drug-
induced alteration in response to mild aversive environment, using a
previously described apparatus (Bull et al. 2003). The maze (black
Perspex) consisted of four arms (45 cm long) arranged at right angles
around a central square (10 cm x 10 cm) and elevated 70 cm above the
floor. The arms consisted of two closed arms with 10 cm high walls and
two open arms with no walls. Rats were injected and 30 min later placed in
the centre of the maze, facing a closed arm. Light intensity was 20 lux on
the closed arms and 60 lux on the open arms. Exploration was recorded for
5 min using Ethovision XT 7 software. Measures derived were number of
open and closed arm entries, total time spent in open and closed arms,
percentage open arm entries ([open arm entries/total arm entries] x 100),
time and percentage time spent in open arms ([time spent in open
arms/total time spent in all arms] x 100). Frequency of unprotected head
dips over the sides of the open arms and protected stretch attends were
also scored manually from video recordings using the computer keypad.
4.3.4.4 Rectal and tail temperature
Rectal and tail temperatures were recorded on day 23 of the MDMA study
and day 9 of the caffeine study as described in section 2.3.3.1.
4.3.4.5 Prepulse inhibition of acoustic startle response
PPI was measured on day 30 of the MDMA cross-sensitisation study and on
day 15 of the caffeine study as described in detail in section 3.3.7.
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4.3.4.6 Tissue collection and neurochemical detection by HPLC-ED
Hypothalamus and right striatum, frontal cortex and hippocampus were
dissected 60 min post-injection in the MDMA cross-sensitisation study and
seven days after the last of six injections in the caffeine study as described
in section 2.3.3.2. HPLC was also performed as described in section
2.3.3.2.
4.3.5 Statistical analysis
Statistical analysis was performed using GraphPad Prism (v 6.02) or SPSS
v 21 software. In the dose response study, LMA data was analysed by two-
way repeated measures ANOVA with treatment as the between-group
factor and time as the within-group factor. Rectal temperature was
analysed by one-way ANOVA. In the MDMA pre-exposure study, LMA,
NOD, temperature and PPI data were analysed using three-way repeated
measures ANOVA with pre-exposure and challenge injections as between-
group factors and time (LMA, temperature), object (NOD) or pre-pulse
amplitude (PPI) as the within-group factors. X-maze data were analysed by
two-way ANOVA with pre-exposure and challenge injection as factors. In
the caffeine co-administration study, LMA, NOD, temperature and PPI data
were analysed using three-way repeated measures ANOVA with drug
injections as between-group factors and time (LMA, temperature), object
(NOD) or pre-pulse amplitude (PPI) as the within-group factors. X-maze
data were analysed by two-way ANOVA with drug injections as factors.
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4.4 Results
4.4.1 Study one: Mephedrone dose-response
This preliminary dose-response study demonstrated a mephedrone dose-
related increase in horizontal activity after habituation (data not shown) to
a novel arena (Fig. 4.2A), such that there were main effects of treatment
(F(2,15)=25.96, p<0.001) and time (F(11,165)=14.24, p<0.001) as well as a
significant treatment x time interaction (F(22,165)=3.85, p<0.001).
Consistent with previous studies 10 mg kg-1 mephedrone elevated
ambulation above control values from 10 min post-injection (p<0.001)
with a return to baseline levels by 55 min. The higher (30 mg kg-1) dose
also elevated ambulation from 10 min post-injection, but in the case there
was no return to control levels by the end of the 60 min monitoring period.
In addition, activity was significantly higher than that following the lower
10 mg kg-1 dose at 10, 15, 35, 45 and 55 min post-injection confirming
that 10 mg kg-1 mephedrone produces sub-maximal effects on LMA.
Mephedrone also produced a dose-related decrease in both rectal
(F(2,15)=14.32, p<0.001) and tail temperature (F(2,15)=1.85, p<0.001; Fig.
4.2B). Both doses of mephedrone significantly decreased tail temperature
60 min post-injection (p<0.001), however only the higher 30 mg kg-1 dose
produced a decrease in rectal temperature at the same time point
(p<0.001), and in each case the temperature in the 30 mg kg-1 treated
group was significantly lower than that of the 10 mg kg-1 treated group
(p<0.05-0.001). Again confirming the effect of 10 mg kg-1 mephedrone
was sub-maximal and therefore suitable to use in the MDMA pre-exposure
and caffeine co-administration studies.
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Figure 4.3 Acute mephedrone administration caused dose-related
locomotor hyperactivity and hypothermia.
Mean ± SEM (A) locomotor activity, expressed as cumulative horizontal ambulation
counts over consecutive 5 min epochs for the 60 min post-injection period, and (B)
rectal and tail temperature (°C) measured 60 min post-injection in adult male
Lister hooded rats (n=6 per group) which were habituated to the LMA boxes for 60
min and then received single i.p. injection of saline vehicle (V, 1 ml kg-1) or (±)-
mephedrone-HCl (Meph, 10 or 30 mg kg-1) on **p<0.01, ***p<0.001 compared
to saline vehicle, where the bar indicates a significant difference between vehicle
and both doses of mephedrone.

p<0.05,

p<0.001 30 mg kg-1 mephedrone
compared to 10 mg kg-1 mephedrone; multiple comparison post-hoc following two-
way repeated measures ANOVA for LMA or following one-way ANOVA for
temperature data.
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4.4.2 Study two: Effects of MDMA pre-exposure on
mephedrone-induced changes to behaviour and
temperature
4.4.2.1 Body weight
Irrespective of treatment all rats gained weight throughout the
experiment, such that there was a main effect of time (F(5,210)=2633,
p<0.001), but no effect of pre-exposure (F(1,42)=0.42, p>0.05) or
challenge treatments (F(2,42)=0.20, p>0.05), nor any pre-exposure x time
(F(5,210)=0.58, p>0.05), challenge x time (F(10,210)=0.27, p>0.05), pre-
exposure x challenge (F(2,42)=0.80, p>0.05), or pre-exposure x challenge x
time (F(10,210)=1.50, p>0.05, Fig 4.3) interactions.
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Figure 4.4 Drug treatment did not affect body weight for the duration of
the MDMA pre-exposure study.
Adult male Lister hooded rats (n=8 per treatment) displayed an increase in body
weight (g, mean ± SEM) throughout the experiment, which was unaffected by pre-
exposure to saline vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) on days 1-7 of the
experiment, or subsequent twice weekly administration of saline vehicle (1 ml kg-1,
V+V or MDMA+V), MDMA (5 mg kg-1, V+MDMA or MDMA+MDMA) or mephedrone
(10 mg kg-1, V+Meph or MDMA+Meph) on days 15, 16, 22, 23, 28 and 29.
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4.4.2.2 Locomotor activity
Habituation to the activity boxes prior to the first challenge injection on
day 15 was confirmed by a decline in horizontal locomotion over the 60
min pre-injection period (data not shown but consistent with section 3.4.2)
and there were no between-group differences in rats pre-exposed to
vehicle or MDMA. Post-injection there were significant main effects of
challenge injection (F(2,42)=21.42, p<0.001), time (F(11,462)=16.31,
p<0.001) as well as a challenge injection x time interaction (F(22,462)=4.75,
p<0.001), Fig 4.4A, B) but no main effect of MDMA pre-exposure
(F(1,42)=2.41, p>0.05), nor any pre-exposure x time (F(11,462)=1.09,
p>0.05), pre-exposure x challenge injection (F(2,42)=1.05, p>0.05), or pre-
exposure x challenge injection x time interaction (F(22,462)=0.72, p>0.05).
Bonferroni multiple comparisons post-hoc tests showed that although
MDMA challenge appeared to have increased activity in the vehicle pre-
exposed group this did not reach statistical significance (Fig 4.4A).
However, in MDMA pre-exposed rats MDMA challenge caused a significant
increase in locomotion from 10-45 min and at 55 min compared to vehicle
challenge to vehicle pre-exposed rats (p<0.05-0.001) and from 15-55 min
compared to vehicle challenge to MDMA pre-exposed rats (Fig 4.4A). In
vehicle pre-exposed rats mephedrone challenge caused significant
hyperactivity at 10, 20 and 30 min post-injection compared to vehicle
challenge to vehicle pre-exposed rats, while mephedrone challenge to
MDMA pre-exposed rats caused hyperactivity from 10-30 min post-
injection compared to vehicle challenge to vehicle pre-exposed rats and
from 20-40 min compared to vehicle challenge in MDMA pre-exposed rats
(Fig 4.4B). Despite the apparent increases in responses to both MDMA and
mephedrone in MDMA pre-exposed rats, there was no significant difference
in horizontal locomotion following MDMA challenge to vehicle or MDMA pre-
exposed groups (Fig 4.4A) nor any difference in horizontal locomotion
following mephedrone challenge to vehicle or MDMA pre-exposed groups
(Fig 4.4B) at any time point.
As on day 15, habituation to the activity boxes prior to the fifth challenge
injection on day 29 was confirmed by a decline in horizontal ambulatory
activity over the 60 min pre-injection period (data not shown). Both MDMA
(Fig 4.4C) and mephedrone (Fig 4.4D) challenge again caused significant
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hyperactivity from 20 and 15 min post-injection respectively, which was
sustained for the duration of the recording period for both compounds in
both vehicle and MDMA pre-exposed rats (challenge F(2,42)=67.6, p<0.001;
time F(11,462)=7.73, p<0.001, challenge injection x time interaction
F(22,462)=10.28, p<0.001). MDMA pre-exposure did not alter the
hyperactivity observed following MDMA or mephedrone challenge, such
that there no main effect of pre-exposure (F(1,42)=0.15, p>0.05), nor any
pre-exposure x challenge injection (F(2,42)=0.65, p>0.05), or pre-exposure
x challenge injection x time interactions (F(22,462)=1.06, p>0.05).
To further examine the effect of MDMA pre-exposure on LMA following
mephedrone or MDMA challenge, total cumulative horizontal locomotion
counts in the 60 min following mephedrone or MDMA challenge were
analysed. There were main effects of pre-exposure (F(1,42)=0.48, p>0.05),
challenge injection (F(2,42)=52.50, p<0.001) and day (F(1,42)=46.38,
p<0.001) on total cumulative LMA counts on both LMA test days, as well as
pre-exposure x day (F(1,42)=4.28, p<0.05), challenge injection x day
(F(2,42)=11.39, p<0.001), pre-exposure x challenge injection (F(2,42)=0.12,
p>0.05) and pre-exposure x challenge injection x day interactions
(F(2,42)=3.38, p<0.05, Table 4.1). Mephedrone increased total LMA counts
in both vehicle and MDMA pre-exposed rats on both test days. MDMA
increased total LMA counts in MDMA pre-exposed rats, but not vehicle pre-
exposed rats on day 15 and in both vehicle and MDMA pre-exposed rats on
day 29. Total LMA counts for mephedrone were also significantly higher on
day 29 than day 15 in both pre-exposed groups, while MDMA displayed
greater horizontal locomotor activity counts on day 29 compared to day 15
in the vehicle pre-exposed rats only.
There were no significant main effects of MDMA pre-exposure or challenge
injection on total rearing or fine movement counts following the final
challenge injection (data not shown).
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Figure 4.5 MDMA pre-exposure did not alter mephedrone-induced
hyperactivity.
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-exposure
period) followed by a 7 day washout. Rats subsequently received an intermittent
challenge of either i.p. saline vehicle (1 ml kg-1), (A, C) (±)-MDMA HCl (5 mg kg-1)
or (B, D) (±)-mephedrone HCl (meph, 10 mg kg-1) on two consecutive days a
week for three weeks. Locomotor activity was measured on days (A, B) 15 and (C,
D) 29, following the first and fifth challenge injections. The pre-exposure and
challenge combinations are abbreviated as follows V+V, V+MDMA, V+Meph,
MDMA+V, MDMA+MDMA or MDMA+Meph. *p<0.05, **p<0.01, ***p<0.001
compared to V+V; *p<0.05, **p<0.01, ***p<0.001 compared to MDMA+V,
Bonferroni post-hoc following three-way repeated measures ANOVA. The bars on
the graphs indicate significance at these time points for (C) V+MDMA and
MDMA+MDMA and (D) V+Meph and MDMA+Meph. For clarity of presentation MDMA
and mephedrone challenge on both days are represented in separate panels but
statistical analyses were performed collectively on all groups for each day.
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4.1 MDMA pre-exposure had no effect on mephedrone-induced increases in
total cumulative LMA counts on day 15 or 29.
Treatment Day 15 Day 29
V+V 533 ± 74 466 ± 73
V+Meph 1695 ± 300** 2742 ± 213***
V+MDMA 1447 ± 181 2629 ± 319***
MDMA+V 569 ± 106 660 ± 110
MDMA+Meph 1851 ± 328****** 2605 ± 235******
MDMA+MDMA 2071 ± 168****** 2381 ± 153******
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-exposure
period) followed by a 7 day washout. Rats subsequently received an intermittent
challenge of either i.p. saline vehicle (1 ml kg-1), (±)-MDMA HCl (5 mg kg-1) or (±)-
mephedrone HCl (meph, 10 mg kg-1) on two consecutive days a week for three
weeks. Locomotor activity was measured on days 15 and 29 following the first and
fifth challenge injections. The pre-exposure and challenge combinations are
abbreviated as follows V+V, V+MDMA, V+Meph, MDMA+V, MDMA+MDMA or
MDMA+Meph. **p<0.01, ***p<0.001 compared to V+V on the same LMA day;
***p<0.001 compared to MDMA+V on the same LMA day; p<0.01, p<0.001
compared to the same treatment on day 15, Bonferroni multiple comparisons post-
hoc following three-way repeated measures ANOVA.
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4.4.2.3 Novel object discrimination
NOD was assessed following the second challenge injection (day 16). There
was no spatial preference for either object during the familiarisation trial
for any treatment group. However, there was a significant main effect of
challenge injection on time spent exploring the two identical objects during
the familiarisation trial (challenge: F(2,42)=18.23, p<0.001, object:
F(1,42)=12.62, p<0.001, data not shown), which resulted from both
mephedrone and MDMA challenge reducing total object exploration,
compared to vehicle challenge in vehicle or MDMA pre-exposed controls.
There was no significant pre-exposure x challenge injection x object
interaction on the profile of novel and familiar object exploration in the
choice trial (F(2,42)=1.63, p>0.05, data not shown). Similarly there was no
significant effect of pre-exposure or challenge injection on the derived
choice trial discrimination ratio (pre-exposure x challenge interaction:
F(2,42)=2.80, p>0.05, Fig 4.5).
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Figure 4.6 Mephedrone and MDMA had no significant effect on the NOD
choice trial discrimination ratio.
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-exposure
period) followed by a 7 day washout period. Rats subsequently received an
intermittent challenge of either i.p. saline vehicle (1 ml kg-1), (A, B) (±)-MDMA-HCl
(5 mg kg-1) or (C, D) (±)-mephedrone-HCl (meph, 10 mg kg-1) on two consecutive
days a week for three weeks. Novel object discrimination was measured on d 16
following the second challenge injection. The pre-exposure and challenge
combinations are abbreviated as follows V+V, V+MDMA, V+Meph, MDMA+V,
MDMA+MDMA or MDMA+Meph.
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4.4.2.4 Elevated plus maze
Following the third challenge injection (day 22), both MDMA and
mephedrone increased anxiety-like behaviour on the x-maze. MDMA and
mephedrone challenge injections reduced the percentage time spent in the
more aversive open arms of the plus maze (pre-exposure: F(1,42)=0.17,
p>0.05; challenge injection: F(2,42)=10.15, p<0.001; pre-exposure x
challenge injection interaction: F(2,42)=3.71, p<0.05, Fig 4.6A) and the
number of exploratory head dips over the sides of the open arms (pre-
exposure: F(1,42)=1.65, p>0.05; challenge injection: F(2,42)=10.02,
p<0.001; pre-exposure x challenge injection interaction: F(2,42)=3.59,
p<0.05, Fig 4.6B). However, the anxiety-like effects of MDMA challenge
were only observed in vehicle and not MDMA pre-exposed rats. In contrast,
the anxiety-like effect of mephedrone challenge on percent open arm time
was only evident in MDMA pre-exposed rats, but the effect on head dips
was evident irrespective of pre-exposure. Stretch attends were not
observed.
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Figure 4.7 MDMA pre-exposure reversed anxiety-related behaviour on the
elevated plus maze following MDMA challenge.
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-exposure
period) followed by a 7 day washout period. Rats subsequently received an
intermittent challenge of either i.p. saline vehicle (1 ml kg-1), (±)-MDMA-HCl (5 mg
kg-1, A, B) or (±)-mephedrone-HCl (meph, 10 mg kg-1, C, D) on two consecutive
days a week for three weeks. (A) Percentage open arm entries and (B) unprotected
head dips on the elevated plus maze were measured on day 22, following the third
challenge injection. The pre-exposure and challenge combinations are abbreviated
as follows V+V, V+MDMA, V+Meph, MDMA+V, MDMA+MDMA or MDMA+Meph.
*p<0.05, **p<0.01, ***p<0.001 compared to V+V; *p<0.05, **p<0.01
compared to MDMA+V; p<0.05 compare to V+MDMA, Bonferroni post-hoc
following three-way repeated measures ANOVA.
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4.4.2.5 Rectal and tail temperature
There was no significant difference in initial rectal and tail temperatures 40
min prior to the fourth challenge injection on day 23 (data not shown).
There was a significant main effect of pre-exposure (F(1,42)=6.39, p<0.05),
challenge injection: (F(2,42)=22.71, p<0.001) and time (F(6,252)= 4.16,
p<0.001) on rectal temperature as well as a challenge x time interaction
(F(12,252)= 5.41, p<0.001) but no pre-exposure x challenge injection
(F(2,42)=3.10, p=0.056), pre-exposure x time (F(6,252)= 1.64, p>0.05) or
pre-exposure x challenge injection x time (F(12,252)=1.30, p>0.05)
interactions. MDMA challenge to individually-housed rats at normal room
WHPSHUDWXUHFDXVHGDVLJQLILFDQWGHFUHDVHLQUHFWDOWHPSHUDWXUHE\Û&DW
60 min) in vehicle pre-exposed rats, which was evident from 40-80 min
post-injection (Fig 4.7A). This response was attenuated in MDMA pre-
H[SRVHGUDWVRQO\GHFUHDVLQJE\Û&DWPLQVXFKWKDWWKLVJURXSRI
rats did not display any significant change in temperature from the vehicle
control groups. In contrast to previous temperature studies (Chapter 2),
mephedrone challenge did not cause a significant decrease in rectal
temperature in either vehicle or MDMA pre-exposed rats (Fig 4.7B). There
was no significant effect of MDMA or mephedrone challenge on tail
temperature (data not shown).
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Figure 4.8 Effect of MDMA pre-exposure on subsequent MDMA and
mephedrone-induced changes in temperature.
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-
exposure period) followed by a 7 day washout period. Rats subsequently received
an intermittent challenge of either i.p. saline vehicle (1 ml kg-1), (A) (±)-MDMA-
HCl (5 mg kg-1) or (B) (±)-mephedrone-HCl (meph, 10 mg kg-1) on two
consecutive days a week for three weeks. Rectal temperature was measured on
day 23 following the fourth challenge injection. The pre-exposure and challenge
combinations are abbreviated as follows V+V, V+MDMA, V+Meph, MDMA+V,
MDMA+MDMA or MDMA+Meph. *p<0.05, **p<0.01, ***p<0.001 compared to
V+V, Bonferroni post-hoc following three-way repeated measures ANOVA. For
clarity of presentation MDMA and mephedrone challenge are represented on
separate figures but statistical analyses were performed collectively on all groups
on each day.
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4.4.2.6 Prepulse inhibition of acoustic startle response
When PPI was assessed on day 30, following the sixth challenge injection,
all groups exhibited the normal attenuation of startle response by exposure
to increasing pre-pulse amplitude (F(2,84)=74.69, p<0.001, Fig 4.8), and
there was no difference in basal startle reactivity or habituation to the
startle across the session in any group. There was no significant main
effect of pre-exposure (F(1,42)=0.001, p>0.05) or challenge injection
(F(2,42)=2.03, p>0.05), nor was there any pre-exposure x challenge
injection x pre-pulse amplitude interaction (F(2,84)=1.43, p>0.05) on % PPI.
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Figure 4.9 MDMA and mephedrone did not alter prepulse inhibition of the
acoustic startle response.
Adolescent male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1) or MDMA (5 mg kg-1) once daily for seven days (pre-exposure
period) followed by a 7 day washout period. Rats subsequently received an
intermittent challenge of either i.p. saline vehicle (1 ml kg-1), (A, B) (±)-MDMA-HCl
(5 mg kg-1) or (C, D) (±)-mephedrone-HCl (meph, 10 mg kg-1) on two consecutive
days a week for three weeks. Prepulse inhibition of the acoustic startle response
was measured on day 30 following the sixth challenge injection. The pre-exposure
and challenge combinations are abbreviated as follows V+V, V+MDMA, V+Meph,
MDMA+V, MDMA+MDMA or MDMA+Meph.
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4.4.2.7 Neurochemistry
There were no significant effects of repeated mephedrone or MDMA
injections on the levels of dopamine or its metabolites in the frontal cortex,
striatum, hippocampus or hypothalamus 60 min after the final challenge
injection (data not shown). In vehicle pre-exposed rats, 5-HIAA content
was reduced in the hippocampus (challenge F(2,42)=6.89, p<0.01, Table
4.2) and striatum (challenge F(2,40)=3.63, p<0.05) by mephedrone and
MDMA respectively. In MDMA pre-exposed rats, MDMA produced a
decrease in hippocampal 5-HT (challenge F(2,38)=4.42, p<0.05) and 5-HIAA
levels, whereas mephedrone had no significant effect on hippocampal 5-HT
or 5-HIAA content in MDMA pre-treated rats. There was no main effect of
pre-exposure or a pre-exposure x challenge interaction on hippocampal or
striatal 5-HIAA or hippocampal 5-HT levels.
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Table 4.2 MDMA and mephedrone challenge injections altered ex vivo 5-HT
and 5-HIAA levels in the hippocampus and striatum.
Treatment 5-HT (pmol mg-1 tissue) 5-HIAA (pmol mg-1 tissue)
Hippocampus
V+V 2.33 ± 0.4 2.62 ± 0.2
V+MDMA 1.64 ± 0.3 2.09 ± 0.1
V+Meph 1.35 ± 0.3 1.80 ± 0.1 *
MDMA+V 2.23 ± 0.2 2.29 ± 0.2
MDMA+MDMA 1.24 ± 0.2 * 1.60 ± 0.2 **
MDMA+Meph 1.85 ± 0.4 2.04 ± 0.2
Striatum
V+V 3.75 ± 0.7 4.02 ± 0.5
V+MDMA 3.23 ± 0.6 2.92 ± 0.2 *
V+Meph 3.23 ± 0.7 3.06 ± 0.5
MDMA+V 3.58 ± 0.6 3.45 ± 0.2
MDMA+MDMA 3.94 ± 0.4 3.00 ± 0.3
MDMA+Meph 3.40 ± 0.2 2.90 ± 0.2
Post-mortem tissue 5-HT and 5-HIAA levels were measured 60 min after the last of
six challenge injections (day 30) of saline vehicle (V, 1 ml kg-1), MDMA (5 mg kg-1)
or mephedrone (Meph, 10 mg kg-1) to adult male Lister hooded rats (n=8 per
group) which had previously received vehicle (1 ml kg-1) or MDMA (5 mg kg-1) on
days 1-7 followed by a washout period from days 8-14. *p<0.05, **p<0.01
compared to V+V (for vehicle pre-exposed rats) or MDMA+V (for MDMA pre-
exposed rats), Bonferroni multiple comparison post-hoc following two-way ANOVA.
The pre-exposure and challenge combinations are abbreviated as follows V+V,
V+MDMA, V+Meph, MDMA+V, MDMA+MDMA or MDMA+Meph.
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4.4.3 Study three: Effects of concomitant caffeine on
mephedrone-induced changes to behaviour and
temperature
4.4.3.1 Body weight
Irrespective of treatment all rats gained weight throughout the experiment
such that there was a main effect of time (F(5,210)=2632.60, p<0.001) but
no effect of either drug alone (caffeine: F(1,42)=0.04, p>0.05; mephedrone:
F(2,42)=0.20, p>0.05) nor any caffeine x mephedrone (F(2,42)=0.80, p>0.05)
caffeine x time (F(5,210)=0.5.8, p>0.05), mephedrone x time (F(10,210)=0.27,
p>0.05) or caffeine x mephedrone x time interactions (F(10,210)=1.50,
p>0.05, Fig 4.9).
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Figure 4.10 Caffeine or mephedrone administration, alone or in
combination, did not affect body weight for the duration of the
experiment.
Adult male Lister hooded rats (n=8 per treatment group) displayed a normal
increase in body weight (g, mean ± SEM) throughout the experiment, which was
unaffected by received twice weekly i.p. injections of saline vehicle (V, 1 ml kg-1),
mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10 mg kg-1) or a combination of
mephedrone and caffeine on two consecutive days each week over three weeks
(days 1, 2, 8, 9, 15, 16).
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4.4.3.2 Locomotor activity
Habituation to the activity boxes prior to injection on both LMA days was
confirmed by a decline in horizontal locomotion over the 60 min
habituation period (data not shown). On day one, mephedrone, caffeine
and co-administration of mephedrone and caffeine had significant main
effects on ambulatory locomotion (caffeine F(1,28)=10.21, p<0.01;
mephedrone F(1,28)=28.91, p<0.001; time F(11,308)=7.42, p<0.001; caffeine
x mephedrone x time interaction F(11,308)=4.16, p<0.001; Fig 4.10A). Post-
hoc tests showed that mephedrone alone increased horizontal locomotion
above the vehicle levels from 10-40 min post-injection whereas the
combination of caffeine and mephedrone increased ambulatory activity
from 10-60 min post-injection with the effect being significantly greater at
60 min post-injection than in rats that received mephedrone alone.
Similar responses were observed on day 16 where mephedrone and
caffeine had a significant main effect on horizontal locomotion (caffeine
F(1,28)=21.53, p<0.001; mephedrone F(1,28)=44.45, p<0.001; time
F(11,308)=7.71, p<0.001; mephedrone x time interaction: F(11,308)=4.39,
p<0.001, Fig 4.10B). Post-hoc tests showed that, as on day 1,
mephedrone alone increased horizontal locomotion above vehicle levels
from 10-40 min post-injection. Also similar to day 1, concomitant caffeine
and mephedrone caused a marked increase in locomotion from 5 min post-
injection which was maintained for the duration of testing.
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Figure 4.11 Caffeine prolonged the effect of mephedrone on locomotor
activity on day 1 but not day 16 of the study.
Adult male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1), mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10 mg kg-1)
or a combination of caffeine and mephedrone (Caff+Meph) twice weekly on two
consecutive days a week for three weeks. Locomotor activity was measured on day
(A) 1 and day (B) 16 following the first and sixth challenge injections. *p<0.05,
**p<0.01, ***p<0.001 compared to V; p<0.01 compared to Meph, Bonferroni
post-hoc following three-way repeated measures ANOVA. The bars indicate
significance from V+V for both Meph alone and in combination with Caff.
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Analysis of the total cumulative LMA counts in the 60 min post-injection
period showed main effects of mephedrone such that mephedrone
(F(1,27)=33.19, p<0.001), alone and in combination with caffeine
(F(1,27)=13.79, p<0.001), increased total locomotor counts on each day
compared to vehicle but there was no significant difference in horizontal
locomotion counts between the first and sixth injections for any treatment
group (caffeine x mephedrone x day interaction: F(1,27)=0.11, p>0.05),
Table 4.3).
4.3 Caffeine had no effect on mephedrone-induced changes in total
cumulative horizontal locomotor counts on day 1 or 16.
Treatment First injection Sixth injection
Vehicle 407 ± 64 542 ± 38
Mephedrone 2087 ± 277*** 2418 ± 374***
Caffeine 1452 ± 204 1631 ± 216
Caffeine+Mephedrone 2708 ± 487**** 3241 ± 223*****
Adult male Lister hooded rats (n=8 per treatment group) received intermittent i.p.
saline vehicle (1 ml kg-1), mephedrone (10 mg kg-1), caffeine (10 mg kg-1) or a
combination of caffeine and mephedrone in a single injection on two consecutive
days a week for three weeks. Locomotor activity was measured on days 1 and 16
following the first and sixth injections. ***p<0.001 compared to vehicle on the
same LMA day; *p<0.05, **p<0.001 compared to caffeine on the same LMA day
Bonferroni multiple comparisons post-hoc following three-way repeated measures
ANOVA.
There was also no significant caffeine x mephedrone x time interaction on
the number of rears on each test day (day 1: F(11,297)=1.94, p>0.05; day
16: (F(11,297)=0.56, p>0.05) data not shown).
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4.4.3.3 Novel object discrimination
NOD was assessed following the second injection (day 2). All rats explored
both objects equally during the familiarisation trial (caffeine x mephedrone
x object F(1,28)=0.04, p>0.05), however, mephedrone treated rats spent
significantly less time exploring than vehicle treated rats (mephedrone:
F(1,28)=9.05, p<0.01, data not shown). Vehicle treated rats successfully
discriminated the novel from the familiar object during the choice trial such
that there was a main effect of object (F(1,28)=4.81, p<0.05), whereas
treatment with caffeine or mephedrone, alone or in combination, impaired
discrimination such that there was no exploratory preference for the novel
object (caffeine x mephedrone x object: F(1,28)=0.47, p>0.05, data not
shown). However, there were no significant main effects of mephedrone
(F(1,28)=0.01, p>0.05), caffeine (F(1,28)=0.70, p>0.05) or their combination
on the discrimination ratio (caffeine x mephedrone: F(1,28)=0.47, p>0.05,
Fig 4.11).
Chapter 4. Psychostimulant interactions
136
Figure 4.12 Mephedrone and caffeine had no significant effect on the NOD
choice trial discrimination ratio.
Adult male Lister hooded rats (n=8 per treatment group) received intermittent i.p.
saline vehicle (V, 1 ml kg-1), mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10
mg kg-1) or a combination of caffeine and mephedrone (Caff+Meph) twice weekly
on two consecutive days a week for three weeks. Novel object discrimination was
measured on day 2 of the study, following the second injection.
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4.4.3.4 Elevated plus maze
Although administration of caffeine or mephedrone did not significantly
alter percentage entries into the open arms following the third injection
(day 8; caffeine x mephedrone interaction: (F(1,28)=0.44, p>0.05), there
was a significant main effect of caffeine (F(1,28)=4.55, p<0.05) as well as a
caffeine x mephedrone interaction (F(1,28)=4.62, p<0.05, Fig 4.12A) on
percentage time spent on the open arms of the x-maze, caused by an
increase in percent time on the open arms in the combined mephedrone
and caffeine treated group, rather than an effect of caffeine alone.
Additionally, administration of mephedrone alone caused a decrease in the
number of exploratory head dips over the sides of the open arms
(F(1,28)=7.96, p<0.01, Fig 4.12B) while simultaneously increasing the
number of stretch attends (F(1,28)=8.49, p<0.01, Fig 4.12C) compared to
vehicle. Caffeine alone did not alter the number of stretch attends
(F(1,28)=1.02, p>0.05) or head dips (F(1,28)=1.15, p>0.05) over the open
arms of the maze, however concomitant caffeine and mephedrone
reversed the mephedrone-induced decrease in head dip counts as well as
increasing the number of stretch attends compared to vehicle (p<0.05).
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Figure 4.13 Caffeine partially reversed mephedrone-induced increases in
anxiety-related behaviour on the elevated plus maze.
Adult male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (1 ml kg-1), mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10 mg kg-1) or
a combination of caffeine and mephedrone (Caff+Meph) twice weekly on two
consecutive days a week for three weeks. (A) Percentage open arm entries, (B)
number of unprotected head dips and (C) stretch attends on the elevated plus
maze were measure on d 8 following the third injection. *p<0.05, **p<0.01, V;
p<0.05 compared to Meph, Bonferroni post-hoc following two-way ANOVA.
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4.4.3.5 Rectal and tail temperature
There was no significant difference in initial rectal and tail temperatures 40
min prior to the fourth injection on day 9. Post-injection there was a
significant main effect of caffeine and mephedrone administration on rectal
temperature over time (caffeine x mephedrone x time interaction:
F(6,168)=2.38, p<0.05, Fig 4.13A). Post-hoc tests showed that mephedrone
decreased rectal temperature from 40-60 min post mephedrone injection
compared to vehicle. Caffeine alone did not significantly alter temperature,
however, concomitant caffeine and mephedrone converted hypothermia to
hyperthermia, where rectal temperature was significantly higher than
mephedrone alone at 60-100 min and significantly higher than vehicle at
120 min post-injection. There was no significant effect of caffeine or
mephedrone on tail temperature (caffeine x mephedrone x time
interaction: F(6,168)=0.86, p>0.05, data not shown).
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Figure 4.14 Caffeine co-administration converted mephedrone-induced
hypothermia to hyperthermia.
Adult male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1), mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10 mg kg-1)
or a combination of caffeine and mephedrone (Caff+Meph) twice weekly on two
consecutive days a week for three weeks. Rectal temperature was measured on
day 9 following the fourth challenge injection. *p<0.05, ***p<0.001 compared to
V; p<0.05, p<0.01 compared to Meph, Bonferroni post-hoc following three-way
repeated measures ANOVA.
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4.4.3.6 Prepulse inhibition of acoustic startle response
On day 15, following the fifth injection, all treatment groups exhibited the
normal attenuation of startle by exposure to increasing pre-pulse
amplitude (pre-pulse: F(2,48)=60.86, p<0.001). There was no difference in
basal reactivity or habituation to the startle pulse alone. There was no
significant effect of caffeine, mephedrone alone or in combination on
percent PPI (caffeine x mephedrone x pre-pulse interaction: F(2,48)=0.09,
p>0.05, Fig 4.14).
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Figure 4.15 Mephedrone administration, alone or in combination with
caffeine, did not alter prepulse inhibition of the acoustic startle.
Adult male Lister hooded rats (n=8 per treatment group) received i.p. saline
vehicle (V, 1 ml kg-1), mephedrone (Meph, 10 mg kg-1), caffeine (Caff, 10 mg kg-1)
or a combination of caffeine and mephedrone (Caff+Meph) twice weekly on two
consecutive days a week for three weeks. Prepulse inhibition of the acoustic startle
response was measured on day 15 following the fifth challenge injection.
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4.4.3.7 Neurochemistry
There was no significant effect of mephedrone alone, or in combination
with caffeine, on ex vivo levels of tissue dopamine, 5-HT or their
metabolites in the hypothalamus, striatum, frontal cortex or hippocampus
collected seven days after the last of six injections (data not shown).
Caffeine alone increased dopamine content (58.81 ± 2.5 pmol mg-1, mean
± SEM) in the striatum compared to vehicle controls (34.5 ± 5.9 pmol mg-
1; F(1,28)=5.38, p<0.05).
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4.5 Discussion
The two main studies in this chapter examined firstly whether pre-
exposure of adolescent rats to MDMA using a dosage schedule reported to
produce locomotor sensitisation to a subsequent injection of MDMA (Aberg
et al. 2007) would also enhance the behavioural responses to mephedrone
and, secondly whether concurrent caffeine administration would alter the
behavioural response to mephedrone. An initial dose-response study
demonstrated that 10 mg kg-1 mephedrone produces submaximal changes
in both locomotor activity and rectal and tail temperature, therefore
allowing any synergistic interaction of MDMA pre-exposure or caffeine co-
administration to be detected in the chosen paradigms. Pre-exposure to
repeated MDMA injection enhanced the locomotor, thermoregulatory and
anxiety-related behavioural effects of MDMA, consistent with the
development of sensitisation. Although there was no alteration in the
locomotor stimulant effects of mephedrone, mephedrone-induced
hypothermia was converted to mild hyperthermia by MDMA pre-exposure
which may be due to cross-sensitisation. Both MDMA and mephedrone
produced an anxiogenic response in the x-maze but MDMA pre-exposure
only prevented the anxiogenic effect of MDMA without altering the
anxiogenic effect of mephedrone. Additionally, caffeine co-administration
had an additive effect on mephedrone-induced hyperactivity, converted
mephedrone-induced hypothermia to hyperthermia and attenuated
anxiety-like behaviours on the x-maze. Finally, MDMA challenge only
decreased hippocampal 5-HT in rats pre-exposed to MDMA during
adolescence but MDMA pre-exposure prevented the mephedrone-induced
decrease in hippocampal 5-HIAA.
Consistent with previous observations in this thesis (Chapter 3) and in
other published work (Lisek et al. 2012), acute mephedrone caused
significant ambulatory hyperactivity in drug naïve rats in both studies.
Administration of MDMA (5 mg kg-1) once daily for seven days induced
locomotor sensitisation to MDMA on day 15, as indicated by the enhanced
locomotor response to the first MDMA challenge in MDMA pre-exposed rats,
thereby confirming the observations of Aberg et al. (2007). However, the
locomotor response to either the first or fifth of six mephedrone challenge
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injections was not enhanced by MDMA pre-exposure, indicating a lack of
cross-sensitisation to the stimulant effects of mephedrone after MDMA. In
contrast, caffeine prolonged the hyper-locomotor response to mephedrone
so that activity remained elevated until the end of the 60 min test session
(instead of returning to vehicle control levels after 40 min in the absence
of caffeine).
MDMA impairs working memory in both humans (Bolla et al. 1998; Parrott
1998) and rats (Piper and Meyer 2004) and mephedrone has also been
reported to impair working memory in human users (Freeman et al. 2012).
In the MDMA pre-exposure study, mephedrone and MDMA challenge both
prevented discrimination between the novel and familiar objects during the
NOD choice trial, but because they also decreased total object-directed
exploration during the familiarisation trial the observed reduction in object
discrimination may be due to reduced attention during learning rather than
a selective memory impairment, and similar findings were obtained in the
mephedrone treated rats in the caffeine co-administration study.
MDMA and mephedrone can cause anxiety in human users (Parrott et al.
2000; Dargan et al. 2011) and it has also been shown that MDMA affects
anxiety-related behaviour in rats (Bull et al. 2003). Administration of low
to medium doses of MDMA (<10 mg kg-1) causes anxiogenic-like behaviour
in the elevated plus maze (increased avoidance of the open arms and
reduced exploratory head dips), but this effect is less marked with higher
doses (Ho et al. 2004). Previous studies have shown that repeated
mephedrone administration has no long-term effect on rodent anxiety-
related behaviour on the elevated plus maze (Motbey et al. 2012; den
Hollander et al. 2013). In the MDMA pre-exposure study presented in this
chapter, MDMA challenge indeed had an anxiogenic effect in vehicle pre-
exposed rats, reducing the percentage time in the more aversive open
arms of the maze as well as the number of exploratory head dips over the
open arms. However, these effects were not seen following MDMA pre-
exposure and it is possible that the combination of seven pre-exposure and
three challenge MDMA injections caused sensitisation to the effects of this
compound on the plus maze since increasing the dose of MDMA can
attenuate the anxiogenic effect (Ho et al. 2004). In contras
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reduced the number of exploratory head dips in both vehicle and MDMA
pre-exposed rats, while reducing the percentage time spent in the open
arms of the maze in MDMA pre-exposed rats only. While MDMA pre-
exposure may be attenuating mephedrone-induced anxiety-like behaviour,
this attenuation was observed in one behaviour, but not the other, so it is
important to not overstate this.
Caffeine administration (10 and 30 mg kg-1) to rats reduces anxiety-
related behaviour in the elevated plus maze (Garcia et al. 2011), whilst
very high doses of caffeine (100 mg kg-1) increase anxiogenic-like
behaviour in the maze (Braun et al. 2011). In the caffeine co-
administration study, mephedrone also reduced percentage time spent in
the open arms of the plus maze as well as the number of head dips, while
increasing the number of stretch attends observed. Interestingly, caffeine
co-administration attenuated the first two responses whilst the number of
stretch attends remained unaffected. Protected stretch attends into the
open arms are a risk assessment behaviour and are related to open arm
avoidance, so while caffeine reduced some anxiety-related behaviour on
the plus maze, it did not completely reverse the anxiogenic effects of
mephedrone.
MDMA can cause hyperthermia in recreational users (Parrott 2012) which
can lead to potentially fatal symptoms of heatstroke, including
rhabdomylosis, myoglobinuria, liver and kidney failure (Green et al. 2004).
Although the hyperthermic and long-term neurotoxic effects of MDMA are
enhanced in hot room temperature conditions, the studies in this were not
performed to determine such toxic effects. Additionally, co-administration
of caffeine and MDMA causes a dose dependent increase in temperature in
the rat, and reverses the MDMA-induced hypothermia to hyperthermia
(McNamara et al. 2006; Vanattou-Saifoudine et al. 2010). It was seen in
chapter 2 that acute mephedrone (10 mg kg-1) and MDMA (10 mg kg-1)
injection both decrease rectal and tail temperature in singly housed rats at
normal ambient temperatures. In the current chapter, MDMA challenge
caused significant hypothermia in vehicle pre-exposed rats only. Repeated
MDMA administration has a cumulative effect on temperature such that
initial hypothermia is converted to hyperthermia by subsequent doses
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(Rodsiri et al. 2011) and increasing the MDMA dose also transforms the
hypothermic to a hyperthermic response (Docherty and Green 2010). The
current attenuation of MDMA-induced hypothermia by MDMA pre-exposure
is therefore more likely to reflect an enhanced response rather than
developed tolerance to MDMA. While mephedrone challenge to vehicle pre-
exposed rats appeared to reduce rectal temperature, this was not
significant from vehicle. Interestingly, this response was not observed in
MDMA pre-exposed rats. Instead this group displayed a modest
hyperthermia towards the end of the recording period. This alteration
probably reflects an enhanced response to mephedrone similar to that
already discussed for MDMA, which may suggest some cross-sensitisation
between the thermoregulatory effects of MDMA and mephedrone, although
since these effects were not significant, further investigation is required. In
the caffeine co-administration study reported in this chapter, mephedrone
also reduced rectal temperature which was converted to hyperthermia in
the presence of caffeine. This may account for the hot flushes and
sweating reported by human users who are likely to be ingesting caffeine
concomitantly with mephedrone (Reissig et al. 2009; Davies et al. 2010;
Rosenauer et al. 2013). As previously mentioned, this is similar to what
has been observed following MDMA and caffeine co-administration.
Locomotor activity was re-assessed after the fifth challenge injection on
day 29 in the MDMA pre-exposure study and after the sixth challenge
injection on day 16 in the caffeine study. In the MDMA pre-exposure study,
MDMA and mephedrone caused sustained hyperactivity resulting in
locomotor sensitisation to mephedrone in both vehicle and MDMA pre-
exposed groups. Since both mephedrone groups developed an enhanced
LMA response on day 29, and there was no difference between the groups
on day 15, this apparent sensitisation occurred independently of MDMA
pre-exposure, suggesting that the two compounds may induce
hyperactivity via slightly different effects on dopamine and 5-HT release.
The lack of sensitisation to MDMA in MDMA pre-exposed rats may be
because these rats had already been exposed and sensitised to MDMA
during the pre-exposure phase. In the caffeine co-administration study,
mephedrone alone and in combination with caffeine also caused significant
hyperactivity on day 16 (sixth injection). However, there was no
sensitisation to the locomotor stimulating effects of mephedrone. This is
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unexpected as the data presented in chapter 3, which followed a similar
dosing schedule as the current study, showed sensitisation to mephedrone.
Finally PPI was investigated as an index of sensorimotor gating, which is
attenuated by drugs that release 5-HT. MDMA has been reported to
attenuate PPI in rats (Vollenweider et al. 1999). However the data
presented in chapter 3 showed that five previous injections of chronic
intermittent mephedrone (1-10 mg kg-1) had no effect on PPI in the rat. In
the current studies, after the sixth or fifth injections, there was again no
significant effect of mephedrone alone, nor any combined effect following
MDMA pre-exposure or caffeine co-administration.
Considering the evidence for locomotor sensitisation in the MDMA pre-
exposure study, it is surprising that there were few changes in brain
regional levels of 5-HT, dopamine and their major metabolites 60 min after
the last challenge injection (after PPI). Although MDMA failed to decrease
hippocampal 5-HT in the vehicle pre-exposed rats it decreased both 5-HT
and 5-HIAA after MDMA pre-exposure (further evidence for the
development of sensitisation in these rats), presumably due to MDMA-
induced release of 5-HT from nerve endings, which results in an acute 5-
HT depletion (Colado and Green 1994). This suggests that previous
exposure to MDMA enhanced the 5-HT releasing effects of acute MDMA. In
vehicle pre-exposed rats MDMA only decreased striatal 5-HIAA.
Mephedrone also decreased hippocampal 5-HIAA in vehicle pre-exposed
rats, probably due to acute neuronal 5-HT release (Kehr et al. 2011;
Baumann et al. 2012; Motbey et al. 2012; Wright et al. 2012). However,
this effect of mephedrone was absent in MDMA pre-exposed rats consistent
with the proposal that cross-tolerance to the acute effects of MDMA and
mephedrone on 5-HT release may develop. Importantly no significant 5-HT
depletion occurred in rats previously exposed to MDMA and subsequently
given vehicle, showing that repeated MDMA did not produce any 5-HT
neurotoxicity.
There was no significant alteration in dopamine, 5-HT or their metabolites
in any brain region dissected seven days after the last of six injections of
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mephedrone alone or in combination with caffeine. Caffeine alone however
did cause an increase in striatal dopamine, which may reflect a change in
dopamine release and metabolism caused by caffeine-induced adenosine
receptor activation.
Collectively, these findings suggest that previous recreational MDMA use or
co-administration of caffeine may exacerbate some of the adverse effects
of mephedrone, such as increasing hyperactivity and hyperthermia, while
attenuating anxiety-like behaviours. However the lack of complete cross-
sensitisation to MDMA suggests that the sub-acute effects of MDMA and
mephedrone may involve differences in their profile of activation of
monoaminergic function (Eshleman et al. 2013).
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5.1 Introduction
MDMA users report the development of tolerance and often ingest repeated
low doses within a short period of time to prolong its subjective effects, but
dose escalation and binge use also increase the risk of adverse effects
(Parrott 2005). Consistent with this, MDMA-induced increases in
extracellular 5-HT are attenuated following binge-type administration in
the rat (Rodsiri et al. 2011) whereas hyperthermia and hyperactivity are
exacerbated (Green et al. 2004; Baumann et al. 2008; Rodsiri et al. 2011).
Multiple re-dosing is also common with mephedrone users attempting to
maintain the desired effects of this short-acting drug, and while a typical
recreational dose is approximately 100 mg, individuals may take up to 4 g
in a single binge session (Schifano et al. 2011; Winstock et al. 2011).
From the studies presented in Chapters 2 and 4, and previously published
studies from other groups, the predominant thermoregulatory effect of
mephedrone following acute administration in the rat appears to be
hypothermia (Miller et al. 2013) even under conditions of elevated ambient
temperature (Wright et al. 2012). However, hyperthermia has been
observed in two studies following rapid repeated dosing (Hadlock et al.
2011; Baumann et al. 2012). Given the established association of
hyperthermia with life threatening adverse effects of MDMA (Docherty and
Green 2010), it is essential to see if there might be similar adverse risk
with repeated mephedrone. The studies presented in the current chapter
therefore examined the temporal profile of the temperature and locomotor
response to short-term repeated mephedrone and established the
involvement of serotonergic and dopaminergic neurons in these changes
because of their established role in the effects of MDMA.
In the studies presented in this chapter, rats received three injections of
mephedrone (10 mg kg-1), at 2 h intervals to mimic the rapid re-dosing
patterns typically favoured by many recreational users and to match
previous preclinical binge-dosing studies with MDMA and mephedrone
(Baumann et al. 2008; Rodsiri et al. 2011; Baumann et al. 2012).
Locomotor activity and core body temperature were monitored continually
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using radiotelemetry to accurately and repeatedly record core body
temperature without the stress associated with more invasive temperature
monitoring techniques such as a rectal probe, which can cause confounding
hyperthermia (Kramer and Kinter 2003). Since the predominant
behavioural effect of mephedrone in previous studies was hyperlocomotion
(Chapters 3 and 4) and the striatum plays a role in motor activity,
extracellular dopamine efflux from this region was measured by in vivo
microdialysis in the conscious rat to correlate neurotransmitter release with
the observed behavioural effects. Previous chapters have shown that a 10
mg kg-1 dose of mephedrone produces robust physiological and
behavioural changes in the rat and, importantly, pilot studies with up to 30
mg kg-1 of mephedrone confirm that the chosen 10 mg kg-1 dose produces
sub-maximal changes in temperature and locomotion (Chapter 4), thereby
allowing potential detection of either sensitisation or tolerance following
repeated administration without concern for ceiling effects.
As previous studies suggest a role of dopamine in mephedrone-induced
hypothermia (Chapter 2), the contribution of serotonergic and
dopaminergic neurons to the physiological and behavioural effects of
mephedrone were also examined using selective monoamine neurotoxins.
Rats received bilateral intracerebroventricular (i.c.v.) injections of either
5,7-dihydroxytryptamine (5,7-DHT) or 6-hydroxydopamine (6-OHDA), to
deplete 5-HT or dopamine respectively, and radiotelemetry was used to
assess the impact of monoamine depletion on the locomotor stimulant and
temperature effects of repeated mephedrone injection.
Following identification of a key role of 5-HT in mephedrone-induced
temperature change, a final study investigated the specific 5-HT receptors
mediating this effect by assessing the impact of selective 5-HT1A and 5-HT7
receptor antagonists on mephedrone-induced changes in rectal
temperature. These two receptors were selected because of their known
role in thermoregulation in the rat (Filip and Bader 2009; Gellynck et al.
2013). This is the first study to concomitantly examine the effects of
repeated mephedrone injection on hyperactivity and hypothermia, as well
as striatal dopamine efflux, in short time periods (20 min intervals to
provide a good temporal resolution) and to establish the differential role of
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dopamine and 5-HT in mephedrone-induced hyperactivity and
hyperthermia to permit a comparison with the established effects of
repeated MDMA injection.
5.2 Aims
The aims of this experiment were to:
(1) investigate of repeated binge-style mephedrone administration on
body temperature, locomotor activity and in vivo extracellular striatal
dopamine efflux in the rat;
(2) identify the roles of 5-HT and dopamine in mephedrone-induced
changes in body temperature and locomotor activity following repeated
dosing;
(3) identify long term ex vivo neurochemical changes following repeated
mephedrone injection and,
(4) to evaluate the role of serotonergic 5-HT1A and 5-HT7 receptors in
mephedrone-induced hypothermia.
5.3 Materials and Methods
5.3.1 Animals
Experimentally naïve young-adult male Lister hooded rats (190-300g;
Charles River UK) were used in all experiments. Rats were housed in
groups of four prior to surgery and in individual wire-top cages post-
surgery, under constant environmental conditions (12 h light:dark cycle
ZLWK OLJKWV RQ DW  K DPELHQW WHPSHUDWXUH   Û& DQG UHODWLYH
humidity 55 ± 10%). Food and water were freely available and wet mash
was provided for five days post-surgery. All experiments were conducted
during the light phase between 09.00 h and 16.00 h. The dose and
behavioural schedule used was chosen to comply with the three Rs of
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humane animal testing. All experiments were conducted in accordance with
the Animals (Scientific Procedures) Act, 1986 and ARRIVE guidelines with
approval of University of Nottingham Local Ethical Committee.
5.3.2 Drugs
(±)-Mephedrone-HCl was purchased from Ascent Scientific, UK.
Desipramine hydrochloride, ascorbic acid and 6-hydroxydopamine
hydrobromide (6-OHDA) were purchased from Tocris Bioscience, UK. 5,7-
dihydroxytryptamine creatine sulphate (5,7-DHT) was purchased from
Sigma Aldrich, UK. Mephedrone and desipramine were dissolved in 0.154 M
saline, and 6-OHDA and 5,7-DHT were dissolved in 0.2% w/v ascorbic
acid. All doses are quoted as the salt.
5.3.3 Study 1: Effect of repeated mephedrone on locomotor
activity and core body temperature
5.3.3.1 Radiotelemetry
Radiotelemetry allows for remote monitoring of behavioural and
physiological changes in freely moving animals and was used in the current
study as it allows for continuous, simultaneous monitoring of temperature
and activity without the need for any undue stress to the animal that may
be caused by conventional techniques, such as rectal temperature
monitoring. The system used in this study (DataScience International,
USA) uses a small implantable transmitter (Model TA10TA-F20) to record
locomotor activity and core body temperature and relays them to the RPC-
1 receivers. Data are then forwarded to the computerised A.R.T. v4
acquisition software via the data exchange matrix. Additionally, the
handling required for rectal temperature monitoring would also prevent
activity measurement in the same animal by infrared activity as measured
in Chapters 3 and 4.
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5.3.3.2 Implantation of radiotemetry transmitter
Sterile radio-transmitters (Model TA10TA-F20, DataScience International,
USA) were surgically implanted into the peritoneal cavity of rats under
anaesthesia, which was induced by inhalation of 4% isoflurane in N2O:O2
2:1 and maintained at 2% isoflurane during the procedure. Rats were
placed on a heat pad during surgery to maintain body temperature. Local
anaesthetic (EMLA cream, AstraZeneca, UK) was applied to the operative
site and a small lateral incision of approximately 1.5 cm was made
approximately 1 cm from the abdominal midline. The radiotransmitter was
implanted vertically to minimise the likelihood of post-operative
complications resulting from GI obstruction. The internal muscle layer was
closed using individual absorbable sutures (Vicryl W9106, Ethicon, USA),
and the skin closed using three wound clips (7 mm, Harvard Apparatus,
USA). The wound was treated with anti-inflammatory gel (Fuciderm gel,
Dechra, UK) and plastic wound dressing (Opsite, Smith and Nephew, UK).
Post-operative fluids (1 ml saline) and analgesia (4 mg kg-1, s.c. carprofen
(Rimadyl), Pfizer, UK) were administered on the day of surgery and
analgesia was continued for a further three days. Wound clips were
removed seven days post-surgery and radiotelemetry recording
commenced nine days post-surgery.
5.3.3.3 Data collection
Rats were transferred to the procedure room 24 h prior to testing. On the
test day, core body temperature and activity were continuously monitored
in the home cage at ambient room temperature (19.9-20.9 °C). Rats (n=5
per treatment group) received a total of three i.p. injections of either saline
Chapter 5. Repeated mephedrone
156
vehicle (1 ml kg-1) or mephedrone (10 mg kg-1) at 2 h intervals. Data were
collected for 10 s every 2 min starting 60 min prior (-60 min) to the first
injection, grouped into 20 min epochs and expressed as mean ± SEM
activity counts and change (°C) from baseline temperature readings
obtained in the same individual (0 min). Total activity counts in the 120
min following each of the three injections were also calculated and are
presented as mean ± SEM.
5.3.4 Study 2: Measurement of extracellular dopamine levels in
the striatum by in vivo microdialysis following repeated
mephedrone
5.3.4.1 Stereotaxic implantation of microdialysis guide cannulae
As the Animals (Scientific Procedures) Act, 1986 project licence in use at
the time of these experiments would not allow radiotelemetry and
microdialysis to be performed in the same animal, microdialysis was
performed in a separate cohort of rats using a previously established
technique (Rodsiri et al. 2011) with some modifications. A CMA 12
polyurethane guide cannula (CMA Microdialysis AB, Sweden) was
implanted just above the striatum under general anaesthesia as described
in section 5.3.3.2. In summary, rats were held in a stereotaxic frame by
blunt ear bars (with EMLA cream at the tip) and an incisor bar set at -3.3
cm below the intra-aural line. A topical lubricant (Lacrilube, Allergan, UK)
was applied to the eyes to prevent drying from the surgical lamps.
Coordinates for the striatum were selected according to Paxinos and
Watson (1997) Rat Brain Atlas (coordinates AP +0.48, ML ±3.0, DV -3.6
from Bregma). An incision was made between the eyes of the rat to the
back of the head to allow for a small hole to be drilled into the skull above
the coordinates using a microtrephan drill. The guide cannula was secured
to the skull with three skull screws and dental cement (Associated Dental
Products Ltd, UK). Guide cannulae were placed on alternating sides so that
half of the rats in each treatment group had a microdialysis probe placed in
the right striatum and half had a probe in the left striatum. Local analgesia
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(Lidocaine hydrochloride) was applied before suturing the wound using
interrupted sutures (Mersilk, W502, Ethicon, USA) and treated with plastic
wound dressing and anti-inflammatory cream as in section 5.3.3.2. Post-
operative fluids (1 ml saline) and analgesia (4 mg kg-1, s.c. carprofen
Rimadyl, Pfizer, UK) were administered on the day of surgery. Rats were
housed individually and allowed to recover for eight days before dialysate
collection commenced.
5.3.4.2 Microdialysis procedure
Seven days post-surgery rats were briefly anaesthetised to insert a
microdialysis probe (CMA 12, 4 mm polyarylethersulpone membrane, 500
µm outer diameter, 3 µl internal volume with a 20 kDa molecular cut-off;
CMA Microdialysis AB, Sweden) through the guide cannula. The probe was
connected to a microinfusion pump (Harvard Scientific, USA) using FEP
microdialysis tubing (Instech Laboratories Inc, USA) via a liquid swivel
system (Instech 375/22, Instech Laboratories Inc, USA) to allow for
unrestricted movement. Rats were placed in individual circular arenas (50
cm diameter, 45 cm height) with sawdust bedding, and food and water
freely available. Artificial cerebrospinal fluid (125 mM NaCl, 13.5 mM
NaHCO3, 1.25 mM KCl, 0.22mM NaH2PO4, 0.9 mM Na2HPO4, 0.3 mM
Na2SO4, 0.5 mM MgCl2, 0.5 mM CaCl22H2O adjusted to pH 7.4) was
continuously perfused at a rate of 1 µl per min. the following day, rats
(n=10 per treatment group) received a total of three i.p. injections at 2 h
intervals of saline vehicle (1 ml kg-1) or mephedrone (10 mg kg-1) and
dialysate samples were collected every 20 min into 5 µl of 0.1 M perchloric
acid containing 0.03 % sodium metabisulfite. Samples were immediately
stored on dry ice and then at -80 °C until analysis by HPLC-ED. The dead
space from the probe to the collection tube resulted in a small delay in the
dialysate samples reaching the collection point of approximately 3 min.
5.3.4.3 Histological confirmation of probe location
After collection of the final microdialysis sample, rats were euthanized by
injection of 1 ml of pentobarbital (Euthatal). Brains were rapidly removed
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and stored in 4 % paraformaldehyde solution at 4 °C until sectioning into
150 µm coronal slices using a vibrotome (Campden Instruments Ltd, UK).
Location of the probe within the striatum was confirmed under a light
microscope using Paxinos and Watson Rat Brain Atlas (1997). See Fig 5.1
for example placement of the microdialysis guide cannulae.
Figure 5.1 Histo
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5.3.5 Study 3: Effect of dopamine or 5-HT depletion on
mephedrone-induced changes in core body temperature
and activity
5.3.5.1 Intracerebroventricular injections
In a third group of rats, bilateral i.c.v. injections were performed under
isoflurane anaesthesia as described in section 5.3.3.2. All rats received
desipramine (15 mg kg-1, i.p.) 30 min prior to i.c.v. injection to protect
noradrenergic neurons from depletion by 5,7-DHT or 6-OHDA. Rats were
held in a stereotaxic frame by blunt ear bars (with EMLA cream at the tip)
and an incisor bar set at -3.3 cm below the intra-aural line. A topical
lubricant (Lacrilube) was applied to the eyes to prevent drying from the
surgical lamps. The stereotaxic coordinates for each injection site were AP
-0.8, ML ±1.5, DV -3.8 from Bregma (Paxinos and Watson, 1997). An
incision was made between the eyes of the rat to the back of the head to
allow for a small hole was drilled into the skull above the coordinates using
a microtrephan drill. Rats received 5 µl of 0.2 % w/v ascorbic acid vehicle,
or 75 µg 5,7-DHT or 150 µg 6-OHDA into each lateral ventricle, at a rate of
5 µl min-1. These doses were chosen as they are reported to deplete 5-HT
and dopamine by a similar percentage (70-75 %) below control levels
(Nowak et al. 2005; King et al. 2009). Local analgesia (Lidocaine
hydrochloride) was applied before suturing the wound using interrupted
sutures (Mersilk, W502, Ethicon, USA). The wound treated with plastic
wound dressing and anti-inflammatory cream as in section 5.3.3.2.
5.3.5.2 Data collection by radiotelemetry
Radiotelemetry transmitters were also implanted into the same rats
immediately after i.c.v. injection using the protocol described in section
5.3.3.2. Using a crossover design, each rat (n=8 per treatment group)
received three i.p. injections at 2 h intervals of saline vehicle (1 ml kg-1) or
mephedrone (10 mg kg-1) 21 days post-surgery, and then received the
opposite treatment 28 days post-surgery. In each case core body
temperature and activity were measured by radiotelemetry as described in
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section 5.3.3.3. Thus every rat received both vehicle and mephedrone in a
pseudorandom order to minimise inter-individual response to the drug
treatment or lesion.
5.3.6 Study 4: Effect of 5-HT1A and 5-HT7 receptor antagonists
on mephedrone-induced decreases in rectal temperature
following a single injection
Rectal temperature measurements were recorded following combined 5-HT
receptor antagonist and mephedrone administration to establish the
specific 5-HT receptors involved in mediating mephedrone-induced
hypothermia, using the method described in section 2.3.4. Rats (n=6 per
treatment group) received saline vehicle (1ml kg-1, i.p.), the 5-HT1A
antagonist WAY-100635 (0.5mg kg-1) or the 5-HT7 antagonist SB-258719
(10 mg kg-1), followed 30 min later by vehicle (1ml kg-1, i.p.) or
mephedrone (10mg kg-1). Rectal temperature was measured immediately
prior to each injection and then at 20 min intervals for the next 2 h.
5.3.7 Neurochemistry
Seven days after radiotelemetry recording (d 35 following i.c.v. injections)
rats were killed by concussion and immediate decapitation and
hypothalamus and right striatum, frontal cortex and hippocampus were
collected on a refrigerated table (4 °C), flash frozen in liquid nitrogen and
stored at -80 °C until analysis of tissue dopamine, 5-HT and their major
metabolites by HPLC-ED, as previously described (section 2.3.3.2). This
HPLC-ED method was also used to quantify extracellular dopamine levels in
microdialysis samples. In addition, tissue noradrenaline levels were
measured in the same regions of sham, 5,7-DHT and 6-OHDA pre-treated
rats by running the samples through the column a second time under
modified HPLC conditions. The mobile phase for noradrenaline detection
consisted of 20 mM KH2PO4/Na acetate, 8 mM KCl, 0.1 mM EDTA, 1 mM
OSA, containing 10 % methanol, adjusted to pH 4.07.
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5.3.8 Statistical analysis
All statistical analyses were performed using GraphPad Prism v 6.02 or
SPSS v21 software. Radiotelemetry data were analysed by two-way
repeated measures ANOVA (with drug treatment and time as between and
within factors respectively) where the rats received saline vehicle or
mephedrone alone (study 1), or by four-way repeated measures ANOVA
(with i.c.v. injection and drug treatment as between-group factors and
time and week as the within-group factors) where rats also received i.c.v.
injections of ascorbic acid vehicle, 5,7-DHT or 6-OHDA and saline vehicle
and mephedrone in a random order crossover design (study 3).
Microdialysis data were analysed by two-way repeated measures ANOVA
(with drug treatment and time as between and within factors respectively,
study 2). HPLC data were analysed by one-way ANOVA where rats received
saline vehicle or mephedrone alone (study 1) or by two-way ANOVA where
they also received i.c.v. injections (study 3). Rectal temperature data were
analysed by three-way repeated measure ANOVA (with 5-HT receptor
antagonist and drug treatment as between factors and time as the within
factor). Bonferroni multiple comparisons post-hoc test was used where
appropriate and p<0.05 was considered statistically significant. All data are
presented as mean ± SEM.
5.4 Results
5.4.1 Study 1: Effect of repeated mephedrone on core body
temperature and activity
Mephedrone (3 x 10 mg kg-1 at 2 h intervals) was administered to a group
of rats which had intraperitoneal radiotransmitter implants for recording of
locomotor activity and body temperature by radiotelemetry.
5.4.1.1 Locomotor activity
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Locomotor activity was recorded in the home cage of individually-housed
rats to determine any psychostimulant-like effect. There were no
significant between-group differences in activity counts in the 60 min prior
to the first injection (data not shown). Mephedrone significantly increased
activity above vehicle control levels for 40 min after the first injection, and
80 min after the second and third injections, such that there were main
effects of drug (F(1,8)=15.5, p<0.01) and time (F(18,144)=12.29, p<0.001),
as well as a drug x time interaction (F(18,144)=3.43, p<0.001, Fig 5.2). The
magnitude of the increase produced by mephedrone was also similar after
each injection although the response to saline injection appeared to be less
with each consecutive injection.
Analysis of the three total cumulative activity counts in the 2 h following
each consecutive injection confirmed that mephedrone caused a
reproducible hyperactivity following each injection, such that there was no
significant difference in total counts between injections (1st: 580 ± 56; 2nd:
567 ± 98; 3rd: 416 ± 115 counts/2 h, mean ± SEM). However, in vehicle
treated rats the total activity counts decreased from 197 ± 105 counts/2 h
following the first injection and 108 ± 26 counts/2 h following the second
to become significantly lower after the third injection (61 ± 15 counts/2 h;
p<0.05 versus first injection) suggesting some habituation to the injection
procedure. This was reflected by main effects of drug (F(1,8)=16.44,
p<0.01), injection number (F(2,16)=15.34, p<0.001) and a drug x injection
number interaction (F(2,16)=3.87, p<0.05) which was therefore due to a
change in the saline group rather than the mephedrone response.
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Figure 5.2 Mephedrone-induced hyperactivity is unaffected by binge
administration of mephedrone.
Adult male Lister hooded rats (n=5 per treatment group) received i.p. injection of
saline vehicle (V, 1 ml kg-1) or mephedrone (Meph, 10 mg kg-1) once every two
hours at 0, 120 and 240 min (as indicated by the arrows). Locomotor activity was
recorded continuously using a previously implanted radiotelemetry transmitter.
Data are represented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared
to vehicle at the same time point, Bonferroni multiple comparisons post-hoc
following two-way repeated measures ANOVA.
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5.4.1.2 Core body temperature
Individual core body temperature was recorded simultaneously with
activity in the home cage. There were no between-group differences in
temperature in the 60 min prior to injection (data not shown), with
baseline values (at the time of the first injection, t=0 min) being 37.8 ±
0.2 °C in rats allocated to vehicle and 37.9 ± 0.1 °C in those due to
receive mephedrone. Following injection there were main effects of drug
(F(1,8)=3.27, p<0.05), time (F(18,144)=14.67, p<0.001) as well as a drug x
time interaction (F(18,144)=4.26, p<0.001) although mephedrone decreased
body temperature to a greater extent than vehicle control from 40-60 min
after the first injection only (Fig 5.3).
The maximum temperature change from baseline following each
mephedrone injection was similar being -1.3, -1.4 and -1.2 °C following
the first, second and third injections respectively, yet this maximum
change (like the time course data) was also only significantly different from
the temperature change in the vehicle control group following the first
injection. This appears to be because body temperature also decreased
following the first vehicle injection and did not return to basal (pre-
injection) values (Fig 5.3).
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Figure 5.3 Repeated mephedrone injection does not alter mephedrone-
induced changes in core body temperature.
Adult male Lister hooded rats (n=5 per treatment group) received i.p. injection of
saline vehicle (V, 1 ml kg-1) or mephedrone (Meph, 10 mg kg-1) once every two
hours at 0, 120 and 240 min (as indicated by the arrows). Core body temperature
was recorded continuously via a previously implanted radiotelemetry transmitter.
Data are presented as mean ± SEM change from baseline (t=0 min, °C). *p<0.05,
**p<0.01, ***p<0.001 compared to vehicle, Bonferroni multiple comparisons
post-hoc following two-way repeated measures ANOVA.
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5.4.1.3 Ex vivo neurochemistry
Hypothalamus and right striatum, hippocampus and frontal cortex were
collected seven days post-injection from rats implanted with radiotelemetry
transmitters. There was no significant effect of mephedrone on the
concentration of dopamine, 5-HT or their metabolites in any region (Table
5.1).
Table 5.1 Effect of repeated mephedrone administration on brain tissue
dopamine and 5-HT levels seven days post-injection.
Tissue levels (pmol mg-1)
Treatment Frontal
cortex
Hippocampus Hypothalamus Striatum
Dopamine
V 0.25 ± 0.02 0.37 ± 0.3 4.64 ± 0.6 62.12 ± 9.4
Meph 0.19 ± 0.03 0.09 ± 0.01 2.89 ± 0.8 57.62 ± 15.4
5-HT
V 2.28 ± 0.2 1.78 ± 0.3 7.32 ± 1.2 4.15 ± 1.2
Meph 2.11 ± 0.3 1.37 ± 0.4 5.24 ± 1.2 6.31 ± 3.1
Dopamine and 5-HT levels were measured seven days after three i.p. injections of
saline vehicle (V, 1 ml kg-1) or mephedrone (Meph, 10 mg kg-1) at 2 h intervals to
individually-housed male Lister hooded rats (n=5 per treatment group) previously
implanted with radiotelemetry transmitters under isoflurane anaesthesia. Data are
expressed as mean ± SEM.
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5.4.2 Study 2: Measurement of extracellular dopamine levels in
the striatum by in vivo microdialysis
Extracellular striatal dopamine levels were measured by in vivo
microdialysis in a separate cohort of rats. There were no between-group
differences in basal extracellular dopamine levels in the 60 min prior to the
first injection (7.32 ± 1.65 pmol ml-1 in rats due to receive vehicle and
5.08 ± 0.85 pmol ml-1 in those to receive mephedrone). Following
injection, ANOVA showed a main effect of drug (F(1,18)=6.29, p<0.05), time
(F(18,319)=7.87, p<0.001) as well as a drug x time interaction
(F(18,319)=3.55, p<0.001, Fig 5.4) and mephedrone rapidly increased
extracellular striatal dopamine levels above vehicle controls for 40 min
after the first and third injections and for 60 min after the second injection,
with a return to baseline between injections.
Peak dopamine levels in mephedrone-treated rats were 284, 521 and
435% above basal following the first, second and third injections,
respectively which were all significantly greater than that seen with vehicle
treatment (p<0.01 to p<0.001) at the same time point. Thus the three
consecutive injections of mephedrone each produced a comparable
magnitude and equivalent time course of elevation in extracellular
dopamine overflow in the striatum.
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Figure 5.4 Mephedrone injection increases extracellular striatal dopamine
efflux as measured by in vivo microdialysis.
Adult male Lister hooded rats (n=10 per treatment group) received i.p. injection of
saline vehicle (V, 1 ml kg-1) or mephedrone (Meph, 10 mg kg-1) once every two
hours at 0, 120 and 240 min (as indicated by the arrows). Data are represented as
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to vehicle, Bonferroni
multiple comparisons post-hoc following two-way repeated measures ANOVA.
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5.4.3 Study 3: Effect of dopamine or 5-HT depletion on
mephedrone-induced changes in activity and core body
temperature
A third group of rats received bilateral i.c.v. injections of 5,7-DHT or 6-
OHDA to investigate the contribution of 5-HT and dopamine to
mephedrone-induced hyperactivity and hypothermia.
5.4.3.1 Locomotor activity
There were no between-group differences in basal activity recorded in the
60 min prior to the first drug injection and, consistent with the previous
experiment, mephedrone caused a rapid increase in locomotor activity
which returned to basal levels between each injection whereas vehicle
produced a very transient and small response in the same rats (Fig 5.5).
Four-way repeated measures ANOVA confirmed main effects of drug
(F(1,18)=237.25, p<0.001), lesion (F(2,18)=22.3, p<0.001) and time
(F(18,342)=28.51, p<0.001) as well as drug x lesion (F(2,42)=12.87, p<0.001)
and drug x time (F(18,342)=13.27, p<0.001) interactions, but no drug x
lesion x time interaction (F(36,342)=0.96, p>0.05). Of note, 5,7-DHT pre-
treatment attenuated the mephedrone-induced hyperactivity such that
there was no significant response to the first injection in 5,7-DHT treated
rats and the responses to the second and third injections were significantly
lower in 5-,7-SHT pre-treated rats than sham controls (Fig 5.5A). In
contrast, 6-OHDA lesion appeared to enhance the locomotor activity
induced by mephedrone compared to that observed in sham controls,
although this effect only reached significance at 40 min after the second
injection (Fig 5.5B).
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Figure 5.5 5-HT and dopamine depletions have different effects on
mephedrone-induced changes in locomotor activity.
Adult male Lister hooded rats (n=8 per treatment group) that had radiotelemetry
transmitters implanted under isoflurane anaesthesia received i.c.v. injection of 0.2
DVFRUELFDFLGYHKLFOHǋOA'+7ǋORUB)2+'$ǋOXQGHU
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isoflurane anaesthesia, followed by repeated i.p. injection of saline vehicle (1 ml kg-
1) or mephedrone (10 mg kg-1) on day 21 post-surgery and then the opposite
treatment 28 days post-surgery. Vehicle and mephedrone were injected once every
two hours at 0, 120 and 240 min (as indicated by the arrows). For clarity 5,7-DHT
and 6-OHDA have been presented as separate figures versus the sham controls but
ANOVA has been performed on all groups. All data are represented as mean ±
SEM, *p<0.05, ** p<0.01, ***p<0.001 sham + mephedrone compared to
sham + vehicle ; ***p< 0.001, **p< 0.01, *p< 0.05 lesion + mephedrone
compared to sham + vehicle, p<0.001, p<0.01, p<0.05 lesion +
mephedrone compared to lesion + vehicle, p<0.001, p<0.05 lesion +
mephedrone compared to sham + mephedrone, Bonferroni multiple
comparisons post-hoc following two-way repeated measures ANOVA.
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Consistent with the previous experiment, analysis of the total cumulative
activity counts in the 2 h following each injection confirmed mephedrone-
induced hyperactivity in sham operated controls and ANOVA showed main
effects of drug (F(1,18)=248.18, p<0.001), injection number (F(2,36)=4.76,
p<0.05) and a drug x injection number interaction (F(2,36)=5.31, p<0.01,
Table 5.2). Lesions significantly altered total mephedrone-induced activity
counts such that there was a main effect of lesion (F(2,18)=22.06, p<0.001)
and a drug x lesion interaction (F(2,18)=13.29, p<0.001). Consistent with
the time course data, 5,7-DHT attenuated the response to mephedrone,
such that there was a significant response to the second injection only
(p<0.001 versus vehicle) and total activity counts following the third
mephedrone injection were lower (p<0.01) in 5,7-DHT lesioned rats than
sham operated controls. In contrast, 6-OHDA lesioned rats exhibited
increased cumulative activity following each mephedrone injection which
did not differ from the response in sham controls following any of the three
injections.
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Table 5.2 Total activity counts following repeated mephedrone
administration to 5-HT or dopamine depleted rats.
Lesion Treatment Injection 1 Injection 2 Injection 3
Sham V 285 ± 63 149 ± 25 139 ± 23
Meph 579 ± 77** 619 ± 70*** 572 ± 73***
5,7-DHT V 226 ± 40 123 ± 23 134 ± 26
Meph 382 ± 44 444 ± 43** 313 ± 50
6-OHDA V 298 ± 50 132 ± 20 182 ± 57
Meph 743 ± 63*** 766 ± 72*** 667 ± 39***
Activity counts were measured following each of three i.p. injections of saline
vehicle (V, 1 ml kg-1) or mephedrone (Meph, 10 mg kg-1) at 2 h intervals, 21 or 28
days after pre-treatment with bilateral i.c.v. injection under isoflurane anaesthesia
RI DVFRUELF DFLG YHKLFOH  ǋO '+7 ǋJ RU 2+'$ ǋJ SHU
side, to individually-housed adult male Lister hooded rats (n=8 per treatment
group). **p<0.01, ***p<0.001 sham + mephedrone compared to sham + vehicle;
**p<0.01, ***p<0.001 lesion + mephedrone compared to sham + vehicle,
p<0.05, p<0.001 lesion + mephedrone compared to lesion + vehicle,
p<0.01 lesion + mephedrone compared to sham + mephedrone, p<0.05
compared to the first injection of the same treatment group, Bonferroni multiple
comparisons post-hoc following three-way repeated measures ANOVA.
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5.4.3.2 Core body temperature
Basal core body temperatures prior to the first injection on each test day
were equivalent bring 37.2 ± 0.2 and 37.5 ± 0.2 °C in sham controls, 36.9
± 0.2 and 37.2 ± 0.2 °C following 5,7-DHT and 37.5 ± 0.2 and 37.4 ± 0.2
°C 6-OHDA treated rats prior to injection of vehicle or mephedrone
respectively. There were main effects of drug (F(1,18)=8.75, p<0.01), lesion
(F(2,18)=4.26, p<0.05) and time (F(18,324)=12.55, p<0.001) as well as drug
x time (F(18,324)=9.19, p<0.001), lesion x time (F(36,324)=1.78, p<0.01) and
drug x lesion x time interactions (F(36,324)=2.10, p<0.001, Fig 5.6).
Mephedrone significantly reduced core body temperature in sham controls
20-80 min after the first, 20-60 min after the second and at 40 and 80 min
following the third injection. However, mephedrone-induced hypothermia
was completely abolished in 5,7-DHT lesioned rats, such that the
temperature did not differ from that observed with vehicle at any time
point, and was significantly attenuated compared to mephedrone-treated
sham controls (Fig 5.6A). Although the duration of mephedrone-induced
hypothermia appeared to be reduced by dopamine depletion in 6-OHDA
pre-treated rats (such that the decrease in temperature was only
significant from 40-80 min and at 40 min following the first and second
injections, respectively, instead of the entire post-injection period), the
magnitude of the mephedrone-induced hypothermia remained similar to
that in sham controls (Figure 5.6B). The maximum temperature change
from baseline following each mephedrone injection in sham controls (-1.2,
-1.2 and -1.0 °C following that first, second and third injections,
respectively) was equivalent.
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Figure 5.6 5-HT and dopamine depletion had different effects on
mephedrone-induced hypothermia.
Adult male Lister hooded rats (n=8 per treatment group) that had radiotelemetry
transmitters implanted under isoflurane anaesthesia received i.c.v. injection of 0.2
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
followed by repeated i.p. injection of saline vehicle (1 ml kg-1) or mephedrone (10
mg kg-1) on day 21 post-surgery and the opposite treatment on day 28 post-
surgery using a cross over design. Vehicle and mephedrone were injected once
every two hours at 0, 120 and 240 min (as indicated by the arrows). For clarity
5,7-DHT and 6-OHDA have been presented as separate figures versus the sham
controls but ANOVA has been performed on all groups. Temperature data is
represented as change from baseline (t=0 min, °C). All data are represented as
mean ± SEM., *p<0.05, **p<0.01, ***p<0.001 sham + mephedrone compared
to sham + vehicle; *p<0.05, **p<0.01, ***p<0.001 lesion + mephedrone
compared to sham + vehicle; p<0.05, p<0.001 lesion + mephedrone
compared to lesion + vehicle; p<0.05, p<0.01 lesion + mephedrone
compared to sham + mephedrone, Bonferroni multiple comparisons post-hoc
following two-way repeated measures ANOVA.
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5.4.3.3 Ex vivo neurochemistry
Dopamine, 5-HT and noradrenaline levels in the hypothalamus, right
frontal cortex, hippocampus and striatum were measured 35 days after
neurotoxin administration to confirm selective monoamine depletion. As
expected the serotonergic neurotoxin, 5,7-DHT significantly reduced 5-HT
to 46% of control in the frontal cortex (F(2,21)=16.67, p<0.001), 13% in
the hippocampus (F(2,20)=7.19, p<0.01) and 42% in the hypothalamus
(F(2,21)=20.95, p<0.001) and 66% in the striatum, although the latter did
not reach statistical significance due to high individual variation (Table
5.3). In contrast, 6-OHDA significantly reduced dopamine to 52% of
control in the striatum (F(2,21)=15.86, p<0.001) and 56%, 80% and 86% of
control in the frontal cortex, hippocampus and hypothalamus, respectively,
although the depletion in these areas was not statistically significant.
However, the 6-OHDA-induced decrease in striatal dopamine was
accompanied by a significant reduction in hippocampal 5-HT (F(2,20)=7.19,
p<0.01) as well as decreased noradrenaline levels in the hypothalamus
and hippocampus (p<0.001), but noradrenaline levels were unchanged in
the other regions examined.
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Table 5.3 Effect of i.c.v. administration of 6-OHDA or 5,7-DHT on brain
tissue dopamine, 5-HT and noradrenaline levels 5 weeks post-surgery.
Tissue levels (pmol mg-1)
Lesion Frontal cortex Hippocampus Hypothalamus Striatum
Dopamine
Sham 0.72 ± 0.2 0.40 ± 0.03 2.96 ± 0.2 55.58 ± 4.5
5,7-DHT 0.46 ± 0.02 0.38 ± 0.02 3.36 ± 0.2 60.42 ± 2.2
6-OHDA 0.40 ± 0.02 0.32 ± 0.01 2.53 ± 0.2 28.63 ± 5.5***
5-HT
Sham 3.46 ± 0.3 3.81 ± 0.4 7.22 ± 0.5 4.40 ± 0.3
5,7-DHT 1.58 ± 0.3*** 0.51 ± 0.1*** 3.03 ± 0.4*** 2.88 ± 0.5
6-OHDA 3.96 ± 0.2 1.91 ± 0.6* 5.39 ± 0.6 5.50 ± 0.5
Noradrenaline
Sham 1.83 ± 0.08 2.81 ± 0.3 16.77 ± 1.5 0.93 ± 0.1
5,7-DHT 1.86 ± 0.1 2.21 ± 0.5 15.90 ± 1.5 1.12 ± 0.2
6-OHDA 1.70 ± 0.08 0.86 ± 0.2** 8.46 ± 1.4** 1.02 ± 0.3
Dopamine, 5-HT and noradrenaline levels were measured five days after bilateral
LFY LQMHFWLRQXQGHU LVRIOXUDQHDQDHVWKHVLDRIDVFRUELFDFLGYHKLFOHǋO
'+7ǋJRU2+'$ǋJSHU VLGH WR LQGLYLGXDOO\KRXVHGPDOH/LVWHU
hooded rats (n=8 per treatment group). Rats also received vehicle or mephedrone
on day 21 post-surgery and then the opposite treatment on day 28 post-surgery,
using a cross over design. *p<0.05, **p<0.01, ***p<0.001 compared to sham
controls, Bonferroni post-hoc following one-way ANOVA.
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5.4.4 Study 4: Effect of 5-HT1A and 5-HT7 receptor antagonists
on mephedrone-induced decreases in rectal temperature
following a single injection
In a final study, rats were pre-treated i.p. with either the selective 5-HT1A
receptor antagonist, WAY-100635 or the selective 5-HT7 receptor
antagonist, SB-258719 to investigate the role of specific 5-HT receptors in
mephedrone-induced hypothermia. As before, basal temperature was
identical in all groups prior to acute drug injection (data not shown).
Subsequent injection of vehicle had no effect on rectal temperature
irrespective of whether rats were pre-treated with WAY-100635 (Fig 5.7A)
or SB-258719 (Fig 5.7B). Mephedrone caused a transient but significant
decrease in rectal temperature at 20 (p<0.001) and 40 min (p<0.05) post-
injection compared with vehicle control, which was consistent with the
duration and magnitude observed in Chapter 2. This mephedrone-induced
hypothermia was partially blocked by WAY-100635 (pre-treatment x drug
x time interaction: F(7,140)=5.42, p<0.001, being reduced in the 20-40 min
post-mephedrone period, Fig 5.7A), but remained completely unaltered by
SB-258719 (Fig 5.7B).
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Figure 5.7 Comparison of the effect of the 5-HT1A receptor antagonist
WAY-100635 and the 5-HT7 receptor antagonist SB-258719 on saline
vehicle (1ml kg-1) or mephedrone (10 mg kg-1) induced change in rectal
temperature.
Adult male Lister hooded rats (n=6 per treatment group) received i.p. saline
vehicle (1 ml kg-1), (A) WAY-100635 (0.5 mg kg-1) or (B) SB-258719 (10mg kg-1)
at -30 min, before saline (1 ml kg-1) or mephedrone (10 mg kg-1) at time=0 min.
Rectal temperature was measured at -30 min and at 20 min intervals from 0 to 120
min, and data are expressed as change in temperature (°C, mean ± SEM) from the
reading taken at 0 min. *p<0.05, ***p<0.001 vehicle mephedrone versus
vehicle+vehicle; p<0.05 antagonist+mephedrone versus vehicle+vehicle;
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p<0.05 antagonist+mephedrone versus antagonist+vehicle, Bonferroni post-hoc
following three-way repeated measures ANOVA.
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5.5 Discussion
This study investigated the effects of repeated mephedrone injection on
core body temperature, locomotor activity and striatal dopamine release in
the rat, since recreational users often rapidly re-dose, and examined the
role of dopamine and 5-HT in mephedrone-induced changes in body
temperature and activity. This is the first study to use radiotelemetry to
obtain a high temporal resolution of changes appropriate for these short
duration responses. The main findings were that (1) the hyperactivity,
hypothermia and increase in extracellular striatal dopamine seen after the
first of three mephedrone injections were comparable in magnitude and
time course to those seen after the second and third injections, (2)
dopamine depletion enhanced hyperactivity but reduced the duration of the
hypothermic response to mephedrone, (3) 5-HT depletion reduced
hyperactivity and abolished mephedrone-induced hypothermia and (4) 5-
HT1A receptor antagonism partially blocked the mephedrone-induced
hypothermic response but 5-HT7 receptor antagonism had no effect.
Importantly, some of these observed effects contrast with those reported
for MDMA, suggesting the possibility of adverse effects following
recreational use.
Initial studies investigating the effects of mephedrone in rats have shown
that it has a high affinity for dopamine and 5-HT transporters as well as
VMAT-2, the 5-HT2A and 5-HT2C UHFHSWRUVDQGĮ1ADQGĮ2A-adrenoceptors
(Lopez-Arnau et al. 2012; Martinez-Clemente et al. 2012; Eshleman et al.
2013; Simmler et al. 2013). Mephedrone also increases extracellular
dopamine and to an even greater extent 5-HT in the nucleus accumbens
(Kehr et al. 2011; Baumann et al. 2012; Wright et al. 2012; Eshleman et
al. 2013). The current study shows that mephedrone also causes a short-
lasting increase in extracellular striatal dopamine in the striatum, the
temporal profile of which was similar following each injection and returned
to baseline before the next injection. The repeated dose of mephedrone
herein given (10 mg kg-1) did not produce any neurotoxic loss of brain
regional dopamine or 5-HT measured seven days post-injection. This is in
marked contrast to MDMA, where a repeated dose schedule which releases
striatal dopamine also produces significant long-term neurotoxic 5-HT
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depletion in the rodent (Green et al. 2003), but similar to methcathinone
where a much larger dose than that needed to elicit behavioural changes is
required to obtain neurotoxicity (Sparago et al. 1996). These data
therefore suggest that rapid repeated mephedrone administration is less
likely to produce monoamine neurotoxicity than MDMA in rats, and
supports the findings of Baumann et al, (2012). However, repeated high
dose administration to mice does cause both dopaminergic and
serotonergic neurotoxicity (Martinez-Clemente et al. 2014). It is important
to note that while dopamine alterations within the striatum was measured
in this study, the hypothalamus is more likely to be responsible for the
temperature changes and there may be regional differences in the effect of
mephedrone on monoamine release.
There is extensive evidence that mephedrone induces hyperactivity in
rodents following both acute and intermittent administration (Kehr et al.
2011; Angoa-Perez et al. 2012; Baumann et al. 2012; Marusich et al.
2012). In the current study, repeated binge-style mephedrone
administration caused reproducible hyperactivity after each injection, the
onset of which occurred within minutes of injection but returned to
baseline levels within an hour. The time courses for both striatal dopamine
release and hypothermia are consistent with a previous study using a
single systemic injection. It is noteworthy that the peak plasma level of
mephedrone in the rat shows a similar temporal pattern following s.c.
injection (Miller et al. 2013). Importantly, the total ambulatory activity
counts following the second and third injections of mephedrone were
comparable to those following the first injection. This response therefore
differs markedly from MDMA where enhanced hyperactivity was observed
following a similar repeated dosing schedule in the same strain of rats
(Rodsiri et al. 2011).
In the current study, central 5-HT depletion markedly attenuated the
hyperactivity observed following mephedrone injection 21 or 28 days later,
while central depletion of dopamine enhanced mephedrone-induced
hyperactivity. Administration of 300 mg kg-1 of pCPA to mice over three
days also reduces mephedrone-induced hyperactivity (Lopez-Arnau et al.
2012). Previous studies show that dopamine denervation supersensitivity
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can occur following 6-OHDA administration, enhancing the hyperlocomotor
response to injection of a dopamine D1 receptor antagonist (Bishop et al.
2003). Since striatal dopamine was only decreased by 52% in the current
study a similar supersensitivity to mephedrone-induced dopamine release
could account for the enhanced locomotor response in 6-OHDA lesioned
rats. The current findings therefore suggest a key role for both dopamine
and 5-HT in mephedrone-induced hyperactivity.
Although hyperthermia has not been recorded in mephedrone users there
is evidence that it alters peripheral thermoregulation since reported
adverse effects include cold/blue fingers, hot flushes and sweating
(Winstock et al. 2011; Wood and Dargan 2012). These changes may result
from peripheral changes in blood flow. Earlier studies have generally failed
to observe hyperthermia in rodents given an acute injection of
mephedrone, even when the animals are grouped or kept under conditions
of raised ambient temperature (Wright et al. 2012). However,
hyperthermia was observed in two previous studies investigating the
effects of repeated mephedrone injection (Hadlock et al. 2011; Baumann
et al. 2012). Of note, both of these used Sprague Dawley rats and s.c.
injections so there could be strain and/or pharmacokinetic differences in
the response (Wright et al. 2012). These repeated injection studies also
used a rectal probe to measure the response at 1 h intervals so the
observed hyperthermia may have resulted from an additive effect of
repeated mephedrone injection combined with stress-induced
hyperthermia associated with rectal temperature measurement as evident
in vehicle control animals (Hadlock et al. 2011; Baumann et al. 2012). The
current study is one of the first to use radiotelemetry to measure the
temperature response following repeated mephedrone injection. Since this
study observed hypothermia even when rapid repeat dosing was
performed it seems unlikely that recreational mephedrone use will result in
the severe and sometimes fatal hyperthermia seen in high dose MDMA
users.
Evidence suggests that dopamine and noradrenaline are important for
MDMA-induced temperature changes (Mechan et al. 2002; Bexis and
Docherty 2005; Green et al. 2005; Bexis and Docherty 2009). In addition,
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5-HT depletion by p-chlorophenylalanine or a neurotoxic dose of MDMA
disrupts the ability of the rat to regulate its response to a subsequent dose
of MDMA (Green et al. 2004; Saadat et al. 2005). Of particular note, in the
current study, 5,7-DHT lesion of serotonergic neurons abolished the
hypothermic response to mephedrone. Furthermore, administration of the
5-HT1A receptor antagonist, WAY-100635, attenuated mephedrone-induced
hypothermia while antagonism of the 5-HT7 receptor had no effect.
Although 5-HT1A receptors are implicated in the hypothermic response their
involvement is almost certainly a consequence of 5-HT release and/or
inhibition of reuptake, since the low affinity of mephedrone for the 5-HT1A
UHFHSWRU.L!ǋ06LPPOHUHWDOPDNHVDQ\GLUHFWHIIHFWXQOLNHO\
Interestingly, pre-treatment with WAY-100635 also prevents the
hypothermic response to MDMA (Rusyniak et al. 2007). In contrast,
mephedrone injection to 6-OHDA lesioned rats produced a hypothermic
response which did not differ from mephedrone-induced hypothermia seen
in sham controls. At first this appears paradoxical since administration of
the dopamine D1 receptor antagonist, SCH 23390 prolonged mephedrone-
induced hypothermia in a previous study (Chapter 2). However, the limited
depletion of dopamine in the hypothalamus makes it difficult to come to
any firm conclusion about the role of dopamine in mephedrone-induced
hypothermia.
This study found no evidence for rapid sensitization or tolerance to
mephedrone during a single binge dosing session. This is in contrast to the
response to MDMA administration where repeated dosing converts the
initial hypothermia to hyperthermia following subsequent injections, as
measured by radiotelemetry (Rodsiri et al. 2011). The limited depletion of
hypothalamic dopamine makes it impossible to completely exclude a role of
this monoamine in mephedrone-induced hypothermia. However, since this
response is unaffected by dopamine D2 receptor blockade and prolonged
by D1 receptor antagonism (Shortall et al. 2013) the available evidence
suggests that mephedrone-induced increases in dopamine efflux are
unlikely to contribute to the drug-induced hypothermia, while modulation
of central serotonergic neurotransmission plays a role in mediating both
the hyperlocomotor and hypothermic effects of mephedrone. Although
caution is required in attempting to translate the relevance of these
findings in the rat to those in man they demonstrate the need to evaluate
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the pharmacology and psychoactive effects of any new amphetamine
analogues on a case-by-case basis and not rely on predictions from
structural analogy.
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The synthetic cathinones received a lot of public attention in recent years,
mostly due to media reports on legal high related deaths. Mephedrone
was the most popular of the cathinones to be used recreationally before
the ban. Its popularity was thought to be due to its perceived likeness to
MDMA, as well as the decline in purity of ecstasy tablets. Before the ban,
mephedrone was found as a constituent of ecstasy tablets and remained as
an active component of legal high products after it was made a controlled
substance. As part of a recent worldwide survey (2013) it has been
confirmed that mephedrone is still amongst the top 20 recreational drugs
used in the UK, but that it is not as popular as MDMA/ecstasy (Fig 6.1).
Preclinical data on the behavioural, physiological and neurochemical effects
of mephedrone have only been published since 2011. In light of this, the
aim of this thesis was to examine mephedrone-induced changes in
behaviour, body temperature or neurochemistry in the rat and to compare
these changes to those observed following MDMA administration.
Recreational users liken mephedrones psychostimulant effects to those of
MDMA, and the chair of the UKs Advisory Council on the Misuse of Drugs is
quoted as saying [cathinone derivatives] are amphetamines by another
name (Dyer 2010). The main findings of this thesis however suggest that
although mephedrone and MDMA share some similarities in their effects on
behaviour and body temperature, they are also some key differences,
suggesting some responses are mediated via similar but modified
mechanisms.
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were group-housed at the time of measurement, but pre-exposure to
MDMA, or concomitant caffeine administration, caused an increase in rectal
temperature (Chapter 2 and 4). Binge-style administration of mephedrone
(3 x 10 mg kg-1 at 2 h intervals) had no accumulative effect on
mephedrone-induced hypothermia. Additionally, mephedrone-induced
hypothermia is also abolished by 5-HT depletion and partially attenuated
by dopamine depletion (Chapter 5).
Single cathinone and MDMA injections cause prolonged hyperactivity in
rats, while mephedrone injection causes transient hyperactivity, with
evidence for sensitisation to both cathinones and mephedrone following
chronic intermittent dosing (a total of six injection administered twice
weekly on consecutive days for three weeks, Chapter 3). Pre-exposure of
rats to MDMA had no effect on mephedrone-induced hyperactivity after one
or five injections, while co-administration of caffeine and mephedrone
prolonged the hyperactive profile of mephedrone following acute injection
(Chapter 4). Interestingly, binge-style administration of mephedrone did
not affect mephedrone-induced hyperactivity and 5-HT depletion (by
bilateral i.c.v. injection) caused a decrease in the magnitude of
mephedrone-induced hyperactivity, while dopamine depletion enhanced it
(Chapter 5).
Cathinone, MDMA and mephedrone disrupted novel object discrimination
but each compound also reduced exploration during the familiarisation trial
(Chapters 3 and 4), which may be due to decreased attention rather than a
specific memory deficit. Further studies using differing tasks would be
required to conform this, for example the 5-choice serial reaction time task
would assess visuospatial attention. Mephedrone was the only compound
to reduce freezing in the retention trial of the conditioned emotional
response task due to attenuation of hippocampal-dependent contextual
association (Chapter 3). Mephedrone also increased anxiety-related
behaviour on the elevated plus maze (Chapter 4) which was enhanced by
MDMA pre-exposure compared to mephedrone alone, without affecting the
mephedrone-induced decrease in the number of head dips over the sides
of the open arms. Co-administration of caffeine increased the time spent
on the open arms of the maze compared to mephedrone alone and
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reversed the decreased number of head dips observed in the mephedrone
alone treated rats. Cathinone, MDMA and mephedrone had no effect on
prepulse inhibition to acoustic startle.
The cathinones and MDMA had varying effects on post mortem tissue
levels of the monoamines and their metabolites. Mephedrone (10 mg kg-1)
decreased 5-HIAA in hippocampal tissue dissected at 1 h post-injection
(following twice weekly injections on consecutive days for three weeks), an
effect not observed in mephedrone treated MDMA pre-exposed rats
(Chapter 4). MDMA also decreased hippocampal 5-HT and 5-HIAA in MDMA
pre-exposed rats, 1 h after the final MDMA injection (13 injections in total),
while a dose of 4 mg kg-1mephedrone increased hippocampal DOPAC and
10 mg kg-1mephedrone and MDMA decreased DOPAC in tissue taken seven
days post-injection (Chapter 3).
In post mortem tissue dissected at 2 h post-injection (Chapter 2),
cathinone (4 and 10 mg kg-1) increased hypothalamic DOPAC while the
higher dose increased striatal dopamine, hypothalamic 5-HT and striatal 5-
HT and 5-HIAA. Methcathinone (10 mg kg-1) increased dopamine and HVA
levels in the frontal cortex, hippocampus and striatum, as well as 5-HIAA
in the striatum. In contrast, MDMA (4, 10 mg kg-1) reduced 5-HT in the
hippocampus, and the highest dose decreased DOPAC and HVA in the
striatum, as well as decreasing 5-HIAA in the hippocampus, hypothalamus
and striatum. Mephedrone had no effect on dopamine, 5-HT or their
metabolites in tissue taken 2 h post-injection but it did cause an increase
in plasma noradrenaline (Chapter 2). Despite mephedrone having no effect
on ex vivo tissue levels of 5-HT or dopamine, it did increase in vivo striatal
dopamine efflux in awake rats, the magnitude and duration of which was
unaffected by binge-style administration (Chapter 5).
6.2 Translational relevance
When conducting preclinical studies it is important to select a dose, and
dose schedule, which is relevant to human use. In order to do this,
Chapter 6. General Discussion
193
pharmacokinetic and pharmacodynamic information from both humans and
animals is essential. The dose levels and schedules used in this study were
selected to mimic those used by recreational users, as well as doses used
in previously published studies where possible. MDMA and mephedrone are
typically consumed at the weekend (Moore et al. 2013), so in Chapters 3
and 4 rats were injected twice weekly on consecutive days a week in an
attempt to mimic this dosing pattern. Mephedrone users also typically re-
dose in a session to maintain the desired effects of this short acting drug
(Schifano et al. 2011) so a further study administered three injections of
mephedrone over 4 h (Chapter 5).
A typical recreational dose of MDMA is one to two tablets (approximately
150 mg of MDMA), which, using allometric scaling, is the equivalent of
approximately 5 mg kg-1 in the rat (Green et al. 2012). However, this does
not take metabolism, bioavailability or protein binding into account. MDMA
not only has a much greater plasma half-life in humans than in rats, it is
more rapidly metabolised to form neurotoxic metabolites in rats than in
humans, and increasing the dose from 1 to 2 mg kg-1 in humans will
increase the plasma concentration of the drug four-fold (Baumann et al.
2009). Therefore, in Chapters 2 and 3, two doses of MDMA (4 or 10 mg kg-
1) were chosen. The lower dose was chosen to mimic that ingested by
human users, and the higher dose was chosen to account for the greater
rate of metabolism of MDMA in rats than humans. Chapter 4 again used a
low dose (5 mg kg-1) as this was found to produce sensitisation to MDMA in
previous studies (Aberg et al. 2007) and is similar to doses used in man.
The most common route of recreational mephedrone administration is
orally or by insufflation, with a typical dose being approximately 100-200
mg, but due to its short duration of action users will re-dose in an attempt
to maintain its desirable effects and may take up 4 g in a single session
(Schifano et al. 2011; Winstock et al. 2011). Since pharmacokinetic
studies of mephedrone in humans have not yet been performed, it is
difficult to infer a suitable dose for preclinical studies. However, post
mortem examination of mephedrone-related fatalities shows that plasma
mephedrone concentration in persons suffering a fatal overdose was in the
region of 2000 ng ml-1. This being similar to a fatal dose of MDMA and
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given the modest differences in molecular weights of MDMA and the
selected cathinones, it was logical to compare the same doses of all
compounds in Chapter 2, and then to use the data from these studies to
select appropriate doses for subsequent studies. Since we have little
information on the metabolism and protein binding of mephedrone in
humans, the interpretation of the preclinical data collected in this thesis
with relation to recreational use is obviously limited. More information in
man is needed but this may be difficult as researchers are less likely to
conduct studies with this compound since it is now a banned substance.
6.3 Is mephedrone an amphetamine by another
name?
The data presented in this thesis suggest that mephedrone shares some
characteristics with MDMA, such that both compounds decrease rectal and
tail temperature in individually housed rats, induce hyperactivity, disrupt
learning in the familiarisation trial of the NOD task, increase anxiety-like
behaviours in the elevated plus maze and increase striatal dopamine
release. Additionally, co-administration of caffeine with mephedrone
causes increased hyperactivity and converts mephedrone-induced
hypothermia to hyperthermia, both of which are characteristic of
concomitant MDMA and caffeine administration (Vanattou-Saifoudine et al.
2012). However, caution should be taken when comparing mephedrone to
existing psychoactive substances. Taking a closer look at the data shows
that the effects of mephedrone are not easily predicted from previous
studies with MDMA, cathinone or methcathinone. For instance,
mephedrone induces hypothermia and a decrease in peripheral tail
temperature, while cathinone and methcathinone administration both
cause increased rectal temperature with no change in tail temperature
(Chapter 2), and mephedrone-induced hypothermia is transient and of a
lower magnitude than the hypothermia observed following MDMA
administration to individually housed rats.
Furthermore, based on the data presented in Chapter 2 it appears that
mephedrone is eliciting temperature changes via different mechanisms to
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0'0$0HSKHGURQHLQGXFHGK\SRWKHUPLDLVHQKDQFHGE\Į1-adrenoceptor
and D2 dopamine receptor antagonists, while MDMA-induced hypothermia
is blocked by D2 receptor antagonism (remoxipride) and potentiated and
SURORQJHG E\ WKH Į2-adrenoceptor antagonist, BRL 44408 (Green et al.
2005). As previously stated, hyperthermia is potentially fatal adverse
effect of MDMA. Interestingly, both group housing and binge-style
repeated administration of MDMA cause hyperthermia in rats, but neither
of these conditions affected temperature in mephedrone treated rats.
As previously stated, repeated MDMA administration to rats produces
behavioural sensitisation to other amphetamine-like psychostimulants,
which is thought to result from enhanced dopamine release in the nucleus
accumbens and striatum (Robinson and Becker 1982; Bradbury et al.
2012) and this is both dose level and administration interval dependent
(Kalivas et al. 1993). Therefore, further evidence for the dissimilarity
between mephedrone and MDMA is the lack of cross-sensitisation to the
hyperlocomotor and anxiogenic-like effects of a challenge dose of
mephedrone in rats previously administered MDMA (Chapter 4).
Mephedrone and MDMA cause acute release of dopamine and 5-HT
measured by in vivo microdialysis (Kehr et al. 2011; Baumann et al. 2012;
Bradbury et al. 2013). It is well established that a high-dose or repeated
administration of MDMA causes long-term 5-HT neurotoxicity in rats (see
section 1.3.3). Acutely MDMA induces 5-HT release resulting in tissue 5-HT
levels being reduced after 2 h but returning to baseline levels within 24 h.
In the following seven days, 5-HT levels begin to decline again resulting in
5-HT depletion (Schmidt et al. 1987; Connor et al. 1998). In this thesis
MDMA did not cause such neurotoxicity but this may be due to the dosing
regime, the time at which tissue was taken or strain of rat used. However,
acutely (2 h post-injection) MDMA (10 mg kg-1) decreased striatal tissue
levels of dopamine and 5-HT metabolites while also decreasing 5-HIAA in
the hypothalamus and hippocampus. In the same timescale, mephedrone
(4 and 10 mg kg-1) decreased hippocampal tissue 5-HT levels only.
However, in complete contrast, cathinone increased striatal dopamine, 5-
HT AND 5-HIAA as well as hypothalamic 5-HT, while methcathinone
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increased dopamine and HVA in the frontal cortex, hippocampus and
striatum, and also increased 5-HIAA in the striatum.
These contrasts are unsurprising due to the differences in receptor binding
profiles between mephedrone and MDMA, cathinone and methcathinone.
Mephedrone, like MDMA, is a non-selective monoamine re-uptake inhibitor
but cathinone and methcathinone are catecholamine reuptake inhibitors
and releasers (Carvalho et al. 2012). Mephedrone binds to the 5-HT2A
UHFHSWRUDQGĮ1ADQGĮ2A-adrenoceptors with low micromolar affinity, but
has very little affinity for 5-HT1A, 5-HT2C or dopamine receptors (Hadlock et
al. 2011; Baumann et al. 2012; Lopez-Arnau et al. 2012; Martinez-
Clemente et al. 2012; Eshleman et al. 2013; Simmler et al. 2013). MDMA
ELQGV WR WKH Į2-adrenoceptor with a similar affinity as mephedrone, and
has little affinity for 5-HT2CRUGRSDPLQHUHFHSWRUVEXWDOVRELQGVWRĮ1- and
ǃDGUHQHUJLF+71 and M2 muscarinic receptors (Battaglia et al. 1988).
6.4 Future studies
All new psychoactive drugs are being taken by users without any important
information about their short and long term effects or interactions with
other pharmacological agents. It is important that each novel substance is
treated as such and investigated on a case-by-case basis, however, it is
impossible to keep up with the rate at which these new drugs are
emerging, as well as with the rapidly changing patterns of recreational
drug use and co-administration. When the first of the studies presented in
this thesis was conducted, at the height of mephedrones popularity, there
were no preclinical publications on the pharmacological effects of
mephedrone. While the data presented in this thesis provide interesting
insight into the effects of mephedrone on certain aspects of behaviour and
neurochemistry in animal models, there are a number of studies that
would be beneficial as a continuation of the work presented in this thesis.
The most common and consistent effects of mephedrone as described in
this thesis, and in various other studies, are hyperactivity and hypothermia
Chapter 6. General Discussion
197
(Kehr et al. 2011; Lisek et al. 2012; Lopez-Arnau et al. 2012; Marusich et
al. 2012; Motbey et al. 2012; Wright et al. 2012; Gregg et al. 2013;
Martinez-Clemente et al. 2013; Miller et al. 2013). The data presented in
WKLVWKHVLVKDYHLQGLFDWHGDUROHIRUWKHĮ1-adrenoceptor, 5-HT1A, dopamine
D1 receptors in the mephedrone-induced hypothermic response, and a
study by another group has shown that D1 dopamine receptor antagonist
pre-treatment inhibits mephedrone-induced hyperactivity but D2 dopamine
receptor antagonist pre-treatment enhances this response (Lisek et al.
2012). Given that mephedrone appears to induce elements of the 5-HT
syndrome (Baumann et al. 2012), and that 5-HT2 receptor antagonism as
well as systemic p-chlorophenylalanine administration to the mouse
(Lopez-Arnau et al. 2012) or central 5,7-DHT administration to rats inhibit
mephedrone-induced hyperactivity (Chapter 5), it would be interesting to
investigate the effects of selective 5-HT receptor antagonists on this acute
hyperlocomotor response in the rat.
Following from this, there are a number of studies investigating the effects
of mephedrone on 5-HT and/or dopamine release in the nucleus
accumbens (Kehr et al. 2011; Baumann et al. 2012; Wright et al. 2012)
and striatum (Chapter 5). This may account for any acute re-inforcing
effects of mephedrone but as previously stated this does not account for
any temperature effects of mephedrone. The hypothalamus plays an
important role in homeostatic functions, including regulation of body
temperature. While this thesis has demonstrated the role of various
receptors in the hypothermic response to mephedrone, whether this is
occurring through peripheral or central nervous system actions has not yet
been distinguished. In order to further differentiate the peripheral actions
of mephedrone from its central actions on altering temperature it would be
beneficial to study the effects of mephedrone on in vivo neurotransmitter
release within the hypothalamus using microdialysis techniques, preferably
following rapid repeated dosing as described in Chapter 5.
Finally, since mephedrone users tend to take other substances
concurrently with mephedrone (Carhart-Harris et al. 2011; Corkery et al.
2012), and that the data presented in this thesis indicate an increased
effect of previous MDMA or concomitant caffeine use on mephedrone-
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induced responses, it would be beneficial to further investigate the effects
of other recreational drugs on mephedrone use. For example, as
mephedrone is commonly taken at night clubs, there is an increased
likelihood that it will be taken with alcohol. Additionally, the majority of
mephedrone users have a lifetime prevalence of cocaine use (for example
92 % of 947 mephedrone users admit to previous use of cocaine; Winstock
et al., 2011a) and although mephedrone has become an illegal substance it
is still found in products sold as legal highs along with other cathinones
such as 3,4-methylenedioxypyrovalerone (MDPV) and MDPV has been
identified post-mortem in a number of mephedrone-related deaths
(Corkery et al. 2012). Based on this information it would be interesting to
examine the behavioural and long-term neurochemical effects of previous
cocaine use on subsequent mephedrone administration in rats, as well as
ethanol or MDPV administration concomitantly with mephedrone, using a
similar protocol as described in Chapter 4, to try to further explain the
adverse effects of mephedrone not observed when it is administered alone.
6.5 Conclusion
Although mephedrone users compare its effects to MDMA, the data
presented in this thesis suggests that these two compounds, as well as
cathinone and methcathinone, have a different, but related pharmacology.
Like MDMA, mephedrone acts via the monoamine systems to elicit a wide
range of behavioural effects including hyperactivity, and hypothermia.
However, in stark contrast to MDMA, mephedrone does not appear to
cause neurotoxicity in the rat, at least under the conditions used herein.
Further studies investigating the effects of mephedrone in human users,
including its pharmacokinetics, are essential in fully understanding the
pharmacology of this drug.
Equally, while MDMA and mephedrone are still amongst the top 20 most
popular drugs in the UK (Winstock 2014), the recreational drug scene is
constantly changing, with novel substances constantly emerging at a rate
much too quick for the appropriate research to be conducted before human
use. Baring this in mind, the legal bans on substances based on generic
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chemical structures that have been put in place further impedes any
scientific research that needs to be conducted as research is limited to
laboratories that have licences to work with these substances. Although
the intention of these generic bans is to protect against human use,
historically this does not prevent people from taking them, and with the
added limitations placed on researching these chemicals, there is little
information available on any potential harms that they may cause.
Additionally, purchasing these substances illegally increases the risk of
taking impure mixtures of several different drugs, which may result in
severe adverse events or death. Instead of generically banning these
substances it would be more beneficial to educate people based on
scientific evidence on the risks associated with taking unknown or new
drugs in a way that they will understand and be receptive to, in order to
limit any potential harms of these novel substances.
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